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“Obstacles are those frightful things you see,
when you take your eyes of your goal.”
-Henry Ford-
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GENERAL INTRODUCTION AND OUTLINE OF 
THE THESIS
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GENERAL INTRODUCTION
The Dutch Cancer Registry reported an incidence of 6149 new patients with bladder 
cancer in the year 2011, with a male to female ratio of 3.4 to 1. In men this represents 
5.2% of all known malignancies. Approximately 70% of cases with bladder cancer are 
non-muscle invasive tumours (NMIBC), in which the tumour is limited to the urothelium 
(Ta, carcinoma in situ) or exclusively invasive in the lamina propria of the bladder wall (T1). 
In the spectrum of NMIBC, carcinoma in situ (CIS) has been recognized as a distinctive 
lesion, with a high risk for recurrence and progression. Muscle invasive bladder cancer 
(MIBC) is by definition a tumour invading at least into the detrusor muscle (≥T2)1.  
The most important risk factor for the development of bladder cancer is smoking. 
However, smoking status does not predict bladder cancer stage or grade. In the male 
population smoking is related to bladder cancer in 50-65% of cases versus 20-30% 
in the female population. After the cessation of smoking the risk for bladder cancer 
decreases with 40% in the first four years up to a 60% decrease after 25 years2. 
Diagnosis and staging
Macroscopic hematuria is the most common presenting symptom for bladder cancer. 
Furthermore, irritative lower urinary tract symptoms (urgency, frequency, pollakisuria 
and dysuria) may be indicative of NMIBC, especially CIS. Urinary cytology has a 
moderate sensitivity and high specificity for high grade non-muscle invasive bladder 
cancer (HG-NMIBC)3,4. Especially for CIS, which is characterized by a lack of cellular 
cohesion, urinary cytology is an accurate test next to visual examination for detection 
and follow-up4. Therefore, in the diagnosis and follow-up of NMIBC, urinary cytology is 
of importance. Urinary molecular markers have been extensively investigated, but (with 
respect to HG-NMIBC) they have not been proven to be of substantial value in daily 
clinical practice. 
Cystoscopy is the most important tool in the diagnostics for NMIBC. The investigation is 
generally performed in the out-patient clinic, with a flexible cystoscope. By inspection of 
the bladder, papillary tumours can be clearly identified. Furthermore the ureteral orifices 
and the prostatic urethra can be inspected. In case of CIS, which displays a flat growth 
pattern, localization with classic white light cystoscopy may not be so straightforward. 
In recent years the introduction of photodynamic diagnostics (PDD) has proven to be of 
significant importance in the identification of CIS, improving the diagnostic accuracy for 
CIS with 39% versus white light cystoscopy 5,6.
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Transurethral resection of the bladder tumour (TUR-BT) is both a diagnostic and 
therapeutic procedure. Main goal of the procedure is to perform a complete resection of 
the bladder tumour. Furthermore, to obtain adequate material to (sub)stage the tumour. 
Thus adequate resection of detrusor muscle underneath the tumour is necessary. A 
surprisingly high variability has been reported in recurrence rates after TUR-BT between 
various institutions, implying important differences in the quality of surgical resection of 
bladder tumours 7. PDD may be used during TUR-BT to minimize positive surgical margins 
and residual disease and thereby reducing recurrence rates 8. In case of HG-NMIBC, 
a restaging TUR-BT is recommended because of the risk of residual disease and/or 
understaging. After initial TUR-BT the risk of residual disease varies between 36-63% 
9,10. Although the use of PDD improves the results of the initial TUR-BT, there is still a risk 
of residual disease of 12%, justifying a second resection. In case of absence of muscle 
tissue in the initial TUR-BT specimen, a second resection is essential to adequately stage 
the patient. Furthermore, even when muscle is present in the initial TUR-BT specimen, 
the reported risk of understaging varies from 24-30%9,11. Therefore, a second TUR-BT 
should be performed after 2-6 weeks for all high grade Ta-1 tumours. 
Carcinoma in situ 
Compared to Ta and T1 tumours, carcinoma in situ (CIS) more often presents as a 
multifocal disease. Furthermore CIS is frequently associated with invasive bladder cancer, 
and is subsequently suspected to be a precursor of invasive urothelial carcinoma12. 
This relationship between CIS and invasive disease has been substantiated by genetic 
and molecular approaches13. In CIS, the coherence and adherence of epithelial cells 
is decreased and this feature may result in denuded biopsies when taken by cold cup 
or with the resection loop14. Although CIS is defined as an overt high grade lesion, 
consensus on the diagnosis does not always exist when the specimen is reviewed by 
several pathologists. There is both intra-observer and inter-observer variability, even 
between severe dysplasia and CIS14,15. When left untreated, CIS of the bladder may 
result in progression to muscle-invasive disease in approximately 50% of patients and in 
disease recurrence in up to 90% of patients16,17. CIS can be found as a primary urothelial 
lesion (i.e. solely CIS in primary pathology specimen) or in combination with another 
form of urothelial carcinoma either concomitantly (i.e. CIS concurrent with another form 
of urothelial carcinoma) or secondarily (i.e. another form of urothelial carcinoma and 
discovery of CIS during follow up) 4,18. Although, it has been reported that patients with 
primary CIS have a better prognosis than patients with concomitant or secondary CIS, 
the risk profiles of these three clinical types of CIS have not yet been fully clarified19,20. 
This issue is addressed in Chapter 2. 
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Treatment for HG-NMIBC consists primarily of complete TUR-BT, followed by adjuvant 
intravesical instillations of bacillus Calmette-Guérin (BCG) in a regimen of one to three 
years2,21,22. Nevertheless, for high-risk and/or recurrent T1 disease, a cystectomy may 
also be considered. To further elucidate the risk profiles of T1 tumours a system of 
substaging has recently been proposed, dividing these tumours in T1-microinvasive 
(T1m) and T1-extensive-invasive (T1e) tumours23. Furthermore, for patients with 
recurrence or persistence of HG-NMIBC during BCG-treatment (BCG-refractory disease), 
or progression to MIBC radical cystectomy is advised13. 
Radical surgery and lymph node staging
Radical surgery consists of bilateral extended pelvic lymphadenectomy (PLND) and total 
cystectomy with urinary diversion. Alternatively external beam radiotherapy and/or 
interstitial (brachy) therapy may be applied in selected cases. The value of the PLND 
is undisputed to accurately stage patients with MIBC24-28. Nevertheless, the extent of 
lymphadenectomy remains a matter of debate throughout the urological community. 
The total number of resected lymph nodes is generally acknowledged as an indicator 
of the quality of surgery29,30. In recent years other lymph node parameters have been 
introduced as prognostic factors, such as the total number of tumour positive lymph 
nodes and the lymph node density (the ratio of positive lymph nodes divided by the total 
number of resected lymph nodes)31-35. Although these parameters have been widely 
accepted in clinical practice, they are very much dependent on the evaluation by the 
pathologist. These issues are addressed in Chapter 3. 
Multimodality treatment for non-organ con-
fined bladder cancer 
Despite the improved anatomical knowledge and refinement of surgical techniques, 
the outcome of patients with MIBC remains meagre, with a reported 5-years overall 
survival ranging from 36% to 62% 36-39. For patients presenting with locally advanced 
disease (T3-T4) and/or lymph node (LN) metastases the prognosis is even worse, with 
5-years survival data ranging from 26% to 38%25,38. For patients with locally advanced 
disease, this poor outcome is probably due to understaging of the LN status and/or 
occult micro-metastases at the time of first diagnosis40. In clinically LN negative (cN0) 
patients with locally advanced disease (T3-4), LN metastases may be found in up to 34% 
of cases at the time of surgery24. 
To improve the outcome of patients presenting with locally advanced MIBC, systemic 
treatment with cisplatin-based combination chemotherapy was introduced, resulting in 
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a moderate increase in overall survival (6.5% at 5-years follow-up) 41-47. Nevertheless, in 
case of complete response after chemotherapy, the benefit for the individual patient may 
be greater. It has been shown that the response to neoadjuvant/induction chemotherapy 
(NIC) is a good predictor for overall survival and recurrence free survival48. The results 
of such a multimodality treatment consisting of NIC and radical surgery are described in 
Chapter 4. 
Considering the toxicity of the chemotherapy regimens and the advanced age of many 
bladder cancer patients, NIC is not used universally. The renal toxicity of cisplatin based 
combination chemotherapy, combined with the advanced age of most patients with 
bladder cancer and their limited performance status are the most common limiting 
factors in the use of cisplatin-based combination chemotherapy. Approximately 30-50% 
of patients with urothelial carcinoma are unfit for cisplatin-based chemotherapy49. In 
2011 Galsky et al. published a consensus definition for patients with metastatic urothelial 
carcinoma who are unfit for cisplatin-based combination chemotherapy50. Patients are 
considered unfit for cisplatin-based treatment when they meet one or more of the 
following criteria: 
 -  WHO performance status ≥2 or Karnofsky performance status ≤60-70%
 -  Creatinine clearance <60 ml/min
 -  Common Terminology Criteria for Adverse Events (CTCAE) version 4,  
 audiometric hearing loss ≥ grade 2
 -  CTCAE version 4, peripheral neuropathy ≥ grade 2 
 -  New York Heart Association (NYHA) heart failure ≥ class III 
Patients with non-organ confined bladder cancer who are considered unfit for 
cisplatin-based treatment may be treated with carboplatin-based NIC. However 
the carboplatin-based treatment is generally considered to be inferior to cisplatin. 
To determine the outcome of patients who were treated with carboplatin-based 
chemotherapy a comparison was made with cisplatin-treated patients. The results of this 
study are described in Chapter 5. 
Lymph node positive bladder cancer 
The issue of understaging of the bladder tumour and the LN status was mentioned 
earlier. This reflects the limitations of current imaging techniques (CT-scan). In clinically 
node negative MIBC patients the reported risk for occult lymph node metastasis ranges 
up to 35%. In theory the use of NIC should reduce the number of pathologically node 
positive patients. This hypothesis was addressed by the study that is described in 
Chapter 6. 
Lymph node positive bladder cancer (NPBC) is a serious disease associated with a poor 
prognosis. In general five-years overall survival of NPBC patients ranges up to 26%25,38. 
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The use of induction cisplatin-based combination chemotherapy in these patients is 
controversial, as most trials investigating the potential benefit of NIC excluded node 
positive patients46. Nevertheless, such a multimodality approach consisting of systemic 
induction chemotherapy followed by local treatment may offer a chance of durable 
response and prolonged recurrence-free survival to some of these patients51. The results 
of such a combined treatment with NIC and subsequent radical surgery are described 
in Chapter 7.
Small cell carcinoma of the bladder 
Histo-pathologically bladder cancer may be divided into urothelial carcinoma (90%) and 
a mixture of other forms: squamous cell carcinoma (8%), adenocarcinoma (1-2%) and 
small cell carcinoma of the bladder (0.5–0.7%). Each of these different subtypes of 
bladder cancer is characterized by a specific tumour biology and subsequent tumour 
behaviour, thus requiring specific approaches to these different tumortypes. For 
example the biological and clinicopathological features of small cell carcinoma of the 
bladder (SCCB) are similar to those of small cell lung carcinoma (SCLC)52,53. Thus the 
treatment approach to this rare tumour has been greatly influenced by the treatment of 
the far more common SCLC. In general SCLC and SCCB are considered to be systemic 
diseases, requiring systemic treatment in addition to local control. In the context of 
SCCB this means that patients with limited disease (LD-SCCB; i.e. tumour confined to 
the pelvis, Tx-4N0-1M0) may be treated with a combination of systemic chemotherapy 
and local radiotherapy54,55. Nevertheless, because of the low incidence of SCCB the 
optimal treatment strategy for these patients remains controversial. Some advocate 
chemotherapy followed by radical surgery, with promising results 56. The long-term 
outcome and the risk of local recurrence of patients with LD-SCCB, who were treated 
with sequential chemoradiation (i.e. systemic chemotherapy followed by external beam 
radiotherapy) are discussed in Chapter 8. 
Some parts of this introduction were previously published:
 -   Meijer RP, van Rhijn BW. Urologie Formularium. Chapter 10: Urotheelcelcarcinoom. 
2011, 1st  Edition; Bohn Stafleu van Loghum
 - Meijer RP, van Rhijn BWG. The Oxford Textbook of Urological Surgery. Chapter 19 
Bladder cancer: high-grade non-muscle invasive disease. 2013 1st Edition; Oxford 
University Press
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THE RISK PROFILES OF THREE CLINICAL TYPES 
OF CARCINOMA IN SITU OF THE BLADDER
BJU Int. 2011; 108(6):839-43
R.P. Meijer, I.E.W van Onna, E.T. Kok, J.L.H.R. Bosch
“Asking the right question is often half the solution to a given problem.”
-Werner Heisenberg-
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ABSTRACT
Objective
To further clarify the risk profiles of three clinical types of carcinoma in situ (CIS) of the 
bladder. 
Materials and Methods
Population-based data from the Comprehensive Cancer Centre Middle Netherlands 
(CCCMN), as part of the nationwide Netherlands Cancer Registry (NCR), were used for 
patients presenting with CIS in the period of 1987 to 2009. Patients with muscle invasive 
bladder cancer on primary diagnosis were excluded. The patients were divided into three 
groups according to their ‘clinical type’, being primary, concomitant or secondary CIS. 
Results
Overall 90 patients with CIS were identified with a mean age of 63.4 years, predominantly 
men (91.1%). Primary CIS (P-CIS) was found in 43 patients (47.8%), concomitant CIS 
(C-CIS) in 21 patients (23.3%) and secondary CIS (S-CIS) in 26 patients (28.9%). Mean 
follow-up was 81.3 (range 8 - 222) months. Recurrence of disease was observed in 68.9% 
of patients, with significantly more recurrences in the S-CIS group (88.5%). Progression 
to muscle invasive disease was seen in 17 patients (18.9%): 8 patients (18.7%) with 
P-CIS, 4 (19.0%) with C-CIS and 5 (19.2%) with S-CIS. Overall 29 patients underwent 
a cystectomy, equally distributed over the three groups. The duration of bladder 
preservation was worse in the C-CIS group but did not differ significantly between the 
groups. Overall survival at 5-years was 79.6% for the total group, with poorer results for 
the C-CIS group, although not statistically significant.
Conclusions
Carcinoma in situ clearly is an entity that requires meticulous treatment and thorough 
follow-up because of its high recurrence rate (68.9%) and high rate of progression to 
muscle invasive bladder cancer (18.9%). The C-CIS group appears to have a poorer 
prognosis with a shorter duration of bladder preservation and a worse overall survival.  
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INTRODUCTION
Non-muscle-invasive bladder cancer (NMIBC) can be subdivided in several subtypes with 
varying risk factors for recurrence and progression. In this broad range of malignant 
bladder tumours, urothelial carcinoma in situ (CIS) has been recognized as a distinctive 
lesion. When left untreated, CIS of the bladder may result in progression to muscle 
invasive disease in approximately 50% of patients and in disease recurrence in up to 
90% of the patients1,2.  Carcinoma in situ can be found as a primary urothelial lesion 
(i.e. solely CIS in primary pathology specimen) or in combination with another form of 
transitional cell carcinoma either concomitantly (i.e. CIS concurrent with another form of 
transitional cell carcinoma) or secondary (i.e. another form of transitional cell carcinoma 
and discovery of CIS during follow-up)3,4. Although, it has been reported that patients 
with primary CIS have a better prognosis than patients with concomitant or secondary 
CIS, the risk profiles of these three clinical types of CIS have not yet been fully clarified5-7. 
The standard treatment for CIS of the bladder primarily consists of intravesical bacillus 
Calmette-Guérin (BCG) instillations7-12. In case of BCG failure a selection of patients 
with CIS will be offered early cystectomy. In general CIS is considered to be a disease 
that requires life long follow-up, because of a considerable risk of recurrence anywhere 
in the urinary tract13,14. The current study was performed to give further insight in the 
risk profiles of the three clinical types of carcinoma in situ (CIS) of the bladder. In clinical 
practice it would be helpful to be able to discriminate ‘high-risk’ from ‘low-risk’ CIS 
before the start of intravesical therapy and as such to tailor the treatment and follow-up 
to this risk-profile.
MATERIALS AND METHODS
Population-based data from the Comprehensive Cancer Centre Middle Netherlands 
(CCCMN), as part of the nationwide Netherlands Cancer Registry (NCR), were used 
for patients presenting with CIS in the period of 1987 to 2009. The NCR is based on 
notification of all newly diagnosed malignancies in the Netherlands by the automated 
pathological archive (PALGA). Additional sources are the national registry of hospital 
discharge diagnoses, haematology departments and radiotherapy institutions 15. 
Information on patient characteristics such as gender, date of birth, and tumour 
characteristics such as date of diagnosis, tumour type, International Classification of 
Diseases for Oncology (ICD-O-3)16, histopathology, stage (TNM) classification17, tumour 
grade and initial treatment, are extracted routinely from the medical records by data 
managers, 6 to 18 months after diagnosis18. The quality of the data is high, due to 
thorough training of the data managers and computerized consistency checks at regional 
and national levels. Completeness is estimated to be at least 95%19. The internal review 
The risk profiles of three clinical types of carcinoma in situ of the bladder
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board of the CCCMN approved the disclosure of registered data from the individual 
urology departments of all hospitals of the CCCMN-region. For completion of the study 
data base, the individual urology departments of the CCCMN-hospitals agreed to the 
retrospective extraction of follow-up data from the patient files. These additional data 
consisted of follow-up investigations (i.e. imaging, urethrocystoscopy, urinary cytology, 
histopathology), regimens of intravesical therapy, re-interventions and adjuvant therapy. 
Patients with muscle-invasive bladder cancer on primary diagnosis were excluded from 
this analysis. 
The patients were divided into three groups according to their ‘clinical type’, being 
primary (1), concomitant (2) or secondary (3) CIS. Overall survival, progression rate and 
recurrence rate were analysed using the Kaplan -Meier method. Cumulative probabilities 
and median survival are given wherever appropriate. Overall survival is defined as the time 
to any cause of death: patients who were alive at the end of follow-up were censored at 
that date. Recurrence was defined as first relapse of disease in the bladder. Progression 
of disease was defined as the development of muscle invasive bladder cancer (MIBC). 
The Kaplan -Meier curves were compared using the log rank test. Statistical significance 
was defined as a p value <0.05. Data analysis was performed with Statistical Package for 
Social Sciences (SPSS), version 15.0 for Windows.
RESULTS
Of all patients diagnosed with bladder cancer in the CCCMN region between 1987 
and 2009, 104 had CIS. Fourteen of these patients were also diagnosed with muscle-
invasive bladder cancer and therefore excluded from this study. The remaining 90 
patients corresponded to the inclusion criteria of this study. These patients had a mean 
age of 63.4 years (range 24 - 85 years), and 91.1% were men. Primary CIS (P-CIS) was 
found in 47.8% of patients, concomitant CIS (C-CIS) in 23.3% and secondary CIS (S-CIS) 
in 28.9%. Urine cytology was performed in 74.4% of patients of which 64.2% was 
high grade and thus suspicious for transitional cell carcinoma. Mean follow-up was 81.3 
months (range 8 - 222). The patient characteristics are shown in table 1. The results from 
the initial pathological evaluation are summarized in table 2. 
Overall 78 of 90 patients (86.7%)  were treated with intravesical BCG immunotherapy 
and 21 of 90 (23.3%) patients were treated with intravesical mitomycin C (MMC). Since 
76.2% of the patients who were treated with MMC, also received BCG, either before 
or subsequent to MMC therapy, there is some overlap between the MMC and BCG 
treatment groups, leaving 7 patients (7.8%) who did not receive any intravesical therapy. 
In the group with P-CIS 52 courses of intravesical therapy were started (4 x MMC; 48 
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2x BCG, median of 12 instillations per course) versus 26 courses in the C-CIS group (4 x 
MMC; 22 x BCG, median of 9 instillations per course) and 44 courses in the group with 
S-CIS (16 x MMC; 28 x BCG, median of 9 instillations per course). 
Table 3 shows the recurrence and progression rates. In the group with S-CIS an 88.5% 
recurrence rate was found, which is significantly higher than the rate found in the other 
two groups (versus P-CIS: p=0.02; versus C-CIS: p=0.04). For the P-CIS group the median 
time to recurrence was 34 months (range 2-136), for the C-CIS group 29 months (range 
2-97) and for the S-CIS group 12 months (range 2-66) respectively. The median time to 
recurrence was overall 29 months (range 2-136). Despite the apparent shorter time to 
recurrence in the S-CIS group, the differences among the three groups, did not reach 
statistical significance (p=0.076). As was stated earlier, progression was defined as the 
Table 1. Patient characteristics
N %
Gender Male 82 91.1
Female 8 8.9
Presenting complaint Macroscopic hematuria 47 52.2
LUTS 30 33.3
UTI 2 2.2
Type of CIS P-CIS 43 47.8
C-CIS 21 23.3
S-CIS 26 28.9
Abbreviations:  LUTS = Lower Urinary Tract Symptoms; UTI = Urinary Tract Infection
Table 2. Primary bladder tumour pathology
Type of CIS P-CIS C-CIS S-CIS Overall
N % N % N % N %
CIS 43 47.8 21 23.3 - - 64 71.1
TaG1 - - 1 1.1 5 4.8 6 6.7
TaG2 - - 3 3.3 6 5.8 9 10.0
TaG3 - - 4 4.4 5 4.8 9 10.0
T1G2 - - 3 3.3 2 1.9 5 5.6
T1G3 - - 10 11.1 8 7.7 18 20.0
Abbreviations:  P-CIS = Primary CIS; C-CIS = Concomitant CIS; S-CIS = Secondary CIS
Table 3. Bladder recurrence and progression rates
Type of CIS P-CIS C-CIS S-CIS Overall
N % N % N % N %
Recurrence in 
the bladder
26 60.5 13 61.2 23 88.5# 62 68.9
Progression to 
MIBC
8 18.7 4 19.0 5 19.2 17 18.9
# Statistically significant (p<0.05)
The risk profiles of three clinical types of carcinoma in situ of the bladder
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development of muscle invasive disease. Progression to muscle invasive disease occurred 
in 18.9% of patients, with no significant differences among the three groups (p=0.96). 
Recurrence in the upper urinary tract occurred in 6 patients (6.7%; 2 in the ureter and 
4 in the renal pelvis). 
Overall 29 patients (32.2%) underwent a radical cystectomy, equally distributed over the 
three groups. In 21 of these patients (72.4%) CIS was demonstrated in the cystectomy 
specimen, either solitary or concomitantly. Lymph node metastasis was found in 3 
patients: 2 with P-CIS and 1 with S-CIS. The pathology results after radical cystectomy 
are shown in table 4. 
Table 4. Pathology results after radical cystectomy
Type of CIS P-CIS C-CIS S-CIS
N % N % N %
CIS only 4 26.7 4 57.1 5 71.4
TaG3 + CIS 1 6.7 - - - -
T1G2 + CIS - - - - 1 14.3
T1G3 + CIS 2 13.3 - - - -
T2G3 + CIS 2 13.3 1 14.3 - -
T3G3 + CIS - - - - 1 14.3
T2G3 - - 1 14.3 - -
T3G3 2 13.3 - - - -
T0 (no residual tumour) 4 26.7 1 14.3 - -
Total radical cystectomy 15 34.9 7 33.3 7 26.9
Figure 1: Duration of bladder 
preservation: P-CIS, primary carcinoma 
in situ; C-CIS, concomitant carcinoma 
in situ; S-CIS, secondary carcinoma in 
situ.
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(p=0.37), although it was markedly shorter in the C-CIS group (figure 1). At five years 
follow-up the bladder preservation rate was 67.1% in the P-CIS group, 56.9% in the 
C-CIS group and 80.4% in the S-CIS group.
Survival was analysed with the Kaplan-Meier method. The five-year overall survival is 
79.6% for the total group. For the subgroups P-CIS, C-CIS and S-CIS, the 5-year overall 
survival is 81.2%, 65.4% and 87.0% respectively (p=0.11; figure 2). Hence the overall 
survival is notably worse for the C-CIS when compared to the other two groups, although 
this difference did not reach statistical significance. 
DISCUSSION
This study substantiates the aggressive nature of CIS of the bladder, with a high risk 
of recurrence (68.9%) and progression to muscle invasive disease (18.9%). Generally 
intravesical BCG immunotherapy is considered to be the first line approach for CIS of 
the bladder. Several studies report on the success of intravesical BCG maintenance with 
disease-free rates of 45-71% and with progression rates decreasing to 14-22%9,12,20,21. 
In the present study most patients (86.7%) were treated with intravesical BCG 
immunotherapy, with a median of 9 instillations per course. The overall recurrence rate 
was 68.9% with significantly more recurrences in the S-CIS group (88.5%). However 
this may be due to the fact that in the S-CIS group intravesical treatment with MMC 
was administered more frequently than in the other two groups or because the S-CIS 
group has already demonstrated to be prone to recurrence. The time to recurrence 
was notably shorter for the S-CIS group (median time to recurrence 12 months) than 
for the other two groups (overall median time to recurrence 29 months). Nevertheless 
Figure 2: Overall survival: P-CIS, 
primary carcinoma in situ; C-CIS, 
concomitant carcinoma in situ; S-CIS, 
secondary carcinoma in situ.
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no statistically significant differences were found (p=0.076), this may be due to the 
relatively small sample size.
When comparing progression rates between studies one should be aware of the 
different definitions of progression that are being used: either progression to a higher 
stage of disease (≥T1) or progression to muscle invasive disease (≥T2). The overall 
progression rate of 18.9% in our study is markedly higher than the rate of 13.9% that 
was reported in the meta-analysis of Sylvester et al., who also defined progression as the 
development of muscle invasive disease22. This difference could be due to the fact that 
the meta-analysis included mostly patients who underwent BCG maintenance therapy, 
whereas the patients in the present study only received a median of 9 BCG instillations. 
However, a more likely explanation may be found in the different follow-up periods. A 
relatively short follow-up of 2.5 years was reported in the meta-analysis, whereas we 
report a median follow-up of 6.0 years. Kaasinen et al. also reported a progression rate 
of 17.8%, but they defined progression as the development of T1 disease or higher23.
The sub-classification of CIS in three clinical types (P-CIS, C-CIS and S-CIS) has been 
used by Jakse et al. in their study evaluating the efficacy of BCG in CIS of the bladder. 
In this study the three groups of CIS responded equally well to BCG8. In contrast to 
this, several studies have reported a significantly higher risk of progression and a worse 
outcome for patients with CIS associated with a T1 papillary tumour versus patients 
with primary CIS5,7,9,23. Ovesen et al. reported that progression of disease was found in 
8% of patients with primary CIS as compared to 57% of patients with concomitant or 
secondary CIS7. However in interpreting such data one should consider the possibility 
of a lead time bias. In our study the progression rates did not differ significantly among 
the three groups.
Radical cystectomy was performed in 29 patients (32.2%), equally distributed over 
the three groups.  In 21 of these patients (72.4%) CIS was found in the cystectomy 
specimen, either solitarily or concomitantly. In the literature a wide range of cystectomy 
rates (up to 50%) has been reported12,24. In the present study, the duration of bladder 
preservation did not differ significantly among the groups. Although the C-CIS group 
appears to have a worse prognosis, with a bladder preservation rate that was 12-24% 
lower than that in the other two groups, statistical significance was not achieved. 
However, the relatively small number of patients in the three groups, which is a problem 
with most subgroup analyses in CIS patient groups, should be taken into account, when 
interpreting these data. 
The C-CIS group also showed a worse overall survival compared to the other two groups, 
although statistically significant differences were not found. At five years follow-up the 
28
2
overall survival for the total group was 79.6%. This is in concordance with previous 
reports, quoting 5-year survival rates that vary between 67 and 87%11,25,26. 
To provide a risk profile for CIS of the bladder, Hudson et al. suggested a different 
definition of patients with high risk CIS (i.e. diffuse CIS, prostatic urethra involvement, 
overexpression of p53). These patients should undergo radical cystectomy without 
delay in case of BCG failure, whereas those with low risk CIS (i.e. focal CIS, lack of 
overexpression of p53) can be offered bladder preserving therapy13. Furthermore Shariat 
et al. suggested a risk profile for CIS, without concomitant muscle invasive disease, based 
on p21 and p53 expression. In their study progression was defined as development of 
T1 disease or higher. They found that p21 expression is independently associated with 
recurrence and progression, whereas combined p21 and p53 overexpression resulted in 
the poorest recurrence, progression and survival rates27. These results suggest that early 
definitive therapy could be advisable in this poor risk group. 
Hudson and Herr found upper urinary tract tumours in 20% of CIS patients with a median 
interval to recurrence of 38 months (range 6-81)13. Likewise, Solsona et al. reported 
recurrence in the upper urinary tract in 21% of patients with CIS, significantly higher 
than in patients without CIS (2.3%)14.  In comparison, in the present study markedly 
fewer recurrences in the upper urinary tract were seen: in 6.7% of patients. Because our 
analysis is performed in a population based registry, the higher recurrence rates in the 
reports of Solsona et al. and Hudson and Herr may reflect the more aggressive tumour 
biology in patients who are treated in tertiary referral centers13 14.
It is clear that CIS is an entity that requires meticulous treatment and thorough follow-
up because a recurrence rate of 68.9% was found and progression to muscle invasive 
bladder cancer occurred in 18.9% of patients. There were no significant differences 
among the three groups with respect to duration of bladder preservation and 
progression to muscle invasive disease. Nevertheless the C-CIS group appears to have 
a poorer prognosis with a shorter duration of bladder preservation and a worse overall 
survival, although not statistically significant.
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STANDARD LYMPH NODE DISSECTION FOR 
BLADDER CANCER: SIGNIFICANT VARIABILITY 
IN THE NUMBER OF REPORTED LYMPH NODES
J Urol. 2012; 187:446-450
R.P. Meijer, C.J.M. Nunnink, A.E. Wassenaar, A. Bex, H.G. van der Poel, B.W. van Rhijn, 
W. Meinhardt, S. Horenblas
“Not everything that counts can be counted,
and not everything that can be counted counts.”
-Albert Einstein-
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ABSTRACT
Purpose
This study was performed to compare the nodal yield after histopathological examination 
of extended bilateral pelvic lymph node dissection (PLND) specimens for bladder cancer 
in two different hospitals. Surgery in both hospitals was performed by the same four 
staff urologists, using a standardized PLND template. 
Materials and Methods
All consecutive patients with bladder cancer who underwent a PLND in the period 
of 1-1-2007 until 31-12-2009 were included in this study. The specimens were sent 
to pathology in a minimum of 2 packages per side. The two pathology departments 
processed the specimens according to their institutional protocols. 
Results
One hundred seventy four patients were included, with a mean age of 62.7 years. In 
hospital A a mean total of 16 lymph nodes were found after dissection versus a mean of 
28 reported lymph nodes in hospital B (p<0.001). No significant differences were found 
evaluating the number of tumour positive lymph nodes (p=0.65). The mean lymph node 
density for hospital A was 9.3% and for hospital B 3.9% respectively (p=0.056).
Conclusions
Despite equal anatomical clearance by the same experienced surgeons, we report a 
statistically significant difference between two pathology departments evaluating the 
number of lymph nodes after PLND for bladder cancer. Unless standardized methods 
have been agreed upon by pathologists, one should be cautious to use the number of 
reported lymph nodes as an indicator of quality of surgery and to use the lymph node 
density as prognostic factor.
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The value of an extended bilateral pelvic lymph node dissection (PLND) is undisputed in 
the treatment of muscle invasive bladder cancer 1-5. Dhar et al have shown 13% node 
positivity in limited compared to 26% node positivity in extended PLND1. These results, 
as well as anatomical and functional studies, underline the need for extended PLND at 
radical cystectomy to accurately stage these patients3,5. The total number of resected 
lymph nodes is generally acknowledged as an indicator of the quality of surgery6,7. Other 
lymph node parameters have been introduced as prognostic factors, such as the total 
number of tumour positive lymph nodes and the lymph node density (the ratio of positive 
lymph nodes divided by the total number of resected lymph nodes)8-12. Although these 
parameters have been widely accepted in clinical practice, they are very much dependent 
on the evaluation by the pathologist. There have been reports on interobserver variability 
between pathologists in different surgical fields13-19. While it is fairly intuitive to argue 
it all has to do with the surgeons’ and/or pathologists’ commitment, a comparative 
study on lymph node yield after surgery for bladder cancer between different pathology 
departments has not been reported so far. In view of the abovementioned assumptions 
on the value of lymph node yield as an indicator of quality of surgery and prognosis, 
such a comparative study seems important. 
To address this issue the present study was performed. Four staff urologists performed 
surgery for bladder cancer in two different hospitals in Amsterdam, a tertiary referral 
hospital (the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, NKI-AVL) 
and a community hospital (the St Lucas Andreas Hospital, SLAH). While the surgical 
template was equal in both hospitals and has been standardized for almost 10 years, 
examination of the  specimens was done in the two different pathology departments. 
MATERIALS AND METHODS
All consecutive patients with bladder cancer who underwent a bilateral extended pelvic 
lymph node dissection (PLND) in the period of 1-1-2007 until 31-12-2009 were included 
in this study. The patients were initially seen at NKI-AVL and had surgery in either of 
the two hospitals, the NKI-AVL or the SLAH. Surgery in both hospitals was performed 
by the same four staff urologists, using an PLND template that was standardized 
almost 10 years ago. The PLND consisted of removal of all lymph nodes in the region 
between: the genito-femoral nerve, the obturator fossa, along the internal iliac artery 
and along the common iliac artery up to the crossing of the ureter. The specimens 
were sent to pathology in a minimum of 2 packages per side (i.e. separate packages for 
the various anatomical regions). The total number of nodal packages was determined 
by each individual surgeon during surgery. Patient and tumour characteristics were 
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collected prospectively in a database from the time of surgery. Some patients did receive 
neoadjuvant chemotherapy prior to surgery, depending on their primary clinical staging. 
The two pathology departments routinely processed the specimens according to their 
institutional protocols. Neither of the two pathology departments had a dedicated 
genitourinary pathologist for the evaluation of the specimens. The detailed method of 
assessment of the lymph nodes in hospital A was as follows: all specimens are fixed 
overnight in formalin. The fat is searched by palpation and scalpel for separate lymph 
nodes by dedicated pathology assistants. Small nodes are submitted as a single piece. 
Larger nodes are bisected and, if necessary, further sectioned. The number of lymph 
nodes submitted in each cassette is reported. The detailed method of assessment in 
hospital B was as follows: fresh or after overnight formalin fixation the nodes were 
found by gently “squashing” the fat with one finger and dissected from the perinodal 
fat. Small uncut lymph nodes were grouped into one cassette. A large lymph node 
was sectioned and put in one or more cassette(s). Sectioned lymph nodes were not 
combined in one cassette. The number of nodes in each cassette was noted so that the 
number of involved nodes could be counted accurately on the glass slide.
The independent samples T-test was used to compare the mean numbers of lymph 
nodes. Furthermore boxplots were created to visualize the differences. Statistical 
significance was defined as a p value <0.05. Data documentation and analysis was 
performed with Statistical Package for Social Sciences (SPSS), version 15.0 for Windows.
RESULTS
In the period of January 2007 until December 2009 one hundred seventy-four patients 
underwent PLND for bladder cancer, with a mean age of 62.7 years. The patient and 
tumour characteristics per hospital are shown in table 1 and 2. No statistically significant 
differences were found between the two hospitals. 
In hospital A, a mean total of 16 lymph nodes were identified after dissection versus a 
mean of 28 reported lymph nodes in hospital B. These results are shown in figure 1. The 
difference in number of reported lymph nodes between the two locations is statistically 
significant (p<0.001). 
All four surgeons had a higher mean lymph node yield in hospital B compared to hospital 
A. We also found statistically significant differences in the mean number of reported 
lymph nodes among the four urologists, despite the standardized surgical template 
(p<0.05). These differences were most apparent in hospital B. The number of lymph 
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3node dissections per surgeon and their lymph node yield are shown in table 3. When 
the mean lymph node yield per individual surgeon in both hospitals was compared, the 
differences between the two locations were also statistically significant (figure 2).
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Table 1. Patient characteristics
N %
Gender Male 136 78.2
Female 38 21.8
Tumour stage Ta 3 1.7
CIS 6 3.4
T1 27 15.5
T2 78 44.8
T3 36 20.7
T4 24 13.8
Lymph node stage N0 150 86.2
N1 12 6.9
N2 10 5.7
N3 2 1.1
Neoadjuvant Chemotherapy Yes 31 17.8
No 143 82.2
Location of Surgery Hospital A 123 70.7
Hospital B 51 29.3
Abbreviations: CIS = Carcinoma in situ
Figure 1: Lymph node yield per hospital In hospital A, a mean total of 16 lymph nodes were identified after 
dissection versus a mean of 28 reported lymph nodes in hospital B (p<0.001).
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Figure 2: Lymph node yield per surgeon All four surgeons had a higher mean lymph node yield in hospital 
B compared to hospital A. We also found statistically significant differences in the mean number of reported 
lymph nodes among the four urologists, despite the standardized surgical template (p<0.05) (table 3).
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Table 2. Tumour characteristics
Hospital A Hospital B p-value
N % N %
Neoadjuvant Chemotherapy Yes 24 19.5 7 13.7
0.37
No 99 80.5 44 86.3
T-stage before surgery  (cT) <T3 78 63.4 36 70.6
0.39
T3-T4 45 36.6 15 29.4
N-stage before surgery (cN) N0 104 84.6 46 90.2
0.48
N1 9 7.3 3 5.9
N2 9 7.3 1 2.0
N3 1 0.8 1 2.0
T-stage at pathology (pT) T0 28 22.8 8 15.7
0.35<T3 41 33.3 16 31.4
T3-T4 54 43.9 27 52.9
N-stage at pathology (pN) N0 81 65.9 38 74.5
0.14
N1 12 9.8 8 15.7
N2 27 22.0 4 7.8
N3 3 2.4 1 2.0
Abbreviations: T-stage = Tumour stage; N-stage = Lymph node stage
3When evaluating the number of tumour positive lymph nodes between the two 
locations, no significant differences were found (p=0.65). The mean number of tumour 
positive lymph nodes was 1.51 in hospital A and 1.20 in hospital B respectively. For the 
total group the mean lymph node density was 7.8%. The mean lymph node density for 
hospital A was 9.3% and for hospital B 3.9% respectively. The difference in lymph node 
density between the two locations was almost statistically significant (p=0.056). There 
was no statistically significant difference considering lymph node positive cases only 
(p=0.13).
Thirty-one patients received neoadjuvant chemotherapy before PLND. The distribution 
of these patients over both hospitals is shown in table 2. The differences in lymph node 
yield between the two hospitals were similar for these patients as compared to the total 
group (data not shown). 
DISCUSSION
The present study shows a significant difference in the total number of reported lymph 
nodes after PLND for bladder cancer between two pathology departments of two 
hospitals, despite standard templates by experienced surgeons and similar presentation 
of the specimens to the participating pathology departments. 
In the past years the number of resected lymph nodes has evolved as a surrogate for 
surgical expertise. A minimum of 10 nodes was seen as the hallmark of well performed 
PLND for bladder cancer14. Fortunately the focus has moved to the anatomical region 
as leading criterion5,20. The present series shows a variable number of reported lymph 
nodes, despite the fact that the number of positive nodes did not differ between the 
two hospitals. 
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Table 3. Lymph node dissections per surgeon
Location N Mean lymph node yield p-value
Surgeon I Hospital A 40 18 <0.001
Hospital B 17 33
Surgeon II Hospital A 41 14 <0.001
Hospital B 9 29
Surgeon III Hospital A 25 15 <0.001
Hospital B 8 33
Surgeon IV Hospital A 15 12 0.03
Hospital B 16 20
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How can these differences be explained? Bochner et al. already demonstrated 
an important variability in histopathological evaluation depending on the way of 
presentation of the surgical specimen: a significant higher lymph node yield was seen 
with the resected specimen delivered in separate packages compared to en bloc 
submission21,22. Another possible explanation may lie in differences in the workup of the 
surgical specimen by the pathology departments. During this workup, the lymph nodes 
are being separated from the perinodal fat, despite the fact that it may be difficult to 
distinguish fatty lymph nodes from adipose tissue. There may be a discrepancy in the 
management of inclusion of tissue samples in separate cassettes for evaluation. Thus 
when several samples are combined in one cassette, this may reduce the total number of 
lymph nodes. Close collaboration between the surgeon and the pathologist may improve 
the histopathological evaluation. Another cause may be found in a higher variation of 
pathologist’s assistants or residents. A dedicated pathologist with expertise in urological 
pathology may improve the final evaluation of the specimens. Lopez-Beltran et al. 
proposed a standardization of the histopathological handling and pathology reporting 
in urological samples23. Such standardization clearly is of the utmost importance. 
Despite the standardized surgical template statistically significant differences were 
also found in the lymph node yield among the four surgeons. These differences may 
reflect variation in thoroughness of surgical clearance during the lymph node dissection. 
Notwithstanding these differences, all four urologists meet the international standard 
of 10 lymph nodes for a PLND. When the mean number of reported lymph nodes per 
surgeon in both hospitals was compared, the differences between the two locations 
remained statistically significant for all four urologists. 
Furthermore the present results show that the total number of lymph nodes reported 
by the pathologist is more susceptible to variation than the number of tumour positive 
lymph nodes found. This discrepancy influences the lymph node density rate directly, 
thus rendering the lymph node density subject to variability as well. Similar results were 
presented by Stein et al. who also found a lower total lymph node yield and consequently 
a higher lymph node density when the surgical specimen was submitted en bloc 22. In 
contrast Evans et al. reported on the lymph node yield in colorectal cancer. In their series 
they did find a higher number of tumour positive lymph nodes in cases with a higher 
overall lymph node yield18.
CONCLUSIONS
Despite equal anatomical clearance by the same experienced surgeons, we report a 
statistically significant difference between two pathology departments evaluating 
40
3the number of lymph nodes after PLND for bladder cancer. No statistically significant 
difference was found in the number of tumour positive lymph nodes. Clearly, next to 
a thorough anatomic surgical procedure, a standardized histopathological evaluation 
is of utmost importance. Unless standardized methods have been agreed upon by 
pathologists, one should be cautious to use the number of reported lymph nodes as 
an indicator of the quality of surgery and to use the lymph node density as prognostic 
factor.
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DIFFERENCES IN HISTOPATHOLOGICAL 
EVALUATION OF STANDARD LYMPH NODE 
DISSECTIONS RESULT IN DIFFERENCES IN 
NODAL COUNT BUT NOT IN SURVIVAL
World J Urol. 2012 Aug 9; Epub ahead of print
L.S. Mertens, R.P. Meijer, E. van Werkhoven, A. Bex, H.G. van der Poel, B.W. van Rhijn, 
W. Meinhardt, S. Horenblas
“Ignorance is a steep hill with perilous rocks at the bottom.”
-Raisuli [The wind and the lion]-
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ABSTRACT
Objective
To analyze whether the reported differences in nodal yield at pelvic lymph node 
dissections (PLND) for bladder cancer, between two hospitals, are reflected in the 
survival rates. 
Patients and methods
We assessed follow-up data of all 174 patients (mean age: 62.7, median follow up: 
3 years) who underwent PLND between 1 January 2007 and 31 December 2009 at 
two different hospitals. PLND was performed according to a standardized template by 
the same urologists for comparable bladder cancer patients. Mean number of reported 
lymph nodes was 16 at hospital A versus 28 at hospital B. We compared the overall 
survival (OS), disease specific survival (DSS) and recurrence free survival (RFS) between 
both cohorts and performed a multivariate analysis.
Results
The cumulative probability for 2-years OS, DSS and RFS for hospital A are 61%, 64% 
and 54%, versus 58%, 58% and 53% for hospital B respectively. Kaplan-Meier survival 
curves did not reveal statistically significant differences between both groups (OS: p 
log-rank=0.75, DSS: p log-rank=0.56, and RFS: p log-rank=0.80). Also after adjustment 
for pT-stage and neoadjuvant chemotherapy, survival was not significantly different 
between hospital A and hospital B. 
Conclusion
Despite differences in lymph node yield in PLND specimens, this study reveals no 
significant differences in survival outcomes between both hospitals. Standardized 
histopathological methods should be agreed upon by pathologists before integrating 
nodal yield and subsequent lymph node density as indicators of the quality of surgery 
and as prognostic factors.
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3INTRODUCTION
The value of bilateral pelvic lymph node dissection (PLND) in the treatment of muscle-
invasive bladder cancer is well-established1-3. Multiple reports demonstrate that an 
increased number of lymph nodes removed is associated with improved survival1,4,5. 
In addition, the lymph node density (ratio of tumour positive lymph nodes to the total 
number of nodes) is suggested to be prognostically relevant6-10. 
 
Meijer et al. carried out a study demonstrating a significant difference between 
two pathology departments evaluating the number of resected lymph nodes in 
PLND specimens (hospital A: 16 versus hospital B: 28, p<0.001), although PLND was 
performed according to a standardized template by the same urologists. The difference 
in lymph node density tended towards significance (hospital A: 9.3 versus hospital 
B: 3.9, p=0.056). The number of tumour positive lymph nodes was not statistically 
different among both groups11, illustrating that the individual pathology department 
methodology influences the number of reported lymph nodes. 
 
Are these differences in nodal yield prognostically relevant? Although thorough 
anatomical dissection is considered more important than total lymph node count12,13, 
this has not been investigated in a setting in which patient and surgery related differences 
were minimized by using the same urologists to perform surgery on comparable groups 
of patients. The cohorts of bladder cancer patients described by Meijer et al. provide this 
opportunity. In this study, we analyze whether the reported differences in nodal yield 
between both groups are reflected in the survival rates. 
 
PATIENTS AND METHODS
Patients. The present study utilized follow-up data of all consecutive patients who 
underwent radical cystectomy (RC) and PLND between 1 January 2007 and 31 
December 2009 at either hospital A (The Netherlands Cancer Institute – Antoni van 
Leeuwenhoek Hospital, Amsterdam, The Netherlands) or hospital B (St Lucas Andreas 
Hospital, Amsterdam, The Netherlands). A total of 174 patients were identified, with a 
mean age of 62.7 years (standard deviation; SD: 11.1). The patients were initially seen at 
hospital A and had surgery at either of the two hospitals, hospital A (n=123) or hospital 
B (n=51). 
 
Patient and tumour characteristics of the patients treated in hospital A and B , as well 
as the reported nodal parameters are displayed in table 1. Some patients received 
induction chemotherapy prior to surgery, depending on their primary clinical staging. A 
Standard lymph node dissection for bladder cancer
47
chapter 3b
cystectomy was performed immediately at the time of PLND or delayed, after induction 
chemotherapy, indicated by pre- or perioperative detection of  gross lymph node 
involvement. Except for the reported differences in nodal yield and lymph node density, 
there were no statistically significant differences in patient and tumour characteristics 
between both groups (table 1).
Table 1. Patient and tumour characteristics of the patients in Hospital A versus Hospital B and reported nodal 
parameters of both groups 
Hospital A 
N=123
Hospital B 
N=51
p-value
N (%) N (%)
Age (Mean ± SD) 63.3 ± 11.5 61.4 ± 9.9 0.30
Neoadjuvant Chemotherapy Yes 24 (19) 7 (14) 0.37
No 99 (81) 44 (86)
T-stage before surgery  (cT) <T3 78 (63) 36 (71) 0.39
T3-T4 45 (37) 15 (29)
N-stage before surgery (cN) N0 104 (85) 46 (90) 0.48
N1 9 (7) 3 (6)
N2 9 (7) 1 (2)
N3 1 (1) 1 (2)
T-stage at pathology (pT) T0 28 (23) 8 (6) 0.35
<T3 41 (33) 16 (31)
T3-T4 54 (44) 27 (53)
N-stage at pathology (pN) N0 81 (66) 38 (74) 0.14
N1 12 (10) 8 (16)
N2 27 (22) 4 (8)
N3 3 (2) 1 (2)
Number of lymph nodes 16 28 <0.001
Lymph node density (%) 9.3 3.9 0.056
Abbreviations: T-stage = Tumour stage; N-stage = Lymph node stage
Surgical template. Surgery in both hospitals was performed by the same 4 urologists 
according to a standard surgical template. The PLND consisted of removal of all lymph 
nodes in the region between: the genito-femoral nerve, the obturator fossa, along 
the internal iliac artery and along the common iliac artery up to the crossing of the 
ureter.  
 
Histopathological evaluation. The specimens were sent to pathology in a minimum 
of 2 packages per side (separate packages for the various anatomical regions). The 
pathology departments handled the specimens according to their institutional guidelines. 
Neither of the two pathology departments had a dedicated genitourinary pathologist 
for the evaluation of the specimens.
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3Hospital A. All PLND specimens were fixed over night in formalin. The perinodal adipose 
tissue was searched for lymph nodes by dedicated pathology assistants. They palpated 
the tissue while sweeping strokes of the scalpel were made. All grossly identifiable nodes 
were submitted for examination. The larger nodes were bisected and, if necessary, 
further sectioned. Small nodes were submitted as a single piece. The number of lymph 
nodes submitted in each cassette was reported. 
Hospital B. Histopathological evaluation of the PLND specimens in hospital B was 
according to the following pattern: fresh or after over night formalin fixation, the lymph 
nodes were searched by gently “squashing” the perinodal adipose tissue with one finger. 
The lymph nodes identified were then singly dissected from the perinodal fat. Large 
lymph nodes were sectioned and put in one or more cassette(s). Sectioned lymph nodes 
were not combined in one cassette. Small uncut lymph nodes were submitted grouped 
into one cassette. The number of nodes in each cassette was noted so that the number 
of involved nodes could be counted accurately on the glass slide.
Follow up. Follow up data on the cohort were collected from the patients’ charts. The 
median follow up was 3 years. We performed survival analyses and compared survival 
outcomes between both hospitals. Overall survival (OS), disease specific survival (DSS) 
and recurrence free survival (RFS) were analysed. 
Statistics. OS was defined as the time from PLND to any cause of death. DSS was 
defined as the time from PLND to the time of death due to bladder cancer, metastases 
of bladder cancer or treatment-related complications. RFS was defined as time from 
PLND to any local or distant recurrence. Data for patients without events of interest 
(death or recurrence) were censored at the date of last follow up visit. The Kaplan-
Meier method was used to generate actuarial survival curves. Kaplan-Meier curves were 
compared using the log-rank test. 
 
Cox proportional-hazards analysis for OS, DSS and RFS was performed. First, Cox 
models were used to calculate the hazard ratio between the two hospitals adjusted 
only for pT-stage and neo-adjuvant chemotherapy. No variables directly related to lymph 
node yield were included here, because if the difference in lymph node yield would 
be a prognostic factor, such variables might diminish the difference between the two 
hospitals. Then, in each analysis, pT-stage, neo-adjuvant chemotherapy, hospital, lymph 
node density, and total lymph node yield were entered into the model, along with the 
pair wise interactions between hospital and lymph node density, and between hospital 
and lymph node yield. Since a test for assessing both interactions simultaneously was 
decisively non-significant, the interactions were left out in the models reported below. 
Standard lymph node dissection for bladder cancer
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All data analysis was performed with Statistical Package for Social Sciences (SPSS), 
version 17.0 for Windows and R version 2.14.1. All reported p values are 2-sided, and 
significance was set at p<0.05. 
RESULTS
The median follow up was 3 years (range 24-48 months). Of all 174 patients, 78 (44.8%) 
died during follow-up; 73 (42%) developed a recurrence. Of the 123 patients treated at 
hospital A, 45 (43.9%) died during follow-up and 50 (40.7%) developed local or distant 
recurrence. Twenty-four of the 51 patients treated at hospital B died during follow up 
(47.1%) and 23 (45.1%) developed recurrent disease. The cumulative probability for 
2-years OS, DSS and RFS for both groups are displayed in table 2.
  
Table 2. Cumulative probability for 2-years survival (OS, DSS, RFS) 
Hospital A
 (95% CI)
Hospital B 
(95% CI)
p-value
(log-rank)
Overall survival 61% (52%–70%) 58% (46%–74%) 0.75
Disease specific survival 64% (55%–73%) 58% (46%–74%) 0.56
Recurrence free survival 54% (46%–64%) 53% (41%-69%) 0.80
Abbreviations: CI = 95% confidence intervals
Figure 1: Overall survival Hospital A versus Hospital B (p=0.75)
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3No statistically significant differences are seen for OS, DSS and RFS (OS: p log-rank=0.75, 
DSS: p log-rank=0.56, and RFS: p log-rank=0.80). Kaplan-Meier survival curves of OS 
and RFS of both groups are shown in figure 1and 2.
Lymph node density showed to be an independent prognostic factor for each hospital 
(HR: 1.29 (95% CI, 1.13-1.46), p=0.0001). In the multivariable models, none of the 
interactions with surgery location were significant (OS p=0.67, DSS p=0.73, and RFS 
p=0.86). 
DISCUSSION
In this study we analysed follow up data of two groups of patients with bladder cancer, 
who were treated in two different hospitals with differences in the number of reported 
lymph nodes and lymph node density. The differences in nodal yield and lymph node 
density between both hospitals are not reflected in survival differences between 
the groups, even when adjusted for pT-stage and the administration of neoadjuvant 
chemotherapy. We demonstrate that no interactions with surgery location were found, 
indicating that the associations between lymph node yield, density and survival outcomes 
were similar for the two hospitals in this cohort. Although no definite conclusion can 
be drawn from the absence of significance in this relatively small study, with quite a 
difference in the number of cases done between the 2 hospitals (hospital A: 123 versus 
Figure 2: Recurrence free survival Hospital A versus Hospital B (p=0.80)
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hospital B: 51), these results suggest that one could call into question the use of lymph 
node yield as a prognosticator. 
 
Some consider lymph node density to be superior to TNM nodal status in predicting 
disease-specific survival after radical cystectomy for bladder cancer14,15. However, lymph 
node density is directly derived from the number of reported lymph nodes and thus also 
subject to variation between pathologists. Most of the studies evaluating the lymph 
node density as a prognostic factor were performed in a single-centre design, with 
one pathology department assessing all specimens, with patient and surgery related 
confounding factors (different surgical templates and urologists or dissimilar patient 
groups). In this study, patient and surgery related differences between the groups were 
minimized by using the same four staff urologists to perform surgery on two comparable 
groups of patients. 
 
Despite the standardized surgical template, Meijer et al. found statistically significant 
differences in the mean number of reported lymph nodes among the four urologists. 
However, all four surgeons had a statistically significant higher mean lymph node yield 
in hospital B compared to hospital A11. Although a possible “surgeon effect” cannot 
be completely eliminated, the major difference between the two groups remains the 
pathology department evaluating the specimens.
 
What are the possible differences between the two histopathological evaluation 
techniques used? First, the number of reported lymph nodes in PLND specimens is 
highly dependent upon pathological evaluation and the individual pathology department 
methodology16,17. Reasons are the differences in the procedures that involve specimen 
handling in the histopathology laboratory. These procedures include collecting, 
identifying, labelling and evaluating tissue. Regarding tissue collection, a significant 
higher number of lymph nodes is identified with the resected specimen delivered to 
the pathology department in separate packages compared to en bloc submission16,17. 
Therefore all specimens were delivered to the pathology department in at least two 
packages per side, in both hospitals. 
 
Second, skills and carefulness of the pathology assistants identifying lymph nodes within 
the adipose tissue might contribute to the differences in nodal yield. Although there are 
currently no established guidelines for handling PLND specimens, it is recognized that 
all grossly identifiable lymph nodes should be submitted for histological examination18. 
Pelvic nodes are often extensively replaced by adipose tissue, leaving only a small 
residual rim of lymphoid tissue, and estimation of node numbers in PLND specimens 
is difficult19. Searching for lymphoid tissue in perinodal adipose tissue was left to 
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3institutional discretion and the thoroughness of this harvest appeared different between 
the 2 hospitals. 
 
There might also be a discrepancy in the management of inclusion of tissue samples in 
separate cassettes for evaluation: When several samples are combined in one cassette, 
without adequately labelling this, the total number of lymph nodes might be reduced. In 
hospital B, sectioned lymph nodes were not combined in one cassette.
Finally, evaluation of the specimens might be influenced by institutional policies and/
or the experience and dedication of the pathologist. Fang et al. assessed the impact 
of an institutional policy requiring a minimum number of lymph nodes at PLND for 
RC. A policy was established that at least 16 lymph nodes needed to be dissected and 
examined, for the specimen to be considered adequately evaluated. The lymph node 
positivity rates did not change significantly, but the proportion of patients with lymph 
node density <20% increased from 43.9% to 65.5% (p=0.04)20. Thorough evaluation 
of PLND specimens obtained at RC can thus be influenced by an institutional policy 
mandating a minimum number of lymph nodes. This could lead to greater confidence 
in pathologic staging and reliability of prognostic indicators, i.e. the nodal yield and 
lymph node density. Such a policy was not employed in either of the 2 hospitals in this 
study. And neither of the two pathology departments in this study had a dedicated 
genitourinary pathologist for the evaluation of the specimens. 
Taken together, differences between the two histopathological evaluation techniques 
in both hospitals seem to be based on the manner of identifying lymph nodes from the 
perinodal adipose tissue and submitting (sectioned) lymph nodes in cassettes. 
 
Clearly, next to a thorough anatomic surgical procedure, a standardized histopathological 
evaluation is of utmost importance. No consensus has yet been achieved on optimal 
histopathological evaluation of urological tumours21. Meijer’s series shows a variable 
number of reported lymph nodes, despite the fact that the number of positive nodes 
did not differ between the two hospitals11. It may be more difficult to distinguish small 
fatty lymph nodes from adipose tissue. On the other hand, the total lymph node count, 
including all macroscopically unsuspected lymph nodes, might be considered clinically 
less important than the number of tumour positive lymph nodes, by the pathology 
departments. 
 
Recently, the focus has been moving from total number of lymph nodes to the 
anatomical region as leading criterion3,22. Previous studies compared the distribution of 
lymph node metastases in a multi-institution cohort of patients undergoing PLND. They 
describe that, despite the same standard surgical template, the number of lymph nodes 
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identified may vary among institutions. Adherence to meticulous dissection technique 
within an extended template is likely to be more important than total lymph node count 
for achieving optimal oncologic outcomes12,13. These results are in accordance with our 
findings in this series of bladder cancer patients, treated in a setting in which patient 
and surgery related differences were minimized, as the difference in the number of 
reported lymph nodes and lymph node density between hospital A and B, were not 
reflected in survival differences between both hospitals. 
CONCLUSION
In conclusion, although the lymph node density has been shown to have prognostic 
value, institutional differences in the number of identified lymph nodes complicate 
the use of absolute lymph node count and lymph node density cut-offs for bladder 
cancer prognosis. Standardized histopathological methods should be agreed upon 
by pathologists, before integrating nodal yield and absolute lymph node density as 
indicators of the quality of surgery and as prognostic factors.
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BLADDER CANCER: A SINGLE INSTITUTION 
EXPERIENCE
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“If you are going through hell, keep going.”
-Winston Churchill-
chapter 4
ABSTRACT
Aim
To evaluate the outcome of patients with locally advanced muscle-invasive and/or lymph 
node positive bladder cancer treated with induction chemotherapy and additional 
surgery. 
Methods
All patients who were treated with induction chemotherapy in our institution between 
1990 and 2010, were retrospectively evaluated using an institutional database. Induction 
chemotherapy consisted of methotrexate, vinblastine, doxorubicin and cisplatin (MVAC), 
or a combination of gemcitabin with either cisplatin or carboplatin (GC). 
Results
In total 152 patients were identified, with a mean age of 59 years (range 31-76). One 
hundred and seven patients (70.4%) received MVAC, 35 patients received GC (23.0%) 
and 10 patients received GC after initial treatment with MVAC (6.6%). Median follow-
up was 68 months (range 4-187 months). Overall 125 patients (82.2%) underwent 
cystectomy, whereas 12 patients (7.9%) received radiotherapy. Fifteen patients had 
no local treatment. Median overall survival was 18 months (95%CI 15–23 months). In 
37.5% of patients with complete clinical response, residual disease was found at surgery 
(negative predictive value, NPV 62.5%). Complete pathological response was seen in 
26.3% of patients, with a 5 year overall survival (OS) estimate of 54% (39%–74%). For 
patients with persisting node positive disease after induction chemotherapy and surgery 
OS was significantly worse (p<0.0001). 
Conclusions
Complete clinical and/or pathological response to induction chemotherapy results in 
a significant survival benefit. The accuracy of the current clinical response evaluation 
after induction chemotherapy is limited. Although surgery may be important for staging 
and prognostic purposes, its role is unclear in node positive disease after induction 
chemotherapy. 
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Muscle-invasive bladder cancer is a serious disease that, despite meticulous and 
timely therapy, consisting of bilateral pelvic lymph node dissection (PLND) and radical 
cystectomy, results in a poor prognosis with a reported 5-years overall survival ranging 
from 36% to 62% 1-4. For patients presenting with lymph node (LN) metastases or locally 
advanced disease (T3-T4) the prognosis is even worse, with 5-years survival data ranging 
from 26% to 38%3,5. For locally advanced patients, this poor outcome is probably due 
to under staging of the LN status and/or occult micro-metastases at the time of first 
diagnosis6. In clinically LN negative (cN0) patients with locally advanced disease (T3-4), 
LN metastases may be found in up to 34% of cases at the time of surgery7.
Systemic treatment with cisplatin-based combination chemotherapy has been shown 
to improve the outcome of patients presenting with locally advanced muscle-invasive 
bladder cancer, albeit at best a 6.5% increase in overall survival at 5-years follow-up 8-14. 
The response to neoadjuvant chemotherapy is an important predictive factor, as patients 
who, at the time of cystectomy, have non-muscle invasive bladder cancer (<pT2) and 
patients without residual bladder cancer (pT0) have a more favourable prognosis up to 
a 5-years survival rate of 69% versus 26% for patients with persistent muscle-invasive 
bladder cancer 15-19. Nevertheless, little is known on the prognostic impact of persisting 
LN metastases after induction chemotherapy. 
Patients presenting at our institute with locally advanced (T3-T4) and/or LN positive 
bladder cancer, who were eligible for surgery have been considered for induction 
cisplatin-based combination chemotherapy since 1990. We analysed the outcome of all 
patients that were treated with this strategy in our institution over the past years. 
PATIENTS AND METHODS
Patients. All patients with locally advanced muscle-invasive bladder cancer (≥T3) and/
or LN positive disease (≥N1), who were treated with at least two cycles of induction 
chemotherapy, and were scheduled for surgery between 1990 and 2010, were identified 
from an institutional bladder cancer database. These patients were all discussed in 
multidisciplinary meetings with representatives from the departments of urology, 
medical oncology, pathology, radiation oncology and radiology. All patients were 
included in this study, also patients who were scheduled for surgery after induction 
chemotherapy but who were not operated due to poor condition, irresectable disease 
or refusal. Patients who refused surgery following induction chemotherapy went on to 
receive either curative radiotherapy or follow-up. 
Induction chemotherapy and surgery in non-organ confined bladder cancer
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Comorbidity was scored using the Charlson comorbidity index, excluding the index 
factor (bladder cancer) 20,21. A Charlson index of less than two, was considered minor 
comorbidity, whereas two or more was considered major comorbidity. 
Staging. Staging was done according to the 2009 TNM-classification, with clinical 
staging pre- and post-chemotherapy based on abdominal CT-scans, chest X-ray, urethro-
cystoscopy and pathological staging after surgery22. Prior to induction chemotherapy, 
LN status was confirmed either by imaging alone (unequivoval lymphadenopathy on 
CT-scan), by imaging in combination with fine-needle aspiration (FNA) or by PLND. Until 
2000 this PLND consisted of removal of all lymph nodes in the region between: medial 
side of the external iliac artery, the obturator fossa, up to the bifurcation of the common 
iliac artery. This was replaced by an enlarged template PLND consisting of removal of all 
lymph nodes in the region between: the genito-femoral nerve, the obturator fossa, along 
the internal iliac artery and along the common iliac artery up to the crossing of the ureter 
or the bifurcation of the aorta. As a rule, all lymph nodes that were clinically suspect 
before chemotherapy were completely removed during post-chemotherapy surgery. 
Thus, in cases with supraregional (retroperitoneal) LN pathology (cM1), a complete 
retroperitoneal lymph node dissection was done after chemotherapy. Generally, the 
surgery was performed within 6 weeks after the final course of chemotherapy. 
Chemotherapy. Induction chemotherapy consisted of a cisplatin-based regimen, being 
either methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) or gemcitabine 
with cisplatin (Gem/Cis). Patients who were considered unfit to receive cisplatin-based 
combination chemotherapy based on impaired renal function, comorbidity or low 
performance status received gemcitabine with carboplatin (Gem/Carbo)23. The patients 
who were treated with MVAC, received either a classic or a high-dose-intensity schedule 
(HD-MVAC), as described by Nieuwenhuijzen et al.24. Toxicity was graded according to 
the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events 
(CTCAE) classification, version 4.0. Evaluation of the clinical response to chemotherapy 
was done by imaging (i.e. abdominal CT-scan) and urethro-cystoscopy after two cycles 
of chemotherapy. Complete response (CR) was defined as no evidence of disease, partial 
response (PR) as any downstaging with persisting evidence of disease, stable disease 
(SD) as no change in tumour burden and progressive disease (PD) as any increase in 
tumour burden (being local and/or lymphadenopathy). In patients with stable disease 
or response another 2 cycles of chemotherapy was added after which renewed staging 
was done, followed by consolidating therapy. In case of progressive disease (PD) the 
chemotherapy was ceased and the patient was evaluated for further therapy (i.e. 
surgery, radiotherapy or palliation only). 
60
4Statistics. Recurrence rates, recurrence free survival (RFS) and overall survival (OS) were 
analysed using the Kaplan-Meier method. Overall survival was defined as the time from 
start of induction chemotherapy to any cause of death: patients who were alive at the 
end of follow-up were censored at that date. Recurrence was defined as first relapse 
of disease, either loco-regional or distant. Recurrence free survival was defined as the 
time from start of induction chemotherapy until first recurrence or death. Loco-regional 
recurrence was defined as relapse in the pelvic region (i.e. iliac fossa, bladder, vagina, 
pelvic mass). Patients with concomitant loco-regional and distant recurrences were 
analysed as distant metastases. Kaplan-Meier curves were compared using the log 
rank test. Multivariable regression analysis was performed including the following 
parameters: age, clinical stage, clinical and pathological response to chemotherapy and 
LN stage after chemotherapy. Statistical significance was defined as a p value < 0.05. 
Data analysis was performed with Statistical Package for Social Sciences (SPSS), version 
15.0 for Windows and R version 2.13.1. 
RESULTS 
Clinical features. In total 152 patients were retrieved from an institutional bladder 
cancer database of 817 patients. Mean age was 59 years (range 31-76). One hundred 
seventeen of these patients (77.0%) received MVAC, 22 patients (14.5%) Gem/Carbo 
and 13 patients (8.6%) Gem/Cis treatment primarily. Ten patients switched from MVAC 
to either Gem/Carbo or Gem/Cis because of toxicity or renal insufficiency. Overall a 
median of 4 courses of chemotherapy was administered. In 25 patients (16.4%) the 
chemotherapy was discontinued due to drug related toxicity: febrile neutropenia (N=8), 
mucositis (N=2), renal insufficiency (N=8), malaise/fatigue (N=5), hearing impairment 
(N=2). Median follow-up was 68 months (range 4-187 months). Patient characteristics 
are shown in table 1. Overall 125 patients (82.2%) underwent cystectomy, whereas 12 
patients (7.9%) received radiotherapy. In 15 patients (9.9%) there was no additional 
treatment for various reasons, being: irresectable disease on exploratory laparotomy, 
inoperability due to comorbidity or extensive progression of disease despite 
chemotherapy. 
Recurrences. Recurrence of disease was seen in 95 patients (62.5%), with a median 
recurrence free interval of 15 months (95%CI 13–17 months). Primary recurrence in the 
urethra was seen in three patients (2.0%). Primary loco-regional recurrence was seen in 
13.8% of patients, whereas primary distant recurrence occurred in 46.7% of patients. 
Survival analysis. Median OS for all patients was 18 months (95%CI 15–23 months), and 
5-years OS 27.2% (95%CI 20.5%–36.3%). The survival curves according to clinical and 
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pathological response are shown in figures 1 and 2. Patients with limited supraregional 
(retroperitoneal) LN involvement (TxNxM1; N=25) showed a median OS of 13 months 
(95%CI 10–28 months)  and a 5-years OS of 19.2% (95%CI 8.4%–43.8%), which is 
comparable to patients with locally advanced disease and regional LN metastases 
(T3-4N1-3M0; N=49), with a median OS of 17 months (95%CI 10–30 months)  and a 
5-years OS of 21.5% (95%CI 12.1%–38.1%) respectively (p=0.52). From the patients with 
a complete clinical response (CR), a complete pathological response (pCR) was found in 
62.5% and a partial pathological response (pPR) in 22.9%. The negative predictive value 
(NPV) of response evaluation based on clinical staging was 62.5% (95% CI 47%–76%). 
For patients with clinically node negative disease after chemotherapy (ycN0; N=117), 
Table 1. Patient characteristics
N %
Gender Male 117 77.0
Female 35 23.0
Charlson Comorbidity Index Minor comorbidity (<2) 137 90.1
Major comorbidity (≥2) 15 9.9
Clinical Tumour stage T1 7 4.6
T2 46 30.3
T3 43 28.3
T4 56 36.8
Clinical Lymph Node stage N0 37 24.3
N1 40 26.3
N2 72 47.4
N3 3 2.0
Retroperitoneal Lymphadenopathy No 127 83.6
Yes 25 16.4
Histo-pathology Urothelial carcinoma 145 95.4
Adenocarcinoma† 3 2.0
Squamous cell carcinoma† 2 1.3
Small cell carcinoma† 1 0.7
Sarcomatoid carcinoma† 1 0.7
Tumour Grade G2 7 4.6
G3 145 95.4
Modality Nodal Stage Confirmation Imaging 52 34.2
Imaging + FNA 34 22.4
PLND 66 43.4
Chemotherapy Regimen Classic MVAC 46 30.3
HD-MVAC 71 46.7
Gem/Cis 14 9.2
Gem/Carbo 31 20.4
Local Therapy RC 125 82.2
EBRT 12 7.9
None 15 9.9
Abbreviations: FNA = fine needle aspiration; PLND = pelvic lymph node dissection; RC = radical cystectomy; 
EBRT = external beam radiotherapy † Mixture of specific subtype and urothelial carcinoma 
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Figure 1. Kaplan-Meier analysis for OS according to clinical response after induction chemotherapy. Complete 
clinical response (CR) to chemotherapy was seen in 31.6% of patients, partial response (PR) in 52.0%, stable 
disease (SD) in 7.9% and progressive disease (PD) in 8.6%. Median OS was 49 months for CR, 17 months for 
PR, 10 months for SD and 8 months for PD. The 5-years OS was 43.9% for CR and 25.3% for PR (p<0.0001).
Figure 2. Kaplan-Meier analysis for OS according to pathological response following induction chemotherapy. 
Complete pathological response (pCR) was seen in 26.3% of patients, partial reponse (pPR) in 28.9%, stable 
disease (pSD) in 23.7% and progressive disease (pPD) in 10.5%. Median OS was 74 months for pCR, 22 months 
for pPR, 15 months for pSD and 10 months for pPD respectively. The 5-years OS was 53.8% for pCR and 33.4% 
for pPR (P<0.0001). Patients with pSD performed significantly better than those with pPD (p=0.006). Patients 
with pPD, who underwent cystectomy had similar OS compared to the patients who were not operated (i.e. 
pathological response not evaluable) (p=0.85).
Induction chemotherapy and surgery in non-organ confined bladder cancer
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the median OS was 23 months (95%CI 19–42 months) versus 8 months (95%CI 7–13 
months) for clinically node positive disease (ycN+; N=35) (p<0.0001). For patients with 
pathologically confirmed persisting node metastases after surgery (ypN+; N=33) the 
median OS was 13 months (95%CI 10–19 months) versus a median OS of 27 months 
(95%CI 28–58 months) for patients with pathologically node negative disease (ypN0; 
N=100) (p<0.0001). In nineteen patients no pathological node evaluation was done after 
induction chemotherapy (ypNx). The Kaplan-Meier curves for OS according to clinical and 
pathological node status after induction chemotherapy are shown in figures 3a/b.
In multivariate analysis, the clinical and pathological response to chemotherapy and the 
clinical node status after chemotherapy (ycN-status) remained significant prognostic 
factors for OS (table 2).
DISCUSSION
This study underlines that patients with locally advanced and node positive bladder 
cancer face a poor prognosis despite induction chemotherapy and consolidating therapy 
(median OS 18 months and 5-years OS 27.2%). Patients with a complete pathological 
response to induction chemotherapy (pCR) after surgery fare significantly better 
(median OS 74 months and 5-years OS 53.8%). Clinical and pathological response to 
chemotherapy and the clinical node status after chemotherapy (ycN-status) are significant 
prognostic factors for OS. In the management of these patients at least three questions 
Figure 3a. Kaplan-Meier analysis for OS according to clinical LN status after induction chemotherapy 
(ycN-status). Median OS for ycN+ (n=35) was 8 months versus 23 months for ycN0 (n=117).  5-years OS was 
9.6% for ycN+ versus 33.5% for ycN0 (p<0.0001).
Figure 3b. Kaplan-Meier analysis for OS according to pathological LN status after induction chemotherapy 
(ypN-status). Median OS for ypN+ (n=33) was 13 months versus 27 months for ypN0 (n=100) and 6 months 
for ypNx (n=19). 5-years OS was 14.6% for ypN+ versus 36.2% for ypN0 and 0.0% for ypNx respectively 
(p<0.0001).
a b
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4remain: How reliable is clinical staging? Is consolidating therapy always necessary and 
should it always be surgery? What should be the management in progressive disease 
during chemotherapy?
Clinical staging. The prognostic value of the clinical response evaluation has been 
reported and is again confirmed by the present study 24,25. Nevertheless, the accuracy 
of clinical staging is limited, considering the fact that in 37.5% of patients with complete 
clinical response, residual disease was found at surgery (NPV 62.5%). The use of FDG-PET/
CT-scan and/or diffusion-weighted magnetic resonance imaging (MRI) into the standard 
workup before and after induction chemotherapy may improve clinical staging 26-28. With 
increased reliability of clinical response evaluation, chemotherapy induced downstaging 
of the primary tumour could be used as a surrogate marker for treatment efficacy 19. 
Consolidating treatment. Considering that one out of three patients harbours occult 
residual disease, consolidating treatment is rational. In the absence of other reliable ways 
Table 2. Multiple Cox regression analysis for overall survival
HR Lower Upper p-value
a) Clinical variables
Age (per 10 years) 1.20 0.96 1.50 0.11
Clinical stage Locally advanced disease 
(T3-4N0M0)
1
0.60
Organ confined disease with LN 
metastases (T1-2N1-3M0)
1.07 0.58 1.99
Locally advanced disease with LN 
metastases (T3-4N1-3M0)
1.12 0.63 1.99
Retroperitoneal 
lymphadenopathy (TxNxM1)
1.51 0.78 2.93
Clinical response to 
chemotherapy
cCR 1
0.02
cPR 1.95 1.18 3.23
cSD 3.77 1.50 9.46
cPD 3.18 1.27 7.92
Clinical LN stage after 
chemotherapy
ycN0 1
0.01
ycN+ 2.19 1.17 4.1
b) Pathological variables
Age (per 10 years) 1.13 0.88 1.44 1.34
Pathological response to 
chemotherapy
pCR 1
<0.0001
pPR 1.67 0.91 3.06
pSD 3.33 1.81 6.13
pPD 6.89 2.93 16.18
Pathological LN stage 
after chemotherapy
ypN0 1
0.23ypN+ 1.42 0.82 2.47
ypNx 2.25 0.67 7.50
Abbreviations: HR = hazard ratio; LN = lymph node
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to assess presence or absence of residual tumour, we favour surgery. While surgery is 
efficacious in locally confined residual tumour, it is very limited in patients with residual 
tumour in the lymph nodes after chemotherapy. Nevertheless, it is striking to observe that 
patients with limited supraregional retroperitoneal LN involvement (TxNxM1) show a similar 
outcome compared to patients with locally advanced disease and regional LN metastases 
(T3-4N+M0). These results corroborate the earlier publication by de Vries et al.6. Based 
on these results, we advise consolidating surgery in responders to chemotherapy with 
supraregional lymph node metastases. On the other hand, patients with clinically node 
positive disease after induction chemotherapy (ycN+) have a significantly worse outcome 
if compared to node negative patients (ycN0). Furthermore, patients with pathologically 
node positive disease despite induction chemotherapy (ypN+) have a significantly poorer 
prognosis compared to pathologically node negative patients (ypN0). Thus, although 
surgery may be important for staging and prognostic purposes, its role is unclear in node 
positive disease after induction chemotherapy. More research is needed to clarify the role 
of consolidating surgery in these patients. Patients with pathologically progressive disease 
after chemotherapy, who were subjected to total cystectomy performed no better than 
the patients who did not undergo surgery. Therefore based on these results we do 
not advise consolidating surgery to patients in our institution with progressive disease 
during induction chemotherapy. Radiation therapy could be considered as a non-surgical 
alternative in these patients. A prospective randomised clinical trial comparing surgery 
and radiotherapy may further elucidate this issue. 
Limitations. To prevent selection bias, the present study included all patients with 
locally advanced and/or LN positive bladder cancer, who were from the onset eligible for 
curative surgery and thus scheduled for induction chemotherapy. Therefore the analysis 
included also patients who, after induction chemotherapy, proved to be inoperable 
either due to progression of disease or comorbidity. To some extent this resulted in a 
heterogenous group, which is a limitation of the study. But it also provides a reflection 
of daily clinical practice. Other limitations consist of the use of different regimens of 
induction chemotherapy and the use of carboplatin instead of cisplatin in some patients 
who were not fit to receive cisplatin based chemotherapy. For these cisplatin-unfit 
patients, no standard alternative regimen is available. However, a recently published 
report did not show significant disease specific survival differences in surgically treated 
patients after carboplatin-based chemotherapy versus cisplatin-based treatment29. 
Therefore the use of a carboplatin-based regimen appears to be justified in these 
cisplatin-unfit patients. 
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CHEMOTHERAPY FOR NON-ORGAN 
CONFINED BLADDER CANCER: A REASONABLE 
ALTERNATIVE FOR CISPLATIN-UNFIT PATIENTS?
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“We learned more from a 3-minute record,
than we ever learned in school.”
-Bruce Springsteen: No Surrender-
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ABSTRACT
Purpose
To investigate the use of induction carboplatin-based chemotherapy in patients with 
non-organ confined UC who are considered unfit for cisplatin. A comparison was made 
with patients who received induction cisplatin-based combination chemotherapy (CBCC). 
Methods
We identified 167 patients with non-organ confined UC who received induction CBCC 
(n=126) or gem/carbo (n=41) at our hospital, between 1990-2010. One hundred twenty-
four patients completed four cycles of CBCC or gem/carbo. Clinical response (ycTNM) 
was evaluated according to RECIST 1.1. Radical cystectomy (RC) and bilateral extended 
pelvic lymph node dissection were performed in 106 patients. Pathological complete 
response (pCR) was defined as no evidence of disease (ypT0N0). Disease specific survival 
(DSS) was analysed using the Kaplan-Meier method. A multivariable analysis was 
performed.  
Results
Complete clinical response rates did not differ significantly among the treatment groups. 
Pathological complete respons in 33.7% of the specimens in the CBCC group versus 
30.3% in the gem/carbo group (P=0.808). We found no significant difference in DSS 
between the patients who started CBCC and those who started gem/carbo. For patients 
who completed 4 cycles and underwent RC, there was no significant difference in DSS 
between both groups either. In the multivariate analysis, pCR was the only variable with 
a significant association with DSS (P<0.045).
Conclusions
Induction gem/carbo for non-organ confined UC achieves comparable clinical and 
pathological response rates as well as survival outcomes to the CBCC schemes. Our data 
suggest that a carboplatin-based regimen can be considered a reasonable alternative for 
cisplatin unfit patients in the preoperative setting. 
70
5INTRODUCTION
Induction cisplatin-based chemotherapy demonstrated 6% absolute survival benefit in 
muscle invasive bladder cancer1-5. Treatment of choice is cisplatin-based combination 
chemotherapy (CBCC). However, safe administration of CBCC is not always possible6,7. 
A major disadvantage of CBCC is its severe cumulative renal toxicity. Since urothelial 
carcinoma (UC) largely is a disease of elderly individuals with age, lifestyle and disease 
associated decreased renal function and performance status, a high rate of severe acute 
toxicity and impaired renal function is a major threat of CBCC treatment. 
Recently, a consensus has been formulated to define patients with (metastatic) UC who 
are unfit for CBCC. CBCC treatment is considered not feasible in patients who meet at 
least one of several criteria, including 1) WHO (World Health Organization) or ECOG 
(Eastern Cooperative Oncology Group) performance status 2 or higher, or Karnofsky 
performance status 60-70% or lower; 2) calculated or measured creatinine clearance 
less than 60 ml per minute; 3) CTCAE (Common Terminology Criteria for Adverse Events) 
version 4, grade 2 or above audiometric hearing loss; 4) CTCAE version 4, grade 2 or 
above peripheral neuropathy and/or 5) NYHA (New York Heart Association) class III or 
greater heart failure6. According to these criteria, approximately 30% to 50% of patients 
with locally advanced and/or lymph node positive UC are considered unfit for cisplatin8.
The toxicity of the regimen and the greater age of many patients may impair the 
widespread use of induction CBCC. As an alternative, carboplatin based regimens may 
be considered. Currently to our knowledge no data support carboplatin based regimens 
as the second best regimen in patients with UC treated in the preoperative setting. Thus, 
we investigated the potential benefit of carboplatin based regimens in patients with 
non-organ confined UC who were considered unfit for induction cisplatin treatment and 
compared this with patients who received a first choice CBCC induction regimen.
PATIENTS AND METHODS
Patients. From our institutional bladder cancer database, we identified 167 consecutive 
patients with non-organ confined UC of the bladder who presented at our hospital 
and received induction chemotherapy between 1990 – 2010. All patients had locally 
advanced UC of the bladder, i.e. stage cT3-4a and/or regional (N+) and/or supraregional 
(para-aortal/paracaval) nodal involvement (nodal involvement below the renal vein) (M+). 
Study exclusion criteria were bladder tumours other than UC, previous chemotherapy 
and evidence of distant metastasis. 
Carboplatin-based induction chemotherapy for non-organ confined bladder cancer
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Pre-treatment staging. Patients were staged by physical examination, cystoscopy, 
laboratory studies and imaging studies (at least: abdominopelvic CT and chest X-ray). 
Renal function (glomerular filtration rate) was calculated according to the modified 
diet in renal disease formula. Radiological evidence of lymph node (LN) metastasis was 
considered in case of  pathologically enlarged LN greater than 1 cm in diameter or 
strong suspicion on positron emission tomography/CT (PET/CT). In 82% of these cases, 
suspicious LN lesions were proven with histology (biopsy or dissection) or cytology (fine 
needle aspiration; FNA).  In general, suspect LN were not  biopsied if other criteria 
for induction chemotherapy were present. Preoperative tumour stage was determined 
according to the UICC9.  
Induction chemotherapy. At our hospital patients with cT3-T4a and/or N+/M+ 
disease (supraregional or regional nodal metastases but below the renal vein) are 
considered candidates for induction chemotherapy. The recommendation for induction 
chemotherapy was made after multidisciplinary consultation (medical oncology, 
urology, pathology, radiology, radiation oncology). Either CBCC or carboplatin-based 
combination therapy was advised. CBCC consisted of an accelerated or classic MVAC 
regimen, as described by Nieuwenhuijzen et al.10, or gem/cis (gemcitabin 1000 mg/
m2 and cisplatin 70 mg/m2  on day 1, gemcitabin 1000 mg/m2 on day 8 and day 15) in 
a 21-day cycle. At our hospital, accelerated MVAC treatment is the preferred cisplatin-
based regimen. Patients considered unfit for CBCC were selected to receive gem/carbo. 
Selection criteria correspond to those described by Galsky et al., including impaired renal 
function, comorbidities and low performance status6. Starting dose levels were AUC 5 
carboplatin on day 1 (30 minutes) and 1000-1250 mg/m2 gemcitabine for 30 minutes 
on days 1 and 8 for a 21-day cycle. 
Response evaluation. Response was assessed after 2 and 4 cycles with cystoscopy, 
restaging CT and/or PET/CT. Clinical post-chemotherapy status (ycTNM). was evaluated 
according to RECIST 1.111. When there was clinically progressive disease after 2 courses, 
chemotherapy ceased and the patient was evaluated for further therapy, i.e. surgery, 
radiotherapy or palliation only. We compared clinical response rates between the 
treatment groups for patients who completed 4 cycles of the regimen. Patients who 
did not complete 4 chemotherapy cycles or who switched from 1 chemotherapeutic 
regimen to another were analyzed as a separate group. For survival analysis, the patients 
who crossed over from CBCC to carboplatin-based chemotherapy were included in their 
original groups.
Histopathology. The decision for subsequent surgery (extended pelvic LN dissection 
and RC) was made after a second multidisciplinary discussion. Histopathological 
investigation of pathology specimens was used as the gold standard for response 
72
5evaluation. Pathologic complete response (pCR) was defined as no evidence of tumour 
in the bladder and lymphatic tissue (ypT0N0); pathologic partial response (pPR) as any 
downstaging from the baseline. Although surgery was uniformly advised in responding 
patients, some refused and went on to receive (preferred) curative radiotherapy or 
follow-up. We compared pathological response rates among both treatment groups for 
patients who completed 4 cycles of the regimen and underwent RC and extended pelvic 
LN dissection. 
Statistics. Differences in patient characteristics and response rates were evaluated 
using Pearson chi-square and Fisher exact tests. Recurrence free survival (RFS), disease 
specific survival (DSS) and overall survival (OS) were analysed using the Kaplan-Meier 
method. OS was defined as the time from the start of induction chemotherapy to any 
cause of death: patients who were alive at the end of follow-up were censored at that 
date. DSS was the period of time until bladder cancer patients died due to bladder 
cancer, metastasis of bladder cancer, or complications related to the treatment of 
bladder cancer. RFS was defined as the time from the start of induction chemotherapy 
until the first recurrence or death. Kaplan-Meier curves were compared using the log 
rank test. All reported P values are 2-sided, with significance at p value ≤ 0.05. We 
performed a multivariable analysis using the variables: chemotherapeutic regimen, 
cT-stage, cN-stage, complete clinical response (cCR) and complete pathological response 
(pCR). Cox proportional hazard regression models were used to identify independent 
predictors for survival. Data analysis was performed with Statistical Package for Social 
Sciences (SPSS), version 17.0 for Windows.
RESULTS
A total of 167 patients with nonorgan confined UC of the bladder received induction 
chemotherapy with CBCC (MVAC in 112 and gem/cis in 14) or gem/carbo (41). Mean 
patient age was 59.4 (SD ± 8.8 years). Table 1 lists baseline patient and tumour 
characteristics.
Compared to the CBCC group, patients in the gem/carbo group were older (mean age: 
58.4 ± 9 versus 65.6 ± 8 years, p<0.001) and had poorer renal function (glomerular 
filtration rate less than 60 ml/min/1.73 m2) in 5.5% versus 43.9% (p<0.001). Besides 
poor renal function (n=18), other reasons for selecting patients for gem/carbo were 
poor performance status and comorbidities (n=18) and pre-existent hearing loss (n=5). 
There were no other significant differences in baseline patient and tumour characteristics 
between the groups.
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Table 1. Baseline patient and tumour characteristics
CBCC N = 126 Gem/Carbo N = 41 p-value
N % N %
Gender Male 95 75.4 33 80.5
0.671
Female 31 24.6 8 19.5
GFR< 60 ml/min 7 5.5 18 43.9
cT-stage T2 46 36.5 13 31.7
0.487T3 38 30.2 10 24.4
T4 42 33.3 18 43.9
cN-stage N0 30 23.8 13 31.7
0.470N1 34 27.0 12 29.3
N2-3 62 49.2 16 39.0
cM-stage M0 106 84.1 35 85.4
0.535
M1 20 15.9 6 14.6
Abbreviations: CBCC = cisplatin-based combination chemotherapy
Figure 1. Overview of full intention-to-treat population, including all patients who started neoadjuvant 
chemotherapy (Cx). CBCC was given in 126 patients (75.4%), of whom 112 (88.9%) received MVAC, including 
68 with accelerated (acc) scheme and 44 with classic scheme, and 14 (11.1%) received gem/cis. Total of 41 
patients (24.6%) received gem/carbo. Of patients with CBCC, toxicity (renal failure, ototoxicity and malaise) 
was most common reason for discontinuation, i.e. 25 or 85.2% of patients who received fewer than 4 cycles. 
Discontinuation due to toxicity occurred in 19.8% of patients in CBCC group vs 12.1% in gem/carbo group. 
Of patients who discontinued CBCC 12 switched to another regimen, including 11 to gem/carbo and 1 from 
MVAC to gem/cis, of whom 11 eventually completed 4 cycles of neoadjuvant chemotherapy. Most common 
reasons for disc ontinuation in patients with gem/carbo were lack of response and toxicity in 5 each. 
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5A total of 43 patients (25.7%) discontinued induction treatment before 4 cycles were 
completed. There was no statistically significant difference in the percent of patients who 
received fewer than 4 cycles between CBCC and gem/carbo groups (31 or 24.6% vs 12 
or 29.3%, p=0.544). This subgroup did not differ significantly in baseline characteristics 
from the subgroup that did not discontinue treatment. Figure 1 shows the full intention-
to treat population, including all patients who started induction chemotherapy and the 
reasons for discontinuation of the chemotherapy. 
A total of 124 patients completed all 4 cycles of CBCC (95 of 126 or 75.4%) or gem/
carbo (29 of 41 or 70.7%) and were eligible for definitive clinical response evaluation. 
Table 2 lists clinical response rates. The number of patients who attained a cCR and a cPR 
did not differ significantly between the treatment groups. Lack of a response was more 
common in the gem/carbo group (p=0.007). Of the 124 patients 106, including 85.5% 
of the 124 who completed 4 chemotherapy cycles and 63.5% of the 167 who started 
induction chemotherapy, underwent RC and were eligible for pathological response 
evaluation (table 2). The number of patients who attained pCR or any down-staging 
from baseline did not differ significantly between the treatment groups (p=0.444 
and p=0.808, respectively). Of the 18 patients who completed 4 cycles of induction 
chemotherapy but did not undergo RC 3 received curative radiotherapy. In 15 patients 
there was no local treatment (figure 1). 
The other study objective was to compare survival outcomes for the 2 treatment groups. 
Median DSS of all patients who started induction chemotherapy was 19 months (95% 
CI 15–23), including 20 months for CBCC and 18 months for gem/carbo (log rank test 
p=0.182). Median DSS of all patients who completed 4 cycles of induction chemotherapy 
Table 2. Clinical and pathological response in the CBCC and Gem/Carbo group
Clinical response CBCC N = 95 Gem/Carbo N = 29 p-value
N % N %
Complete response (cCR) 32 33.7 8 26.7 0.652
Partial response (cPR) 58 61.1 14 48.3 0.283
No response 5 5.3 7 24.0 0.007
Pathological response CBCC N = 83 Gem/Carbo N = 23 p-value
N % N %
Complete response (pCR) 28 33.7 7 30.4 0.808
Any downstaging from baseline 59 71.1 14 60.9 0.444
Extent of response No response 24 28.9 9 39.1 0.446
Local response 32 38.6 8 34.8
0.875Nodal response 5 6.0 1 4.3
Local and nodal response 22 26.5 5 21.7
Abbreviations: CBCC = cisplatin-based combination chemotherapy
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Figure 3. Overall survival of patients who completed 4 cycles of induction chemotherapy and underwent RC: 
CBCC (black) versus gem/carbo (grey) (p=0.361)
Figure 2. Recurrence free survival of patients who completed 4 cycles of neoadjuvant chemotherapy and 
underwent RC. CBCC (black) vs gem/carbo (grey) (p=0.862). 
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5was 22 months, including 22 months for CBCC and gem/carbo (log rank test p=0.424). 
Median DSS of patients who completed 4 cycles of induction chemotherapy and 
underwent RC was 23 months (95% CI 10–36), including 23 months for CBCC and 29 
months for gem/carbo (log rank test p=0.769). Comparison of OS and RFS revealed no 
statistically significant difference between the CBCC vs gem/carbo groups (22 vs 22 
months, log rank test p=0.361 and 15 vs 16 months, log rank test p=0.862). Figures 2 
and 3 show Kaplan-Meier curves of RFS and OS in these patients.
On multivariate analysis pCR was the only variable with a significant association (DSS HR 
0.4, 95% CI 0.2–1.0, p=0.045). There was no statistically significant difference in DSS, 
OS or RFS between the CBCC and gem/carbo groups.
DISCUSSION
This study was done to investigate the treatment results of induction carboplatin based 
regimens in patients with non-organ confined UC who were considered unfit for cisplatin. 
The 2 main study objectives were to analyze the clinical and pathological response 
rates, and compare survival outcomes of patients treated with induction gem/carbo vs 
first choice induction CBCC. We found comparable complete clinical and pathological 
response rates among both groups. However, the number of clinical non-responders 
was significantly higher in the gem/carbo group. It has been described that the efficacy 
of chemotherapeutic regimens for metastatic UC is affected by the pretreatment 
prognostic features of the treated populations. Poor performance status was found to 
be an independently predictive factor of poor response and survival in patients with 
metastatic UC12. The poorer initial performance status of patients receiving gem/carbo 
might explain the difference in clinical non-response, between the patients who started 
CBCC versus the patients who started gem/carbo.
When comparing the survival of patients who started induction chemotherapy, we found 
that CBCC led to relatively better DSS than gem/carbo, although this was not statistically 
significant. Subsequently we analyzed the actual treatment effect by examining the 
survival of patients who completed 4 cycles of induction chemotherapy, underwent RC 
and, thus, were eligible for pathological response evaluation. This difference in survival 
was also not statistically significant between the CBCC and gem/carbo group. Patients 
who attained pCR had significantly better DSS than patients who did not attain a pCR. 
This favourable outcome of patients with pCR after induction chemotherapy was also 
reported by others1,13. 
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To our knowledge, this is the first study investigating the role of carboplatin as an 
alternative induction regimen for bladder cancer patients who are ineligible (unfit) for 
cisplatin. In a phase II trial, Smith et al. investigated the effect of a paclitaxel, carboplatin 
and gemcitabine combination for UC in an induction setting. They describe a pCR after 
cystectomy in 12/43 patients (27.9%)14. In that study, carboplatin was administered in a 
combination with paclitaxel. Similar to cisplatin-based regimens, a paclitaxel containing 
combination is not suitable for unfit patients with a low performance status. Another 
difference to our study is that when Smith et al. assessed the pCR rate, they only 
assessed the primary tumour. Although a subgroup of patients had nodal involvement, 
pathological nodal status was not mentioned14. Due to the mentioned differences in 
study design it is difficult to compare all of our results to those of Smith et al. However, 
our pCR rate was in accordance with that described by Smith et al.14. 
Similar to the induction setting, there is no standard chemotherapy regimen 
recommended for patients with metastatic UC who are unfit for cisplatin-based 
chemotherapy. In this setting, a combination of gemcitabine and carboplatin has proven 
to be an active and effective alternative in unfit patients, but inferior to a cisplatin-based 
regimen15-19. Carboplatin-based chemotherapy in the metastatic setting is investigated 
by De Santis et al.18. In a phase II/III study, they compared the efficacy and toxicity 
of two carboplatin-based chemotherapy regimens (gem/carbo versus methotrexate/
carboplatin/vinblastine) in patients with advanced UC who were unfit for CBCC. Each 
treatment arm was active and safe in this group of unfit patients and no significant 
differences were found in response and survival. However, the latter scheme led to more 
toxicity18. 
In our study, CBCC caused toxic side effects, including renal failure, ototoxicity 
and malaise. Due to these toxic effects treatment was discontinued in 20 patients 
(approximately 20%) in the CBCC group. Of those who discontinued CBCC due to 
toxicity 11 switched to a carboplatin based regimen and received 1 to 3 additional cycles 
of induction gem/carbo. Carboplatin has the advantage of convenient administration 
and it is a generally well tolerated regimen20-22. Our results suggest that patients who 
suffer from severe toxicity of cisplatin may switch to a gem/carbo regimen. They might 
benefit from that strategy rather than ending the induction chemotherapy before 4 
cycles have been administered. 
The limitations of this study are those inherent to retrospective studies. Notably we did 
not compare 2 similar groups. Patients unfit for the standard chemotherapy combination 
were compared to the standard treatment group. The decision of whether a patient 
was considered unfit for cisplatin was made by our medical oncologists based on the 
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5mentioned criteria. Greater age, poorer renal function and lower performance status are 
characteristics to be expected among patients in the gem/carbo group. In this context 
not all patients who were considered unfit for cisplatin were eligible for induction 
gem/carbo. In those with creatinine clearance less than 30 ml per minute, at high risk 
for cardiovascular or vascular events, and/or with recent treatment with a platinum 
derivate carboplatin based induction chemotherapy was also withheld. Prompt surgery, 
radiotherapy or palliative treatment was generally advised.
We acknowledge the problem of selection bias. Unfit patients with UC and poor general 
health often cannot complete all induction chemotherapy cycles or they are ineligible for 
extirpative treatment after chemotherapy. In our study approximately 36% of patients 
did not complete 4 cycles of the initiated regimen or did not undergo RC. As such, 
comparing response rates is difficult and recognition of the patient subset is important. 
In light of this limitation we first calculated the survival outcome of all patients who 
started induction chemotherapy. Subsequently we focused on the survival of patients 
who eventually completed the scheduled 4 cycles and underwent RC. To overcome 
potential bias it would be interesting to prospectively investigate patients considered for 
induction gem/carbo chemotherapy using an intention-to-treat protocol.
CONCLUSION
Induction gem/carbo for nonorgan confined UC achieves clinical and pathological 
response rates, and overall survival comparable to those of the MVAC or gem/cis 
schemes. Our data suggest that a carboplatin based regimen can be considered a 
reasonable alternative for cisplatin unfit patients in the preoperative setting. Based on 
our data we will continue to consider induction treatment with gem/carbo in cisplatin 
unfit patients.
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ABSTRACT
Objective
To investigate the influence of neoadjuvant chemotherapy (NAC) on the incidence of 
lymph node (LN) metastases in clinically node-negative (cN0) patients with muscle 
invasive bladder cancer (MIBC). 
Patients and methods
Between 1990–2012, 828 consecutive patients underwent radical cystectomy (RC) with 
extended pelvic lymph node dissection (PLND) , of them 441 were staged cT2-4N0M0. 
Eighty-three patients received NAC followed by RC and 358 underwent RC only. The 
PLND template and  the indication for NAC remained the same during the study 
period. The incidence of occult lymph node metastases in both groups was compared. 
Unadjusted and adjusted odds ratios (OR) were calculated to investigate the influence 
of NAC, cT-stage, gender and the preoperative staging modality used (CT or PET/CT) on 
the occurrence of LN metastases. Overall (OS) and disease specific survival (DSS) were 
analysed using the Kaplan-Meier method.
Results
Patients in the NAC-group had more often locally advanced MIBC than patients in the 
non-NAC group (cT3-4: 88.0% versus 30.2%). Of the NAC patients, 19.3% had LN 
metastases versus 28.5% of the non-NAC patients (p=0.099). In the cT3-4 patients, 
the occurrence of LN metastases was significantly lower in the NAC group compared 
with the non-NAC group (21.9% versus 40.7%, respectively, p=0.002). In multivariable 
analysis, adjusting for cT-stage, gender and staging method, NAC was independently 
associated with a decreased likelihood of LN metastases (OR: 0.41, 95% CI 0.21–0.79; 
p=0.008). Among the cT3-4 patients, median OS was significantly longer in the NAC 
group versus the non-NAC group (68.0 versus 23.0 months, p=0.047)
Conclusion
These data suggest that, next to a downstaging effect on the primary bladder tumour, 
NAC is also associated with reduced incidence of occult LN metastases at the time of RC. 
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Radical cystectomy (RC) including an extended pelvic lymph node dissection (PLND) 
is currently standard practice in patients with muscle invasive bladder cancer (MIBC) 
who do not have radiological signs of metastases1. However, approximately half of the 
patients later on develop metastases and their prognosis is poor2-5. This is attributed to 
the presence of (occult) metastases at time of surgery. A relation between pathological 
T-stage and lymph node (LN) metastases was found at pathological examination in 
patients with clinically node-negative (cN0) bladder cancer (BC), with the percentage of 
lymph node (LN) metastasis undergoing cystectomy increasing from 2-5% in ≤pT1 and 
8-18% in pT2 to 36-46% in ≥pT3 tumours2-7. 
Occult LN metastases are LN metastases which are histopathologically diagnosed (pN+) in 
initially cN0 patients. One of the aims of neoadjuvant chemotherapy (NAC) is to eliminate 
occult (micro)metastases prior to surgery. NAC has shown an absolute improvement of 
overall survival by 5-7% in patients with cN0M0 MIBC 8-12. Because micrometastases 
are more frequent in locally advanced (cT3-4N0M0) MIBC, it is anticipated that NAC 
has a greater benefit in locally advanced MIBC as compared to organ confined MIBC. 
Therefore, several institutes, including ours, have developed criteria (see materials and 
methods) to identify MIBC patients at a higher risk for micrometastatic spread in whom 
NAC is nowadays considered standard of care13. 
Pathological nodal stage is suggested to be one of the most important prognosticators14. 
However, previous (randomized) studies have focused on the local tumour stage and 
not on nodal involvement8,13,15. A pathological complete response rate of the bladder 
tumour of 40% has been described with NAC versus 10-15% with surgery alone8. By 
contrast, data on the influence of NAC on nodal involvement as well as data on the 
incidence of occult LN metastases after NAC are scarce. 
 
We hypothesize that NAC reduces the percentage of occult LN metastases. For this 
purpose, the nodal status after NAC was evaluated and compared to nodal status after 
surgery alone. This was addressed in a consecutive series of cN0 patients with or without 
NAC who underwent RC using the same PLND template during the study period.
PATIENTS AND METHODS
Patients. This study was performed in accordance with institutional ethical guidelines, 
based on good clinical practice. Using our prospectively maintained BC database, 
we identified the patients who underwent RC between 1990 - 2012. Patients who 
underwent a salvage cystectomy after pelvic radiation therapy, as well as patients who 
did not undergo an PLND at time of RC or who underwent a previous (e)PLND were 
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excluded. Patients who did not have proven muscle invasive tumours at transurethral 
resection (TUR) were excluded.
Pre-treatment staging. Patients were clinically staged by physical examination, 
cystoscopy, transurethral resection (TUR) of the tumour, laboratory studies and imaging 
studies (at least abdominal/pelvic computed tomography (CT) and chest X-ray). Since 
2010, routine staging with 18F-fluorodeoxyglucose (FDG) - positron emission tomography 
(PET) combined with CT was performed. Preoperative TNM stage was determined 
according to the UICC 16. 
Patients with MIBC staged cN0M0 were eligible for this study. cN0 was defined as 
no clinical evidence of lymph node metastases by radiological criteria.  Lymph node 
metastasis was considered to be evident if: LN > 1,0 cm in diameter on conventional 
imaging and/or strong suspicion on PET/CT. 
Neoadjuvant chemotherapy. NAC was introduced in our institute in 1990. According 
to our institutional policy, NAC is advised to cN0M0 MIBC patients with cT3-4a urothelial 
carcinoma (UC) and/or (2) lymph-angio invasion at TUR, and/or (3) hydroureteronephrosis 
and/or (4) palpable mass at physical examination.
Treatment of choice is cisplatin-based combination chemotherapy, consisting of an 
accelerated or classic MVAC regimen, as described by Nieuwenhuijzen et al.14, or gem/cis 
(gemcitabine 1000-1250 mg/m2 and cisplatin 70 mg/m2on day 1 in 4 hrs, gemcitabine 
1000 mg/m2 on day 8 in 30 min) in a 21-day cycle. Patients who were considered unfit 
for cisplatin were selected to receive carboplatin-based combination chemotherapy; 
gem/carbo 17. Selection criteria correspond to those described by Galsky et al.18. Starting 
dose levels were AUC 5 carboplatin on day 1 in 30 minutes and 1000-1250 mg/m2 
gemcitabine in 30 minutes on days 1 and 8 for a 21-day cycle. 
Multidisciplinary rounds were held to identify patients eligible for NAC and to determine 
the chemotherapy scheme. In patients with ≤cT2N0M0 BC or patients ineligible for 
NAC, immediate RC was advised. Adjuvant chemotherapy was not given. 
Surgical template and histopathology. During the whole study period, RC included 
an PLND according to an anatomically clearly defined template which consisted of 
removal of all lymph nodes in the region between the genitofemoral nerve, the obturator 
fossa, along the internal iliac artery and along the common iliac artery at least up to the 
crossing of the ureter 19. Surgery was performed by 5 experienced staff urologists.
All PLND specimens were sent to the pathology department containing a minimum of 
2 packages per side. The specimens were handled in a standard fashion as described 
recently 20. The number of resected lymph nodes and the presence of lymph node 
metastases were routinely determined. Patients were classified as pathologically node 
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after NAC). The ypN or pN-stage and the lymph node density were also reported. 
Statistics. Preoperative characteristics as well as the histopathological characteristics of 
the NAC group and non-NAC group were compared with the chi-square test, Fisher’s 
exact test or independent samples T-test. 
Unadjusted and adjusted odds ratios were calculated to investigate the association 
between the presence of occult LN metastases and NAC, gender, cT-stage en pT-stage 
separately. Then, binary logistic regression models were used to calculate the odds ratio 
between the NAC and non-NAC group, adjusted for cT-stage and gender. To rule out the 
influence of preoperative PET/CT scanning, staging modality was also entered into the 
model, along with the interactions between NAC, cT-stage, gender and the occurrence 
of LN metastases. Postoperative histopathological variables (i.e. (y)pT-stage) were not 
included. 
Overall survival (OS) and disease specific survival (DSS) were analysed using the Kaplan-
Meier method. OS was defined as the time from PLND to any cause of death: patients 
who were alive at the end of follow-up were censored at that date. DSS was the period 
of time until patients died due to BC (metastasis of BC, or related to the treatment). 
Data analysis and collection was performed with Statistical Package for Social Sciences 
(SPSS), version 20.0 for Windows. All reported p values are 2-sided, with significance at 
p value ≤ 0.05.
RESULTS
A total of 828 patients, underwent RC for MIBC at our hospital in the study period. 
Two hundred fifty seven patients were excluded due to (1) non-muscle invasive disease 
(n=148), (2) the administration of radiotherapy before RC (n=90), (3) the absence of a 
bilateral PLND at the time of RC (n=15) and (4) lack of sufficient staging information 
(n=4). Of the 571 remaining patients, 441 were staged as clinically lymph node negative 
(cT2-4N0M0) and were eligible for analyses. Eighty- three (18.8%) received NAC. Of 
these 83 patients, 39 (47.0%) were treated with MVAC, 25 (30.1%) with gem/cis and 19 
(22.9%) with gem/carbo. All patients received at least 2 cycles of NAC; 2 (2.4%) received 
2 cycles; 8 (9.6%) received 3 cycles; 73 (88.0%) received 4 cycles. The remaining 358 
patients (81.2%) did not receive NAC (non-NAC).
Baseline patient and clinical tumour characteristics of the NAC and the non-NAC group 
are presented in table 1. The mean age of the study group was 63.1 (SD±10.3) years. 
As expected, patients with NAC had more often clinically locally advanced disease than 
non-NAC patients (cT3-4 in 88.0% versus 30.2%, respectively, p<0.001), and were more 
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often staged with both CT and PET/CT than the non-NAC patients (26.5% versus 8.9%, 
respectively, p<0.001). 
Table 1. Baseline patient and tumour characteristics of the NAC and the non-NAC groups before radical 
cystectomy
NAC (N=83) Non-NAC (N=358) p-value
Age  (Mean ± SD) 61.2 ± 9.4 63.5 ± 9.4 0.063
N % N %
Gender Male 62 74.7 269 75.1
0.933
Female 21 25.3 89 24.9
cT-stage T2 10 12.0 250 69.8
<0.001T3 41 49.4 69 19.3
T4 32 38.6 39 10.9
Staging modality CT 61 73.5 326 91.1
<0.001
CT & PET/CT 22 26.5 32 8.9
Abbreviations: NAC = neoadjuvant chemotherapy; SD = standard deviation; cT-stage = clinical tumour stage; 
CT = computed tomography; PET = positron emission tomography
Table 2.  Histopathological parameters of radical cystectomy specimens and nodal packages for all patients in 
the NAC and the non-NAC group
NAC (n=83) Non-NAC (n=358) p-value
ypT/pT-stage T0 36 43.4 59 16.5
<0.001
Ta/cis 2 2.4 5 1.4
T1 2 2.4 15 4.2
T2 16 19.3 88 24.6
T3 13 15.7 143 39.9
T4 14 16.9 48 13.4
Patients with LN metastases 16 19.3 102 28.5 0.099
ypN/pN-stage N0 67 80.7 256 71.5
0.183N1 9 10.8 46 12.8
N2-3 7 8.4 56 5.6
Number of resected LNs (Mean ± SD) 17.04 ± 11.29 14.77 ± 9.66 0.100
LND (Mean ± SD) 3.7% ± 0.13 6.3% ± 0.15 0.07
LND in (y)pN+ patients (Mean ± SD) 10.3% ± 0.08 7.8% ± 0.04 0.400
Abbreviations: LN = lymph node; pT-stage = pathological tumour stage; pN-stage = pathological nodal stage; 
SD = standard deviation; The prefix y indicates stage after neoadjuvant chemotherapy
The histopathological parameters of the RC specimen are displayed in table 2. In the 
NAC group, significantly more patients had no residual tumour in the bladder (43.4% 
versus 16.5%, p<0.001). Histopathological evaluation revealed LN metastases in 118 of 
441 patients (26.8%). 19.3% of the NAC patients had LN metastases versus 28.5% of 
the non-NAC patients (p=0.099). Among the patients with cT3-4 disease (table 3), LN 
metastases were found in 21.9% (NAC) and 40.7% (non-NAC), respectively (p=0.002). 
Of note, the number of resected lymph nodes was not different between NAC and 
non-NAC patients.   
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gender, categorized cT-stage, categorized (y)pT-stage and staging modality related to 
the occurrence of LN metastases. There was a trend towards a significant interaction 
between the occurrence of LN metastases and the administration of NAC in the 
unadjusted analyses (unadjusted odds ratio 0.60; 95% CI 0.33-108; p=0.090). If 
adjusted for gender, cT-stage and staging method, the occurrence of LN metastases was 
significantly decreased in the NAC group, compared with the non-NAC group (adjusted 
odds ratio 0.41; 95% CI 0.21-0.79; p=0.008). The absence of clinically locally advanced 
disease (≤cT2 versus cT3-4) was also independently associated with a decreased 
likelihood of nodal involvement at RC (odds ratio 0.47; 95% CI 0.29-0.75; p=0.001). 
Table 3. Histopathological parameters of radical cystectomy specimens and nodal packages for cT3-4N0M0 
patients in the NAC and the non-NAC group
NAC  (n=73) Non-NAC  (n=108) p-value
N % N %
pT-stage (ypT / pT) T0 29 39.7 6 5.6
<0.001
Ta/cis/1 4 5.5 1 0.9
T2 13 17.8 10 9.3
T3 13 17.8 56 51.9
T4 14 19.2 35 32.4
Patients with LN metastases 16 21.9 44 40.7 0.002
pN-stage (ypN / pN) N0 59 80.8 64 59.3
0.007N1 7 9.6 17 15.7
N2-3 7 9.6 27 25.0
Number of resected LNs (Mean ± SD) 16.72 ± 9.9 13.75 ± 9.0 0.039
LND (Mean ± SD) 3.7% ± 0.11 10.9% ± 0.20 0.003
LND in (y)pN+ patients (Mean ± SD) 15.6% ± 0.07 13.1% ± 0.06 0.200
Abbreviations: LN=lymph node; pN-stage=pathological nodal stage; LND=lymph node density; SD=standard 
deviation; The prefix y indicates the stage after neoadjuvant chemotherapy
Table 4. Unadjusted and adjusted odds ratios for NAC and non-NAC, gender, categorized cT- stage, categorized 
(y)pT-stage and staging modality related to the occurrence of LN metastases
Unadjusted Odds ratio Adjusted Odds ratio
Odds ratio (95% CI) p-value Odds ratio (95% CI) p-value
NAC vs non-NAC 0.60 (0.33 – 1.08) 0.090 0.41 (0.21 – 0.79) 0.008
Female vs Male 0.97 (0.60 – 1.59) 0.914 0.980 (0.60 – 1.61) 0.937
cT-stage cT2 vs cT3-4 0.64 (0.42 – 0.97) 0.037 0.47 (0.29 – 0.75) 0.001
pT-stage pT0 vs pT1-2 0.15 (0.7 – 0.31) <0.001 N/A
pT1 vs pT3-4 0.39 (0.23 – 0.65) <0.001 N/A
PET/CT vs CT 0.67 (0.33 – 1.35 0.260 0.75 (0.36 – 1.53) 0.422
Abbreviations: LN=lymph node; CI=confidence interval; cT-stage=clinical tumour stage; NAC=neoadjuvant 
chemotherapy; PET=positron emission tomography; CT=computed tomography, N/A=not applicable
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Figure 1a Kaplan-Meier OS curves of all cN0M0 patients who received NAC (dark grey) versus patients who did 
not receive NAC (grey) (p=0.663) and of the cT3-4 patients who received NAC (light grey) versus cT3-4 patients 
who did not receive NAC (black) (p=0.047). 
Figure 1b Kaplan-Meier DSS curves of all cN0M0 patients who received NAC (grey) versus patients who did not 
receive NAC (dark grey) (p=0.644) and of the cT3-4 patients who received NAC (black) versus cT3-4 patients 
who did not receive NAC (light grey) (p=0.130).
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after a median follow-up of 24 months (IQR: 8-60 months). Eighty-seven percent of 
the deaths occurred due to BC. There were no statistically significant differences in 
OS and DSS between the NAC and non-NAC groups (median OS NAC 68.0 months; 
95%CI 51.8-84.2 versus median OS non-NAC 54.0 months; 95% CI 36.8-71.2; p=0.663) 
(median DSS NAC 68.0 months; 95% CI 51.7-84.3 versus median DSS non-NAC 168 
months; 95% CI, not reached; p=0.644). Among the cT3-4 patients, the patients in the 
NAC group had a statistically significant longer OS than the patients in the non-NAC 
group (median OS NAC 68.0 months; 95% CI 53.4-82.6 versus median OS non-NAC 
23.0 months; 95% CI 7.2-38.8; p=0.047). The difference in DSS was not statistically 
significant (median DSS NAC 68.0 months; 95% CI 53.4-82.6 versus median DSS 
non-NAC 31.0 months; 95% CI 8.4-53.6; p=0.130). Kaplan-Meier curves of OS and DSS 
are displayed in figures 1a/b. In addition, we also calculated the survival data of patients 
with (occult) tumour positive lymph nodes at the time of surgery. The median OS was 
58.0 months (95% CI 0-128.9) in the NAC group versus 18.0 months (95% CI 10.0-26.0) 
in the non-NAC group (p=0.292) and the median DSS 58.0 months (95% CI 0.0-128.9) 
versus 21.0 months (95% CI 12.6-29.4), respectively (p=0.419).
DISCUSSION
The present study was performed to investigate the incidence of “occult” LN metastases 
in cN0M0 BC patients who received NAC. We found that the occurrence of LN 
metastases in cN0 patients who received NAC was lower compared to patients who did 
not receive NAC. This difference was found to be statistically significant, after adjusting 
for confounding factors of which the cT-stage was the most important.
Previous studies on the prognosis of patients with MIBC have shown that the presence 
of LN metastases at PLND is an important independent predictor of survival in patients 
who were not treated with NAC 2,5,21; 5-year survival drops dramatically from 70-80% in 
patients with MIBC (pT2N0) to 20-35% in patients with LN involvement 22. In the NAC 
setting, the (y)pN-stage is also an important prognosticator14. The presence of occult LN 
metastases has thus been linked to poor prognosis in both patients with and without 
NAC.
The use of NAC has been advocated to improve survival of patients with locally advanced 
BC and/or lymph node metastasis and should be considered in patients with MIBC 13. Its 
rationale is twofold: (1) to enhance operability by downsizing the local bladder tumour 
and (2) to eradicate occult metastases prior to surgery. In our series, we confirmed the 
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effect of NAC on T-stage: no residual  tumour (ypT0) was found in 43.4% of the patients 
in the NAC group, versus 16.5% pT0 in the non-NAC group (p<0.001). 
Our results are consistent with those by Grossman et al., who report on a randomized 
Intergroup trial conduct by the Southwest Oncology Group (SWOG 8720, INT-0080), in 
which patients with cN0M0 MIBC were assigned to NAC followed by RC or RC alone. 
Thirty-eight percent of the surgical specimens in the NAC group were pathologically 
free of cancer (ypT0) versus 15% (pT0) in the upfront RC group (P<0.001) 8. Because 
we selected the patients who received NAC, the comparable results might suggest 
that the effect of NAC on pT-stage does not depend on clinical T-stage but more on 
chemosensitivity of the tumour. On the other hand, because our study was not a 
randomized study, it is obviously prone to more bias. In addition to the effect of NAC on 
T-stage, our results also demonstrate that patients who received NAC had fewer occult 
LN metastases than patients without NAC. The difference in nodal involvement risk 
was most pronounced in the cT3-4 patients, who – according to our institutional policy 
– meet the primary criterion to receive NAC. In this group, LN metastases occurred 
in 40.7% of the patients – almost double the percentage of the NAC group (21.9%, 
table 3). Moreover, NAC was independently associated with a decreased likelihood of 
LN metastases in multivariable analysis.
Whereas several important studies on NAC have been performed, the influence of 
NAC on the occurrence of LN metastases has hitherto not received much systematic 
investigation. In the study by Grossman, the pathological nodal status was not 
mentioned 8. Moreover, it remained unclear how many patients underwent PLND and 
what the extent of the PLND was. In a secondary analysis, Herr et al. reported the 
pathological nodal status of the patients in the SWOG trial23. Patients receiving NAC 
had fewer positive nodes (p=0.04) than patients who had surgery alone23. However, 
the extent of the PLND appeared highly variable. Only 54% of the patients in SWOG 
8710 had a PLND comparable to the PLND performed in our institute23. In another 
study, Griffiths and colleagues demonstrated that NAC offers an absolute survival 
benefit for patients with MIBC 12. However, after NAC, the patients were treated with 
RC, radiotherapy or a combination of both. Also in that study, no information regarding 
the pathological nodal status of the patients who underwent surgery was provided. 
Finally, Rosenblatt, on behalf of the Nordic Urothelial Cancer Group,  reported the effect 
of NAC on tumour downstaging 15, showing that survival benefits of NAC are reflected 
in downstaging of the primary tumour. In contrast to the previous studies, Rosenblatt 
did mention the nodal status postoperatively; 12% in the NAC arm and 15% in the 
control (p=0.338). However, due to the lack of preoperative nodal staging with CT 
during the years of inclusion, all patients in their study were staged as Nx, making it 
difficult to compare our results to those of Rosenblatt and co-workers15. 
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bladder tumour and/or on survival, the present paper provides new information with 
regard to the nodal status after NAC and adds further support to the concept that 
NAC, next to reducing local bladder tumor, plays a role in eradicating occult metastases 
in MIBC. Important strengths of the present study are that the patients included in 
this study were all staged cN0M0 and were treated uniformly. Furthermore, all PLNDs 
were performed according to a standardized surgical template with clear anatomical 
boundaries, which has remained the same during the study period 19.
Certain limitations of the present study need to be discussed: This is a retrospective, 
single-centre, observational study with all inherent limitations. The authors acknowledge 
selection and cohort bias: For example, unfit MIBC patients or patients with progressive 
disease were not eligible for extirpative treatment after NAC. In the current study, 
11/94 patients with cN0M0 BC who started NAC at our hospital in this period, did not 
undergo subsequent surgery. In 4 cases due to progressive disease. The others received 
radiotherapy with curative intent. It is important to recognize such subgroups because 
study findings may be influenced by these. However, if the 4 patients who showed 
clinically progressive disease, were considered to have pathologically tumour positive 
lymph nodes, the difference in incidence of occult LN metastases between the NAC 
and the non-NAC group among the patients with cT3-4 disease, remains statistically 
significant (NAC: 26.0% versus non-NAC: 40.7%, P=0.012). Another weakness is the 
use of three different chemotherapeutic regimens. However, a previous report of our 
group showed comparable pathological response rates17. The authors also acknowledge 
that the NAC and non-NAC group are very different in terms of tumour stage. Along 
with the institutional policy for NAC, patients in the NAC-group had a significantly higher 
cT stage than patients in the non-NAC group. As explained in the introduction section, 
patients who have a higher cT-stage are more likely to have occult distant metastases 
2-7. Nevertheless, despite the higher cT stage in the NAC-group, we found an almost 
significant reduction in node positive disease if NAC was used. When adjusting for 
cT-stage, the effect of NAC on the presence of occult LN metastases was statistically 
significant, indicating the beneficial effect of NAC in terms of nodal stage.
Whether the decreased number of patients with LN metastases in the NAC group 
translates into improved survival cannot be concluded from the present study. Although 
we did find a significantly longer OS of the cT3-4 patients in the NAC group versus the 
non-NAC group, we are aware that this may be skewed by selection of medically more 
fit and/or younger patients to receive NAC. A (prospective) multicenter setting with a 
higher number of cases could aid in solving this question and may demonstrate whether 
the reduced incidence of nodal involvement after NAC translates into improved survival. 
The incidence of occult LN metastases depends on more factors than NAC only and 
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cT-stage. One factor is the extent of the PLND template, which has been standardized in 
the present study 7. Next to a thorough anatomic surgical procedure, histopathological 
evaluation is important for assessing the occurrence of occult LN metastases. 
Theoretically, NAC may influence pathological assessment of specimens. After NAC, for 
instance, LNs may be smaller and atrophic, therefore more difficult to identify 24. This 
may potentially lead to false positive down staging of the bladder specimen and nodal 
packages. In the present study, we did not observe such an effect as the number of 
resected nodes was even slightly higher in the NAC group. Nevertheless, it is essential 
for pathologists to be familiar with chemotherapy changes and to know how to handle 
and assess specimens after NAC in order to not overlook occult LN metastases in these 
patients. 
Additionally, a few studies have suggested that molecular and/or immunological 
techniques, for instance uroplakin II and cytokeratin-20, might be of additional value 
for detecting very small LN metastases, which are missed by conventional pathologic 
analysis 25-27. Such techniques were not used in the present study and will be subject of 
future studies to refine the prognosis of our patients.
Given the 20 – 30% of clinically node-negative patients who show lymph node 
metastases at the time of RC, with or without chemotherapy, there is an urgent 
need for preoperative LN assessment methods to improve. Currently, CT scanning is 
recommended for evaluating preoperative nodal involvement 1. It has been suggested 
that PET/CT is of additional value 28,29. Therefore, staging PET/CTs have been performed 
at our hospital in patients with MIBC since 2010. The imaging modality used (CT and 
PET/CT or CT alone) was entered into the multivariable model, in order to rule out 
the influence of PET/CT in the interaction between NAC and LN metastases. So, steps 
towards better preoperative LN staging are made, however yet, the most reliable way 
of staging LNs has remained PLND, and the importance of a thorough LN dissection in 
presumably cN0 patients should remain standard of care in MIBC. 
CONCLUSION
Our data confirm that, NAC is associated with downstaging of primary MIBC. We show 
that the use of NAC also leads to a significant reduction of occult LN metastases at 
RC for cT3-4N0M0 MIBC. A multicenter prospective study may show that the reduced 
incidence of nodal involvement for patients treated with NAC translates into improved 
survival.
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INDUCTION CHEMOTHERAPY FOLLOWED BY 
SURGERY IN NODE POSITIVE BLADDER CANCER
Urology 2013; Epub ahead of print
R.P. Meijer, L.S. Mertens, B.W. van Rhijn, A. Bex, H.G. van der Poel, W. Meinhardt, 
J.M. Kerst, A.M. Bergman, A. Fioole-Bruining, E. van Werkhoven, S. Horenblas
“There is a tide in the affairs of men.
Which, taken at the flood, leads on to fortune;
Omitted, all the voyage of their life
Is bound in shallows and in miseries.
On such a full sea are we now afloat,
And we must take the current when it serves,
Or lose our ventures.”
-William Shakespeare: Julius Caesar [Act 4, Scene 3]-
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ABSTRACT
Objectives
To evaluate the outcome and prognostic factors of patients with node positive bladder 
cancer (NPBC), who were eligible for surgery and treated with induction chemotherapy. 
Methods
All consecutive patients with NPBC, who were treated with at least two cycles of 
induction chemotherapy and initially scheduled for surgery, between 1990 and 2012, 
were identified from an institutional bladder cancer database. Induction chemotherapy 
consisted either of MVAC or gemcitabine with cisplatin (Gem/Cis) or carboplatin (Gem/
Carbo). 
Results
One hundred and forty-nine patients with NPBC (mean age: 60 years; range 31-79 
years) were treated with induction chemotherapy. Median cancer specific survival (CSS) 
was 20 months and 5-years CSS 29.2%. In case of complete pathological response to 
induction chemotherapy (N=40; 26.8%) median CSS was 127 months and 5-years CSS 
63.5% (p<0.0001). Clinical and pathological response to chemotherapy were predictive 
parameters with respect to CSS and recurrence free survival (RFS). Combined local and 
nodal response resulted in a significantly better outcome, compared to isolated nodal or 
local response (p<0.0001). 
Conclusions
Prognosis for NPBC remains poor despite the use of induction chemotherapy. Nevertheless, 
in the present series one out of four patients showed complete pathological response 
to NIC with subsequently a significant cancer specific survival benefit (median CSS 127 
months and 5-years CSS 63.5%). Clinical and pathological response to chemotherapy 
are predictive parameters for outcome. 
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A major development in optimizing treatment outcome of patients with invasive bladder 
cancer has been the introduction of cisplatin-based combination chemotherapy1-4. 
Rationale behind this multimodality treatment strategy, consisting of chemotherapy 
and surgery, is the eradication of microscopic metastatic disease. Despite the fact that 
urothelial cancer is considered to be a chemosensitive tumour, the absolute survival 
benefit associated with neoadjuvant/induction chemotherapy (NIC) is 6.5% at 5-years 
follow-up5. Considering the toxicity of the chemotherapy regimens and the advanced 
age of many patients, NIC is not used universally. Lymph node positive bladder cancer 
(NPBC) is a serious disease associated with a poor prognosis. In general five-years overall 
survival of NPBC patients ranges up to 26%6,7. The use of induction cisplatin-based 
combination chemotherapy in NPBC may be even more controversial, as most trials 
investigating the potential benefit of NIC excluded node positive patients5. Nevertheless, 
such a multimodality approach offers a chance of durable response and prolonged 
recurrence-free survival to some of the patients5,8,9. 
The response to NIC has proven to be an important prognosticator. Rosenblatt et 
al. postulated that downstaging of the primary tumour after chemotherapy may be 
considered a surrogate marker for treatment efficacy, which translates into survival 
benefit10. In their report on the Nordic cystectomy trials, they showed a 31.1% survival 
benefit at 5-years follow-up for complete downstaging in the NIC group versus the 
control arm10. 
In the present study we focused on patients with NPBC, who were treated with NIC 
and who were eligible for surgery. We analyzed the outcome of all patients that were 
treated with this strategy in our institution over the past years. 
MATERIALS AND METHODS
Patients. Our institutional strategy for NPBC patients consists of NIC, followed by a 
bilateral pelvic lymph node dissection (PLND) and radical cystectomy. Patients with 
lymph node metastases extending to the mediastinum or supraclavicular regions were 
deemed to be incurable and therefore no candidate for consolidating surgery after 
chemotherapy. All consecutive patients with NPBC, who were treated with at least two 
cycles of NIC and were eligible for surgery, between 1990 and 2012, were identified from 
an institutional bladder cancer database. All patients were discussed in multidisciplinary 
urologic oncology meetings with representatives from the departments of urology, 
medical oncology, radiation oncology, radiology and pathology. Patients who refused 
Induction chemotherapy and surgery in node positive bladder cancer
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surgery following NIC went on to receive either curative external beam radiotherapy 
(EBRT) or follow-up.
 
The 2009 TNM-classification was used for clinical staging11. Clinical staging was done 
pre- and post-chemotherapy, based on abdominal CT-scans, at least a chest X-ray and 
urethro-cystoscopy. Prior to NIC, node status was confirmed either by imaging alone 
(unequivocal lymphadenopathy on CT-scan; i.e. suspect lymph nodes with short axis > 
10mm), by imaging in combination with fine-needle aspiration (FNA) or by PLND. 
Chemotherapy. NIC consisted of a cisplatin-based regimen, being methotrexate, 
vinblastine, doxorubicin and cisplatin (MVAC) or gemcitabine with cisplatin (Gem/
Cis) or carboplatin (Gem/Carbo) in case of impaired renal function. The patients who 
were treated with MVAC, received either a classic or a high-dose-intensity schedule 
(HD-MVAC), as described by Nieuwenhuijzen et al.8. Treatment schedules for Gem/
Cis consisted of: gemcitabine 1,000 mg/m2 and cisplatin 70 mg/m2 on day one, and 
gemcitabine 1,000 mg/m2 on day eight, in a 21-day cycle. Furthermore for Gem/Carbo 
starting dose levels were: AUC 5 carboplatin on day one (30 minutes) and 1,000 to 1,250 
mg/m2 gemcitabine for 30 minutes on days one and eight for a 21-day cycle. Toxicity 
was graded according to the National Cancer Institute (NCI) Common Terminology 
Criteria for Adverse Events (CTCAE) classification, version 4.0. After two cycles of NIC 
the clinical response was evaluated by imaging (i.e. at least an abdominal CT-scan) and 
urethro-cystoscopy. Complete response (CR) was defined as no evidence of disease, 
partial response (PR) as any downstaging with persisting evidence of disease, stable 
disease (SD) as no change in tumour burden and progressive disease (PD) as any increase 
in tumour burden (being local and/or lymphadenopathy). In case of CR, PR or SD after 2 
cycles of chemotherapy another 2 cycles were added after which renewed staging was 
done, followed by consolidating therapy. In case of PD after 2 cycles of chemotherapy 
the treatment was ceased and the patient was evaluated for further therapy (i.e. surgery, 
radiation therapy or best-supportive care). 
Surgery. Consolidating surgery consisted of a radical cystectomy including a bilateral 
pelvic lymph node dissection (PLND). Until 2000 this PLND consisted of removal of all 
lymph nodes (LN) in the region between: medial side of the external iliac artery, the 
obturator fossa, up to the bifurcation of the common iliac artery. This was replaced by an 
enlarged template PLND consisting of removal of all lymph nodes in the region between: 
the genito-femoral nerve, the obturator fossa, along the internal iliac artery and along 
the common iliac artery up to the crossing of the ureter or the bifurcation of the aorta. All 
lymph nodes that were clinically suspect before chemotherapy were completely removed 
during post-chemotherapy surgery. Thus, in cases with supraregional (retroperitoneal) 
lymph node pathology, a complete retroperitoneal lymph node dissection was done 
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did not undergo surgery after NIC, pathological response could not be determined, 
therefore they were labelled as ‘not evaluable’ with respect to pathological response. 
The response to NIC was further subclassified into local response of the bladder tumour 
versus lymph node response (i.e. any downstaging in these two parameters), to evaluate 
the prognostic value of these variables. 
Statistics. Recurrence was defined as first relapse of disease, either loco-regional or 
distant. Recurrence free survival (RFS) was defined as the time from start of NIC until first 
recurrence or bladder cancer-related death. Patients with persistent measurable disease 
despite chemotherapy, who did not undergo definitive local treatment, were excluded 
from the RFS analysis. Cancer specific survival (CSS) was defined as the time from start 
of NIC until bladder cancer-related death. Patients who were alive at the end of follow-
up were censored at that date. Recurrence rates, RFS and CSS were analysed using the 
Kaplan-Meier method. Kaplan-Meier curves were compared using the log rank test. 
Multivariable regression analysis was performed including the following parameters: 
age, clinical stage, clinical and pathological response to chemotherapy, clinical local and 
nodal response and lymph node stage after chemotherapy (ypTN). Statistical significance 
was defined as a p value < 0.05. Data analysis was performed with Statistical Package 
for Social Sciences (SPSS), version 20.0 for Windows and R version 2.13.1. 
RESULTS
One hundred and forty-nine patients with NPBC were treated with NIC in our institution 
in the period from 1990 until 2012. Mean age was 60 years (range 31-79 years). 
Median follow-up was 57 months (interquartile range, IQR: 24-104 months). Patient 
characteristics and chemotherapy regimens are shown in table 1. Overall a median of 4 
courses of NIC were administered. Due to toxicity four patients switched from HD-MVAC 
to Gem/Carbo and two patients switched from MVAC to Gem/Carbo. Chemotherapy 
was discontinued prematurely due to drug related toxicity in 21 patients (14.1%): febrile 
neutropenia (N=5), mucositis (N=2), renal insufficiency (N=6), malaise/fatigue (N=5), 
hearing impairment (N=3). The median time from the final course of chemotherapy until 
surgery was six weeks.
One hundred and eighteen patients underwent surgery whereas fourteen patients were 
treated with EBRT instead. Seventeen patients did not receive local therapy because 
of comorbidity, refusal of surgery or progressive/metastatic disease. Median CSS for 
the total group was 20 months (IQR: 10-73 months) and 5-years CSS 29.2%. The CSS 
and RFS curves according to clinical lymph node stage are shown in figure 1. Patients 
Induction chemotherapy and surgery in node positive bladder cancer
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with cN2-3 and patients with cM1 disease (retroperitoneal lymph node metastases) had 
a comparable outcome (median CSS 15 months). CSS data according to clinical and 
pathological response to NIC are shown in table 2. Complete responders to NIC show 
a significantly better CSS compared to incomplete- and non-responders (p<0.0001). In 
clinically complete responders, residual disease after surgery was present in 38.5% of 
patients. The negative predictive value (NPV) of the clinical response evaluation was 
61.5%. After multivariable analysis the pathological response to chemotherapy remained 
a significant prognostic factor for CSS (table 3).
Overall recurrence of disease was seen in 57.7% of patients with a median time to 
recurrence of 15 months. In cN1 patients the recurrence rate was 48.1% versus 64.5% 
for cN2-3 patients and 60.6% for patients with retroperitoneal lymph node metastases 
(cM1). 
Figure 2 shows the CSS and RFS curves according to clinical local response in the bladder 
versus nodal response after NIC (table 4). The differences in CSS between isolated nodal 
response and local response did not reach statistical significance (p=0.26). 
Table 1. Patient characteristics
N %
Gender Male 112 75.2
Female 37 24.8
Clinical Tumour stage cT1 9 6.0
cT2 57 38.3
cT3 38 25.5
cT4 45 30.2
Clinical Lymph Node stage cN1 54 36.2
cN2-3 62 41.6
cM1 (supraregional LN) 33 22.1
Tumour Grade G2 5 3.4
G3 144 96.6
Modality Nodal Stage Confirmation Imaging 44 29.5
Imaging + FNA 40 26.8
PLND 65 43.6
Chemotherapy Regimen Classic MVAC 32 21.5
HD-MVAC 60 40.3
Gem/Cis 19 12.8
Gem/Carbo 38 25.5
Local Therapy RC 118 79.2
EBRT 14 19.4
None 17 11.4
Abbreviations: HD-MVAC = high-dose-intensity MVAC;  LN = lymph nodes; FNA = fine needle aspiration; 
PLND = pelvic lymph node dissection; RC = radical cystectomy; EBRT = external beam radiotherapy
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DISCUSSION
Node positive bladder cancer (NPBC) generally is a serious disease with a poor prognosis. 
Nevertheless, in the present series 26.8% of patients showed complete pathological 
response to NIC with subsequently a significant cancer specific survival benefit (median 
CSS 127 months and 5-years CSS 63.5%). 
Legend Figure 1. CSS and RFS according to clinical lymph node status
a) Kaplan-Meier analysis for CSS according to clinical lymph node status (cN) (P=0.092). For cN1 patients 
median CSS was 33 months and 5-years CSS 42.1%. Furthermore CSS of cN2-3 patients was similar to cM1 
patients (retroperitoneal lymph node metastases) with a 5-years CSS of 22.7 and 22.8% respectively and a 
median CSS of 15 months (P=0.80).
b) Kaplan-Meier analysis for RFS according to clinical lymph node status (cN). Median RFS was 28 months for 
cN1, 14 months for cN2-3 and 13 months for M1 respectively (P=0.03).
Table 2. Cancer specific survival according to clinical and pathological response to induction chemotherapy
Response evaluation N % Median CSS
(months)
5-years 
CSS (%)
p-value
Clinical response CR 52 34.9 36 43.3
<0.0001
PR 71 47.7 16 25.0
SD 18 12.1 12 19.7
PD 8 5.4 6 0.0
Pathological response pCR 40 26.8 127 63.5
<0.0001
pPR 42 28.2 22 26.6
pSD 35 23.5 15 16.6
pPD 15 10.1 10 0.0
Not evaluable 17 11.4 12 0.0
Abbreviations: CSS = cancer specific survival; CR = complete response; PR = partial response; SD = stable 
disease; PD = progressive disease
a b
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Although clinical response evaluation proves to be an important predictor for clinical 
outcome, the accuracy of response evaluation remains limited. In clinically complete 
responders, residual disease after surgery was present in 38.5% of patients. In order to 
improve clinical response evaluation after chemotherapy, novel imaging techniques such 
as FDG/PET-scan and diffusion-weighted magnetic resonance imaging (MRI) may be 
used, but they require further validation12-14. 
Although a trend was seen that favours CSS for cN1 patients, the differences versus 
cN2-3cM0-1 patients were not statistically significant. These differences may be more 
pronounced with larger sample size. On the other hand, the RFS was significantly better 
for cN1 patients versus cN2-3M0-1 patients (P=0.03). Bruins et al. reported on the 
higher recurrence risk for patients with multiple lymph node metastases versus patients 
with low volume lymph node metastases, this was confirmed by the present study and 
may be useful for prognostic purposes15. Notably the CSS of cN2-3 patients was similar 
Table 3. Multivariable analysis for disease specific survival 
HR Lower Upper p-value
Age (per year) 1.00 0.98 1.03 0.78
Clinical staging Organ confined node 
positive disease
(T1-2N1-3M0)
1.00
0.58
Locally advanced node 
positive disease 
(T3-4N1-3M0)
1.24 0.72 2.15
Retroperitoneal 
lymphadenopathy
(TxNxM1)
1.39 0.70 2.78
Clinical response CR 1.00
0.70
PR 1.02 0.48 2.20
SD 0.53 0.14 1.95
PD 0.86 0.20 3.79
Clinical response 
local versus nodal
No response 1.00
0.34
Isolated local response 1.18 0.40 3.45
Isolated nodal response 0.60 0.24 1.53
Combined local and nodal 
response
0.59 0.20 1.72
Pathological 
response 
pCR 1.00
0.002
pPR 2.31 1.07 4.98
pSD 4.02 1.67 9.67
pPD 7.29 2.63 20.17
Not evaluable 2.13 0.33 13.86
Pathological node 
stage after 
chemotherapy
ypN0 1.00
0.28ypN+ 1.32 0.73 2.37
ypNx 3.90 0.64 23.81
Abbreviations: HR = hazard ratio; CR = complete response; PR = partial response; SD = stable disease; 
PD = progressive disease
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to cM1 patients, corroborating the earlier publication by De Vries et al.16. Thus patients 
with supraregional (retroperitoneal) lymph node metastases may be eligible for NIC 
followed by consolidating surgery. 
Despite earlier reports on the improved outcome following NIC, clinicians remain 
reluctant to initiate this strategy, because of the potential toxicity involved. According 
to a report from the National Cancer Data Base in 2007, peri-operative chemotherapy 
was administered to 11.6% of patients with stage III bladder cancer in the USA. Thus 
Legend Figure 2. CSS and RFS according to clinical response (local versus lymph node response)
a) Kaplan-Meier analysis for CSS according to clinical local response in the bladder versus nodal response after 
NIC (P<0.0001) (Table 4). 
b) Kaplan-Meier analysis for RFS according to clinical local response in the bladder versus nodal response after 
NIC (P=0.002) (Table 4).
Table 4. Outcome according to local response in the bladder versus lymph node response after induction 
chemotherapy
N % Median CSS
(months)
5-years 
CSS (%)
p-
value
Median RFS
(months)
5-years 
RFS (%)
p-
value
Clinical response
<0.0001 0.002
Combined local and 
nodal response
76 51.0 33 38.7 21 36.3
Isolated local 
response
11 7.4 14 10.4 9 11.4
Isolated nodal 
response
38 25.5 17 34.0 14 19.5
No response 24 16.1 10 0.0 10 0.0
Overall 149 100.0 20 29.2 15 26.6
Abbreviations: CSS = cancer specific survival; RFS = recurrence free survival
a b
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underlining the fact that perioperative chemotherapy is underused in stage III bladder 
cancer17. Preferably such a multimodality approach would be initiated only in patients 
who are most likely to benefit from such toxic chemotherapy regimens and high-risk 
surgery. Therefore, one of the most important issues remains the chemosensitivity of the 
individual bladder tumour. In non-responders, NIC delays surgical intervention and (in 
theory) may impede an opportunity for cure. Although the curative potential of surgery 
alone, in a group of patients who do not respond to chemotherapy, may be seriously 
questioned. There have been varying reports on the use of molecular markers to predict 
prognosis and chemosensitivity of bladder tumours. Especially the tumour suppressor 
proteins p53 and retinoblastoma (pRb) and their downstream effectors (e.g. p21) have 
been investigated in this respect18-20. The implementation of molecular markers may be 
the basis for indivualizing treatment for patients with NPBC 18,20. 
Response to chemotherapy was assessed after two cycles based on earlier publications, 
showing that, in case of no response, further chemotherapy is futile21. The present study 
confirms the predictive value of clinical and pathological response to chemotherapy with 
respect to CSS and RFS. This underlines the earlier report by Rosenblatt et al.10. In the 
current series clinical response was further stratified into local response in the bladder 
versus nodal response. Patients with combined local and nodal response had a significantly 
better outcome when compared to isolated nodal or local response (p<0.0001). Isolated 
nodal response was associated with a better CSS (median CSS 17 months; 5-years CSS 
34.0%) when compared to isolated bladder response (median CSS 14 months; 5-years 
CSS 10.4%), although the differences did not reach statistical significance and it must 
be noted that the numbers in these groups are limited. Limitations of the present study 
consist of the retrospective design and the use of varying regimens of chemotherapy. 
The use of carboplatin instead of cisplatin may be noted as a limitation although recently 
Mertens et al. reported the comparable clinical and pathological response rates for 
patients who were unfit to receive cisplatin and who were treated with carboplatin-
based NIC22.
CONCLUSIONS
Prognosis for NPBC remains poor despite the use of induction chemotherapy. 
Nevertheless, in the present series one out of four patients showed complete 
pathological response to NIC with subsequently a significant cancer specific survival 
benefit. Clinical and pathological response to chemotherapy are predictive parameters 
for outcome. Isolated nodal response on imaging is associated with a better outcome 
when compared to isolated local response in the bladder.
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“We haven’t learned to disagree without being violently disagreeable”
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ABSTRACT
Objectives
To elucidate the long-term outcome and the risk for local recurrence of patients with 
limited disease small cell carcinoma of the bladder (LD-SCCB, Tx-4N0-1M0), treated 
with neoadjuvant chemotherapy followed by external beam radiotherapy (sequential 
chemoradiation).
Methods 
All consecutive patients with primary small cell carcinoma of the bladder (N=66), treated 
in our institution between 1993 and 2011 were retrospectively evaluated from an 
institutional database. The present study focused on the patients with LD-SCCB that 
were treated with sequential chemoradiation (N=27). Recurrence rates, overall survival 
(OS) and cancer specific survival (CSS) were analysed using the Kaplan-Meier method.
Results
Median time to recurrence was 20 months, median OS 26 months, 5-years OS 
22.2%, median CSS 47 months and 5-years CSS 39.6%. For complete responders 
after neoadjuvant chemotherapy (N=19) median CSS was 52 months with a 5-years 
CSS 45.9% versus a median CSS of 22 months and 5-years CSS 0.0% for incomplete 
responders (N=8) (P=0.034). Eight patients (29.6%) underwent transurethral resections 
(TUR-BT) for local recurrences in the bladder. At the end of follow-up 4 patients had 
undergone cystectomy for recurrence of disease resulting in a bladder-preservation rate 
of 85.2%. Median time to local recurrence was 29 months and median time to distant 
recurrence 10 months.
Conclusions
Sequential chemoradiation for LD-SCCB results in a reasonable outcome with a high 
bladder preservation rate. Response to neoadjuvant chemotherapy is a significant 
prognostic factor. 
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Small cell carcinoma of the bladder (SCCB) is a relatively rare condition, accounting 
for approximately 0.5-0.7% of urothelial malignancies 1-3. Due to this low incidence, 
the published reports on this topic encompass limited numbers of patients (ranging 
from 5-88) and consensus on the optimal treatment strategy has not been reached 4-6. 
Initially radical cystectomy was considered the standard of care for patients with clinically 
localized disease. However, the high rate of metastases has led to the introduction of 
multimodality approaches with systemic chemotherapy combined with either surgery 
or radiotherapy 3-7. Recently Koay et al. reported on a large subset of patients from the 
Surveillance, Epidemiology, and End Results (SEER)-Medicare database with SCCB treated 
with chemotherapy and radiotherapy versus cystectomy with chemotherapy, showing 
no significant differences in overall survival between the two treatment modalities 8. 
The biological and clinicopathological features of SCCB are similar to those of small cell 
lung carcinoma (SCLC)9,10. Thus the treatment approach to this rare tumour has been 
greatly influenced by the treatment of the far more common SCLC. In the approach of 
SCLC a distinction is made between patients with limited disease (tumour confined to the 
hemithorax, mediastinum or supraclavicular lymph nodes) and patients with extensive 
disease (tumour outside these areas). Patients with limited disease (LD) SCLC are generally 
treated with a combination of systemic chemotherapy and local radiotherapy 11-14. This 
multimodality treatment is applied to address the risk of occult micrometastases at the 
time of diagnosis. Patients with extensive disease (ED) SCLC are treated with palliative 
chemotherapy only. Considering the similar tumour biology of SCCB and SCLC, some 
authors define limited (LD) and extensive disease (ED) SCCB in analogy to SCLC 5,7. In 
this staging approach patients with tumour confined to the pelvis are defined as limited 
disease. In recent years a similar staging system has been advocated in several other 
reports 5,15. Furthermore, the treatment approach for LD-SCCB in our hospital was also 
inspired by the multimodality treatment applied for LD-SCLC (i.e. systemic chemotherapy 
combined with external beam radiotherapy). This bladder-sparing strategy has been 
applied for LD-SCCB in our institution since 1993. The present study was performed 
to further elucidate the long-term outcome and the risk of local recurrence of patients 
with LD-SCCB, who were treated with sequential chemoradiation (i.e. neoadjuvant 
chemotherapy followed by external beam radiotherapy). 
METHODS
Patients. All consecutive patients with primary SCCB, based on the WHO criteria10,16, 
who were treated at the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital 
in the period between 1993 and 2011, were identified from an institutional consecutively 
Sequential chemoradiation for small cell carcinoma of the bladder
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maintained database. The patients with primary SCLC were excluded. Patient records 
for all cases were retrieved and the relevant data were extracted. Staging was done 
according to the 2009 TNM-classification17. In analogy to SCLC, patients with any local 
stage, no distant metastases and involvement of maximally one locoregional lymph 
node less than 2 cm on imaging (Tx-4N0-1M0) were defined as having limited disease 
(LD-SCCB), all others (Tx-4NxM1/ Tx-4N2-3M0) as extensive disease (ED-SCCB). Patients 
were staged with cystoscopy, urinary cytology, laboratory evaluation, CT-scan of the 
abdomen and chest X-ray before chemotherapy. These investigations were also used at 
a 3-monthly interval for the follow-up. All patients underwent transurethral resection of 
the bladder tumour (TUR-BT) prior to chemotherapy. In general, patients with LD-SCCB 
were treated with neoadjuvant chemotherapy followed by external beam radiotherapy. 
Exceptionally, cystectomy was performed in cases of previous radiotherapy to the pelvis 
or uncontrollable local symptoms. Patients with ED-SCCB were considered for palliative 
chemotherapy7. For the present study we focused on patients with LD-SCCB who 
were treated with neoadjuvant chemotherapy followed by external beam radiotherapy 
(sequential chemoradiation).
Chemotherapy. Neoadjuvant chemotherapy was analogous to accepted regimens for 
SCLC, except for patients with <50% SCCB in combination with urothelial carcinoma 
in the primary TUR-BT specimen, who were treated with 4 courses methotrexate 30 
mg/m2, vinblastine 3 mg/m2, doxorubicine 30 mg/m2 and cisplatin 70 mg/m2 (M-VAC). 
Over the past years the cisplatin-based SCLC regimens changed. Four courses ifosfamide 
1.2 g/m2 (maximum 1.75 g), VP-16 (etoposide) 75 mg/m2 and cisplatin 20 mg/m2 
(VIP) day 1–4, repeated after 21 days were later replaced by 4 courses cisplatin 75 
mg/m2 day 1 with etoposide 100 mg/m2 intravenous (CE) day 1–3, repeated after 21 
days. Patients with contraindications for cisplatin but a performance score WHO ≤ 2, 
received 5 courses cyclophosphamide 1.0 g/m2 (day 1), doxorubicine 45 mg/m2 (day 1) 
and etoposide 100 mg/m2 (day 1–3) (CDE) repeated after 21 days. Later that regimen 
was changed to carboplatin AUC 5 (day 1) with etoposide 100 mg/m2 intravenous (CaE) 
day 1–3, repeated after 21 days18. Response to neoadjuvant chemotherapy was based 
on CT-scan and cystoscopy. In doubtful cases TUR-BT or biopsy was performed19. For 
practical purposes regarding the limited number of treated patients, two groups were 
created based on local and systemic response to chemotherapy: complete response and 
incomplete response (including partial response, stable disease and progressive disease). 
Radiotherapy. External beam radiotherapy (EBRT) was applied using 8-18 MV photons 
with a three- or four-field technique. The median dose was 60Gy. The target area 
consisted of the bladder and the tumour. In case the total dose was 70 Gy, 50 Gy was 
given to the bladder and tumour with a 20 Gy boost to the tumour area only, as was 
previously published18. Because of the increased risk for local toxicity in the bladder, 
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general in SCLC patients radiotherapy is applied concomittantly with the chemotherapy. 
Prophylactic cranial irradiation was not performed. 
Statistics. Recurrence rates, cancer specific survival and overall survival were analysed 
using the Kaplan-Meier method. Overall survival (OS) was defined as the time from 
diagnosis to any cause of death. Cancer specific survival (CSS) was defined as the time 
from diagnosis to cancer-related death. Patients who were alive at the end of follow-up 
were censored at that date. Recurrence was defined as first relapse of disease, either 
local or distant. Local recurrences in the bladder were further specified according to 
the histopathology report (i.e. recurrence of small cell carcinoma or transitional cell 
carcinoma). Time to recurrence was defined as the time from start of neoadjuvant 
chemotherapy until first recurrence. Patients with concomitant local and distant 
recurrences were analyzed as distant metastases. Kaplan-Meier curves were compared 
using the log rank test. 
Statistical significance was defined as a p value <0.05. Data analysis was performed with 
Statistical Package for Social Sciences (SPSS), version 18.0 for Windows. 
RESULTS
Overall. Sixty-six patients with SCCB were treated in the period between 1993 and 2011, 
with a median age of 62.0 years (range 39-89), predominantly males (78.8%). In total 
50 patients (75.8%) had LD-SCCB and sixteen patients (24.2%) ED-SCCB. Some patients 
with LD-SCCB were not treated with chemoradiation for various reasons, including 
previous radiotherapy to the pelvis or uncontrollable local symptoms. For patients with 
LD-SCCB (N=50) the median overall survival (OS) was 22 months (IQR: 10-60 months), 
2-years OS 48.8% and 5-years OS 22.8%, whereas for ED-SCCB (N=16) the median OS 
was 11 months (IQR: 7-17 months), 2-years OS 15.8% and 5-years OS 7.9% respectively 
(P=0.018). Survival curves according to extent of disease are shown in figure 1. For the 
entire group (N=66) distant recurrences consisted of bone metastases in 16 patients 
(24.2%), pulmonary metastases in 9 patients (13.6%), liver metastases in 7 patients 
(10.6%) and symptomatic brain metastases in 8 patients (12.1%). 
Sequential chemoradiation for LD-SCCB. Twenty-seven patients (54.0%) with LD- 
SCCB were treated with neoadjuvant chemotherapy (median 4 courses) followed by 
EBRT. The characteristics of these patients are shown in table 1. Median OS of these 
patients was 26 months (IQR: 12-60 months) and 5-years OS 22.2%. For this group 
median CSS was 47 months and 5-years CSS 39.6%. 
Sequential chemoradiation for small cell carcinoma of the bladder
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Complete response to chemotherapy was seen in 70.4% of patients and incomplete 
response in 29.6% (partial response N=4; stable disease N=3; progressive disease N=1). 
For complete responders median OS was 38 months and 5-years OS 26.3%, versus a 
median OS of 11 months and 5-years OS 0.0% for incomplete responders respectively 
(P=0.035). Median CSS was 52 months for complete responders with a 5-years CSS 
Table 1. Characteristics of patients with LD-SCCB treated with bladder-sparing strategy (N=27)
N %
Histo-pathology SCC > 50% 17 63.0
SCC < 50% 5 18.5
Unknown % SCC 5 18.5
Clinical Tumour stage T2 18 66.7
T3 5 18.5
T4 3 11.1
Tx 1 3.7
Clinical Nodal stage N0 24 88.9
N1 1 3.7
Nx 2 7.4
Chemotherapy CDE 5 18.5
VIP 2 7.4
CaE 5 18.5
CE 12 44.4
GC 1 3.7
MVAC 2 7.4
Abbreviations: SCC = small cell carcinoma; CE = cisplatin/etoposide; CDE = cyclophosphamide/doxorubicine/
etoposide; GC = gemcitabin/cisplatin; VIP = ifosfamide/etoposide/cisplatin; CaE = carboplatin/etoposide; 
MVAC = methotrexate/vinblastine/doxorubicine/cisplatin
Figures 1a + b. Kaplan-Meier analyses for OS (1a) and CSS (1b) according to extent of disease (LD-SCCB (N=50) 
versus ED-SCCB (N=16)). Median OS was 22 months for LD-SCCB and 11 months for ED-SCCB respectively. 
Five-years OS was 22.8% for LD-SCCB and 7.9% for ED-SCCB (p=0.018). For LD-SCCB median CSS was 32 
months and 5-years CSS 38.2% versus 12 months  and 8.7% for ED-SCCB respectively (p=0.004).
a b
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CSS 0.0% respectively (P=0.034). Survival curves according to clinical response to 
neoadjuvant chemotherapy are shown in figure 2. All patients with incomplete response 
to neoadjuvant chemotherapy achieved complete local response following radiotherapy. 
a b
Figures 2a + b. Kaplan-Meier analysis for OS (2a) and CSS (2b) according to clinical response after neoadjuvant 
chemotherapy (LD-SCCB treated with bladder-sparing strategy; N=27). Complete response to chemotherapy 
was seen in 70.4% of patients and incomplete response in 29.6% (partial response N=4; stable disease N=3; 
progressive disease N=1). For complete responders median OS was 38 months and 5-years OS 26.3%, versus 
a median OS of 11 months and 5-years OS 0.0% for incomplete responders respectively (p=0.035). Median 
CSS was 52 months for complete responders with a 5-years CSS 45.9% versus a median CSS of 22 months for 
incomplete responders with a 5-years CSS 0.0% respectively (p=0.034).
Recurrence of disease was seen in 20 patients (74.1%), of which 7 local recurrences in 
the bladder (25.9%), 12 distant recurrences (44.4%) and 1 patient with simultaneously 
local and distant recurrences (3.7%). Median time to local recurrence was 29 months 
(IQR: 22-44 months) and median time to distant recurrence 10 months (IQR: 7-17 
months). During follow-up 8 patients (29.6%) underwent TUR-BT for local recurrences. 
Characteristics of these patients with local recurrences in the bladder are shown in table 
2. At the end of follow-up the bladder-preservation rate in this group was 85.2%. Distant 
recurrences consisted of bone metastases in 6 patients (22.2%), pulmonary metastases 
in 4 patients (14.8%), liver metastases in 3 patients (11.1%) and brain metastases in 4 
patients (14.8%). 
Sequential chemoradiation for small cell carcinoma of the bladder
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DISCUSSION
Sequential chemoradiation for LD-SCCB results in a reasonable outcome with a high 
bladder preservation rate. In general the prognosis of SCCB is poor, with the 5-years 
OS ranging from 8 to 44% for limited disease 3,5,18. In earlier reports only platinum-
based combination chemotherapy has been associated with significant improvement 
of survival regardless of the regimen used 4,13,20. The present study showed a median 
OS of 26 months and 5-years OS 22.2% and a median CSS of 47 months with 5-years 
CSS 39.6% for patients with LD-SCCB treated with sequential chemoradiation. Lohrisch 
et al. report a median OS of 41 months and 5-years OS of 44% for patients with 
LD-SCCB treated with sequential chemoradiation 5. This discrepancy can be explained 
by the relatively small sample size of the report by Lohrisch et al. (N=10). Complete 
responders to neoadjuvant chemotherapy fare significantly better with a median CSS 
of 52 months and 5-years CSS of 45.9%. These results underline that response to 
neoadjuvant chemotherapy is a significant prognostic factor. The use of various regimen 
of neoadjuvant chemotherapy comprises a limitation of the present study, but reflects 
changes in clinical practice throughout the years. With the exception of 5 patients 
(18.5 %) with renal function impairment who received CDE prior to the introduction of 
carboplatin all regimen were platinum-based (Table 1). A report by Siefker-Radtke et al. 
showed a median OS of 58 months in patients with localized SCCB (≤cT3bN0M0) who 
were treated with neoadjuvant chemotherapy and surgery (bilateral pelvic lymph node 
dissection and cystectomy) 21. These promising results were recently corroborated by 
another report from the same MD Anderson group 22. The substantial differences in OS 
of patients in the present study with bladder preserving strategy versus the mentioned 
Table 2. Local recurrences in the bladder in patients with LD-SCCB treated with bladder-sparing strategy
Gender Age 
(years)
TNM-
stage
Chemotherapy 
regimen
Histopathology
Primary Tumour
Clinical 
response
Histopathology 
Recurrence
Time to Recurrence 
(months)
Treatment of recurrence Status at end of 
follow-up
M 62 T2N0M0 MVAC SCC < 50% CR SCC 49 TUR-BT + Cystectomy DOOD
M 68 T3N0M0 CDE SCC > 50% CR SCC 26 TUR-BT + Cystectomy DOD
M 74 T2N0M0 CaE SCC > 50% CR CIS 22 TUR-BT + BCG DOOD
M 55 T2N0M0 CE SCC > 50% PR CIS 12 TUR-BT + BCG AWD
F 52 T3N0M0 GC SCC > 50% SD Unknown 5 Best supportive care ‡ DOD
M 58 TxNxM0 CE Unknown % SCC CR UCC + CIS 31 TUR-BT + Cystectomy DOOD
M 66 T3N0M0 CE Unknown % SCC CR UCC + CIS 44 TUR-BT + Cystectomy AWOD
M 57 T4NxM0 CDE Unknown % SCC CR UCC + SCC 29 TUR-BT + Chemotherapy† DOD
† Scheduled for salvage cystectomy, developed pulmonary metastases prior to surgery; ‡ Patient with 
simultaneous local and distant recurrences, therefore no local therapy was performed; Abbreviations: CDE 
= cyclophosphamide/doxorubicine/etoposide; CaE = carboplatin/etoposide; CE = cisplatin/etoposide; GC = 
gemcitabin/cisplatin; MVAC = methotrexate/vinblastine/doxorubicine/cisplatin; CR = complete response; PR 
= partial response; SD = stable disease; SCC = small cell carcinoma; UCC = urothelial cell carcinoma; CIS = 
carcinoma in situ; BCG = Bacillus Calmette-Guérin maintenance intravesical treatment; DOD = died of disease; 
AWD = alive with disease; AWOD = alive without disease; DOOD = died of other disease
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tumour stage, different regimens of chemotherapy and clinical versus pathological 
TNM staging. Patient selection may be another confounding factor. A comparison of 
reported outcomes from our series with studies involving cystectomy may therefore be 
biased by these factors. Unfortunately, it is very likely that the paucity of the disease 
precludes randomized studies. In the absence of case-matched comparisons of reported 
study data we cannot rule out that sequential chemoradiation may indeed be inferior 
to neoadjuvant chemotherapy and cystectomy in these patients. On the other hand, 
the results from the SEER-database did not show significant differences in OS between 
chemotherapy with radiotherapy versus cystectomy  with 5-years OS of 19% for the 
bladder-sparing strategy versus 26% for cystectomy with chemotherapy. It should be 
noted that the results from the SEER-database are potentially confounded by the lack of 
details concerning radiotherapy and chemotherapy regimens. To determine the optimal 
treatment approach for this rare and aggressive entity, a multi-center case-matched 
comparison between different treatment modalities (e.g. neoadjuvant chemotherapy 
with either surgery or radiotherapy) would be invaluable. 
In analogy to SCLC, the division of patients with SCCB into groups with limited (LD-SCCB) 
and extensive disease (ED-SCCB) provides a useful classification for both treatment and 
prognosis. Patients with LD-SCCB have a significantly better outcome compared to 
patients with ED-SCCB. 
The risk of local recurrence of transitional cell carcinoma after primary mixed tumours has 
been reported in several studies, especially in long term survivors after chemoradiation 
5,6. In the present group of LD-SCCB treated with sequential chemoradiation, local 
recurrence in the bladder was seen in 29.6% of patients. Histopathology of the 
recurrences in the bladder revealed small cell carcinoma in 2 patients (7.4%) and 
transitional cell carcinoma in 6 patients (22.2%). The median time to local recurrence 
was 29 months. Therefore, following a bladder-sparing approach, regular follow-up 
Table 2. Local recurrences in the bladder in patients with LD-SCCB treated with bladder-sparing strategy
Gender Age 
(years)
TNM-
stage
Chemotherapy 
regimen
Histopathology
Primary Tumour
Clinical 
response
Histopathology 
Recurrence
Time to Recurrence 
(months)
Treatment of recurrence Status at end of 
follow-up
M 62 T2N0M0 MVAC SCC < 50% CR SCC 49 TUR-BT + Cystectomy DOOD
M 68 T3N0M0 CDE SCC > 50% CR SCC 26 TUR-BT + Cystectomy DOD
M 74 T2N0M0 CaE SCC > 50% CR CIS 22 TUR-BT + BCG DOOD
M 55 T2N0M0 CE SCC > 50% PR CIS 12 TUR-BT + BCG AWD
F 52 T3N0M0 GC SCC > 50% SD Unknown 5 Best supportive care ‡ DOD
M 58 TxNxM0 CE Unknown % SCC CR UCC + CIS 31 TUR-BT + Cystectomy DOOD
M 66 T3N0M0 CE Unknown % SCC CR UCC + CIS 44 TUR-BT + Cystectomy AWOD
M 57 T4NxM0 CDE Unknown % SCC CR UCC + SCC 29 TUR-BT + Chemotherapy† DOD
† Scheduled for salvage cystectomy, developed pulmonary metastases prior to surgery; ‡ Patient with 
simultaneous local and distant recurrences, therefore no local therapy was performed; Abbreviations: CDE 
= cyclophosphamide/doxorubicine/etoposide; CaE = carboplatin/etoposide; CE = cisplatin/etoposide; GC = 
gemcitabin/cisplatin; MVAC = methotrexate/vinblastine/doxorubicine/cisplatin; CR = complete response; PR 
= partial response; SD = stable disease; SCC = small cell carcinoma; UCC = urothelial cell carcinoma; CIS = 
carcinoma in situ; BCG = Bacillus Calmette-Guérin maintenance intravesical treatment; DOD = died of disease; 
AWD = alive with disease; AWOD = alive without disease; DOOD = died of other disease
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with cystoscopy is mandatory for a prolonged period (≥24 months). In some cases 
local recurrence in the bladder can be treated with conservative therapy (e.g. TUR-BT 
and adjuvant intravesical BCG-instillations). In the group with LD-SCCB and sequential 
chemoradiation, the bladder-preservation rate was 85.2%. 
Because of experience with an  increased risk for local toxicity in the bladder after 
concurrent chemoradiation, in our institution EBRT is scheduled after the neoadjuvant 
chemotherapy. There have been reports on the beneficial effects of concurrent 
administration of radiosensitizing agents (e.g. cisplatin-based chemotherapy) potentiating 
the cytotoxic effect of radiotherapy 23. As the techniques of EBRT have evolved in recent 
years and the risks of local toxicity have been further reduced, the use of concurrent 
chemoradiation may be expected to gain terrain. 
Patients with SCLC have a significant risk for the development of brain metastases (up to 
60% within 2-3 years after starting treatment). Therefore patients with complete response 
to chemotherapy are offered prophylactic cranial irradiation 24,25. Similarly patients with 
SCCB show a risk for the development of brain metastases. Siefker-Radtke et al. reported 
up to 26.7% brain metastases in patients with SCCB 21. In the present study 8 patients 
(12.1%) with SCCB developed symptomatic brain metastases. The difference is explained 
by regular brain scanning during follow-up versus symptom-oriented imaging. There are 
no studies indicating superiority of prophylactic cranial irradiation to cranial irradiation 
in SCCB patients with symptomatic brain metastases. In a literature review including 
our own data the risk of developing symptomatic brain metastases was 10.5%, which 
is higher than in urothelial cell carcinoma but significantly lower than in SCLC (60%) 26. 
Therefore we did not perform prophylactic cranial irradiation in patients with SCCB.  
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SUMMARY AND GENERAL DISCUSSION
“Do not think your way superior to that of another’s
Do not venture to judge but see things with fresh and open eyes
Do not condemn but praise when you can
And when you can’t, be silent.
Time is now a gift for you, a gift of freedom.
To think and remember and understand the ever perplexing past.
And to recreate yourself anew in order to transform time.”
-Ben Okri-

9Introduction
This thesis underlines the aggressive nature of bladder cancer. In the Dutch Cancer 
Registry bladder cancer is reported in the top five of most common tumour localizations 
in men and in the top ten in women. Nevertheless, the public awareness of this disease 
is low. Hopefully this thesis will contribute to the awareness among both clinicians and 
the general population. Furthermore I hope this thesis will improve the multidisciplinary 
approach to this life-threatening disease. 
High-grade non-muscle invasive bladder cancer 
High-grade non-muscle invasive bladder cancer (HG-NMIBC) represents a group of 
urothelial carcinomas with a high risk for recurrence and significant risk of progression to 
muscle invasive bladder cancer (MIBC). Despite well-defined histo-pathological criteria, 
there is significant inter-observer variability among pathologists when classifying Ta 
versus T1 tumours and grading urothelial tumours. Concordance between pathologists 
ranges from 40-60% for staging (Ta versus T1) and from 70-78% for classifying carcinoma 
in situ (CIS)1-3. Therefore, revision of histo-pathology by a dedicated uro-pathologist has 
been advised for T1 high-grade tumours (Ta versus T1) and carcinoma in situ (CIS)4,5. 
The study described in chapter 2 showed that CIS indeed is a disease with a high risk 
for recurrence (68.9%) and a high rate of progression to muscle invasive bladder cancer 
(18.9%). In this study the concomitant CIS group appeared to have a poorer prognosis 
with a shorter duration of bladder preservation and a worse overall survival compared 
to primary and secondary CIS, although not statistically significant6. To provide another 
risk profile for CIS of the bladder a different subdivision has been proposed, identifying 
patients with high-risk CIS (i.e. diffuse CIS, prostatic urethra involvement, over-expression 
of p53). These patients are to undergo radical cystectomy (RC) without delay in case of 
BCG failure, whereas those with low-risk CIS (i.e. focal CIS, lack of over-expression of 
p53) may still be offered bladder-preserving therapy7. These results also suggest that 
early definitive therapy could be advisable in this poor-risk group. CIS of the bladder is 
also recognized as a risk factor for the development of upper urinary tract tumours after 
radical cystectomy8.
The dilemma of bladder-sparing treatment for patients with HG-NMIBC versus early 
cystectomy has been mentioned earlier. Some reports have been published on the 
results of early cystectomy for patients with primary CIS. Although the disease-specific 
survival (DSS) rates in these series are generally excellent (ranging from 85-91%), the 
rate of overtreatment with early cystectomy is substantial (up to 50% of patients) 9,10. 
On the other hand, the window of opportunity to optimally treat these patients with 
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high-risk NMIBC must be taken into account. In a retrospective analysis, the DSS proved 
to be significantly poorer for patients with progressive MIBC (5-years DSS 28%) versus 
patients with primary MIBC (5-years DSS 55%)11,12. A possible explanation for this worse 
outcome of patients with progressive MIBC may be found in the fact that high-risk 
NMIBC tumour biology consists of therapy-sensitive cells and therapy-insensitive cells. 
Intravesical instillations may lead to selection of resistant cell-lines and a more aggressive 
tumour biology that subsequently progresses to invasive disease11. For high grade T1 
disease, early radical cystectomy may be considered for selected high-risk patients (e.g. 
young patients with multifocal disease, concomitant CIS and tumour in the prostatic 
urethra, micropapillary UC)13.
Lymph node staging
In case of progression of NMIBC after conservative treatment or in case of primary 
MIBC, radical surgery remains the gold standard. As was stated earlier, in case of 
radical surgery the quality of bilateral pelvic lymph node dissection (PLND) is of the 
utmost importance14-16. The quality of surgical resection is generally measured by the 
histopathological lymph node count17,18. Furthermore lymph node parameters such as 
lymph node density are used as predictive factors for DSS19-21. In chapter 3 two studies 
were described concerning this matter. The histopathological outcomes of PLNDs in 
two different hospitals were compared. These studies show a statistically significant 
difference between the two pathology departments evaluating the number of lymph 
nodes after PLND for bladder cancer, despite equal anatomical clearance by the same 
experienced surgeons. Nevertheless, no statistically significant difference was found in 
the number of tumour positive lymph nodes. Furthermore there were no differences in 
overall survival (OS) and recurrence free survival (RFS) between the two hospitals22,23. 
Clearly, next to a thorough anatomic surgical procedure, a standardized histopathological 
evaluation is of the utmost importance. Unless standardized methods have been agreed 
upon by pathologists, one should be cautious to use the number of reported lymph 
nodes as an indicator of the quality of surgery and to use the lymph node density as 
prognostic factor.
Multimodality treatment in bladder cancer
Nowadays the multidisciplinary approach has generally been adopted as ‘standard of 
care’ in the field of oncology. Over the years bridges have been built between surgical 
specialties and the departments of radiotherapy, medical oncology and pathology to 
increase the quality of oncological care. Some clinicians may fear these developments, 
whereas others embrace them in order to go forward. Such a multimodality treatment 
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9approach is based on the concept of synergy: “the interaction of elements that when 
combined produce a total effect that is greater than the sum of the individual elements” 
(figure 1). This concept of synergy will inevitably be a key facet in improving the outcome 
of patients with muscle invasive and non-organ confined bladder cancer. 
Induction chemotherapy
Multimodality treatment in MIBC consists primarily of neoadjuvant/induction 
chemotherapy (NIC) followed by surgery or radiation therapy. The study that was 
reported in chapter 4 gives an overview of the outcome of patients with non-organ 
confined bladder cancer who were eligible for surgery and treated with NIC at 
the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital. Response to 
chemotherapy was assessed after two cycles based on earlier publications, showing 
that, in case of no response, further chemotherapy is futile24. This study affirms that 
the prognosis of patients with locally advanced and node positive bladder cancer is 
generally poor: despite induction chemotherapy and consolidating local therapy median 
OS was 18 months and the 5-years OS 27.2%. Patients with a complete pathological 
response to induction chemotherapy after surgery fare significantly better (median OS 
74 months and 5-years OS 53.8%). Clinical and pathological response to chemotherapy 
and the clinical node status after chemotherapy (ycN-status) were significant predictive 
factors for OS25. 
Most trials investigating the potential benefit of NIC excluded node positive patients, 
nevertheless hypothetically this group of poor prognosis patients may benefit the most26. 
In the study that was outlined in chapter 7, including only node positive patients, one 
syn•er•gy [sin-er-jee] 
noun, plural syn•er•gies.
 1.   the interaction of elements that when combined produce a total effect 
that is greater than the sum of the individual elements, contributions, 
etc.; synergism.
 2.   Physiology, Medicine/Medical . the cooperative action of two or more 
muscles, nerves, or the like.
 3.   Biochemistry, Pharmacology . the cooperative action of two or more 
stimuli or drugs.
 Origin:  1650–60;  < Neo-Latin synergia  < Greek synergía,  equivalent to synerg   
( ós ) 
Figure 1.
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out of four patients showed complete pathological response to NIC with subsequently 
a significant DSS benefit (median DSS 127 months and 5-years DSS 63.5%). In this 
series clinical and pathological response to chemotherapy were predictive parameters 
for outcome. Furthermore, clinically isolated nodal response is associated with a better 
outcome when compared to isolated local response in the bladder27. As was discussed 
in chapter 4, patients with pathologically progressive disease after chemotherapy, who 
were subjected to total cystectomy performed no better than the patients who did not 
undergo surgery. Therefore based on these results we do not advise consolidating surgery 
to patients in our institution with progressive disease during induction chemotherapy. 
Radiation therapy could be considered as a non-surgical alternative in these patients.
 
Another issue that is addressed in chapter 4 concerns the limited reliability of the 
current imaging techniques with respect to clinical staging. The negative predictive 
value for clinical staging by current imaging techniques was 62.5%. Meaning that in 
37.5% of patients with a complete clinical response after chemotherapy, residual tumour 
was found at surgery25. The introduction of novel imaging modalities such as FDG-PET/
CT-scan and diffusion-weighted magnetic resonance imaging (MRI) in the standard 
workup before and after induction chemotherapy may improve clinical staging28-30. The 
limitations of current imaging techniques are also reflected by the number of occult 
LN metastases that are found after PLND and cystectomy in patients with MIBC. This 
percentage of occult LN metastases is highly dependent on the primary tumour stage: 
2-5% in ≤pT1, 8-18% in pT2 and 36-46% in ≥pT3 tumours31-36. Hypothetically the 
use of NIC reduces this percentage of occult LN metastases in patients with MIBC. 
To substantiate this hypothesis, the study in chapter 6 was performed in which a 
consecutive series of clinically node negative (cN0) patients, who were treated with or 
without NIC were compared. These patients all underwent RC using the same PLND 
template during the study period. In the patients with locally advanced disease (cT3-4), 
the occurrence of LN metastases was significantly lower in the NIC group compared 
with the non-NIC group (21.9% versus 40.7%). This underlines the importance of NIC to 
erradicate occult micro-metastatic disease37. 
Despite several publications supporting this multimodality treatment approach with 
pre-operative chemotherapy, this treatment strategy has not been adopted as standard 
of care for non-organ confined bladder cancer 26,38-41. According to a report from the 
National Cancer Data Base in 2007, peri-operative chemotherapy was administered 
to 11.6% of patients with stage III bladder cancer in the USA. Thus underlining the 
fact that perioperative chemotherapy is underused in stage III bladder cancer42. 
This is in concordance with a survey among Dutch urologists, in which was shown 
that only 25% of the respondents to the survey considered NIC for bladder cancer. 
Furthermore approximately 10% of eligible patients actually received neoadjuvant 
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9combination chemotherapy (personal correspondence with principal investigator dr 
J.L. Boormans). This may be due to the fact that many clinicians are reluctant to start 
NIC with respect to the potential toxicity it elicits. Ideally such toxic treatment would 
be started only in patients, who are likely to benefit, based on tumour characteristics. 
There have been varying reports on the use of molecular markers to predict prognosis 
and chemosensitivity of bladder tumours. Especially the tumour suppressor proteins 
p53 and retinoblastoma (pRb) and their downstream effectors (e.g. p21) have been 
investigated in this respect43-45. The implementation of molecular markers may be the 
basis for indivualizing treatment for patients with non-organ confined bladder cancer 
43,45. Stadler et al. performed a phase III trial to evaluate chemosensitivity of patients 
with p53 inactivation determined by immunohistochemistry (IHC)45. Unfortunately this 
trial, randomizing patients with aberrant p53-IHC to 3 cycles of adjuvant MVAC versus 
observation, produced inconclusive results due to study limitations such as: high patient 
refusal rate, failure to receive assigned therapy and limited power of the study (due 
to better than expected overall patient outcome in case of aberrant p53-IHC). Such 
molecularly targeted therapy may require a combination of several molecular markers 
(e.g. p53, pRb, p21 and p27) in order to predict clinical outcome and response to 
treatment44. 
Cisplatin-unfit patients
When patients are unfit to receive cisplatin-based combination chemotherapy, they 
may be submitted to surgery immediately, as generally other regimens of induction 
chemotherapy (e.g. carboplatin-based treatment) are considered to be inferior compared 
to cisplatin-based treatment. However, as was described in chapter 5, carboplatin-based 
induction chemotherapy may prove to be a reasonable alternative for cisplatin-unfit 
patients with non-organ confined bladder cancer. The concerning study showed that 
induction treatment with gemcitabine and carboplatin for non-organ confined bladder 
cancer achieves comparable clinical and pathological response rates as well as survival 
outcomes to the cisplatin-based regimens46. 
Sequential chemoradiation for small cell 
carcinoma of the bladder
The bladder-sparing strategy, consisting of sequential chemoradiation (i.e. NIC  followed 
by external beam radiotherapy), for patients with limited disease small cell carcinoma 
of the bladder (LD-SCCB), represents another multimodality treatment approach. 
The study that was reported in chapter 8 concerning sequential chemoradiation in 
LD-SCCB, showed reasonable outcome results with a high bladder preservation rate 
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(85.2%). Although the prognosis of patients with LD-SCCB treated with sequential 
chemoradiation remains poor, with a median DSS of 47 months and 5-years DSS 39.6% 
47. Because of experience with an increased risk for local toxicity in the bladder after 
concurrent chemoradiation, in our institution external beam radiotherapy is scheduled 
after the NIC. However, recently there have been reports on the beneficial effects of 
concurrent administration of radiosensitizing agents (e.g. cisplatin-based chemotherapy) 
potentiating the cytotoxic effect of radiotherapy 48. As the techniques of external beam 
radiotherapy have evolved in recent years and the risks of local toxicity have been further 
reduced, the use of concurrent chemoradiation may be expected to gain terrain. 
Notwithstanding these results, the optimal treatment strategy for these patients with 
LD-SCCB remains controversial, because of the low incidence of the disease. Some 
advocate NIC followed by radical surgery, with promising results 49. To determine 
the optimal treatment approach for this rare and aggressive entity, a multi-center 
case-matched comparison between different treatment modalities (e.g. NIC with either 
surgery or radiotherapy) would be invaluable. 
Conclusions
In conclusion, to improve the poor outcome of patients with high-risk bladder cancer:
- The multidisciplinary approach is essential
- More accurate clinical staging with novel imaging techniques is inevitable
- Molecularly targeted therapy will result in personalized cancer care
130
9References
 1. Bol MG, Baak JP, Buhr-Wildhagen S, Kruse AJ, Kjellevold KH, Janssen EA, Mestad O and Ogreid P: Repro-
ducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carci-
noma of the bladder. J Urol. 169: 1291-4, 2003.
 2. Sylvester RJ, van der Meijden A, Witjes JA, Jakse G, Nonomura N, Cheng C, Torres A, Watson R and Kurth 
KH: High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology. 66: 90-107, 2005.
 3. Witjes JA, Moonen PM and van der Heijden AG: Review pathology in a diagnostic bladder cancer trial: 
effect of patient risk category. Urology. 67: 751-5, 2006.
 4. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J and Roupret M: EAU guidelines 
on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 59: 997-1008, 
2011.
 5. van Rhijn BW, van der Kwast TH, Alkhateeb SS, Fleshner NE, van Leenders GJ, Bostrom PJ, van der Aa MN, 
Kakiashvili DM, Bangma CH, Jewett MA et al.: A new and highly prognostic system to discern T1 bladder 
cancer substage. Eur Urol. 61: 378-84, 2012.
 6. Meijer RP, van Onna IE, Kok ET and Bosch R: The risk profiles of three clinical types of carcinoma in situ of 
the bladder. BJU Int, 2010.
 7. Hudson MA and Herr HW: Carcinoma in situ of the bladder. J Urol. 153: 564-72, 1995.
 8. Volkmer BG, Schnoeller T, Kuefer R, Gust K, Finter F and Hautmann RE: Upper urinary tract recurrence after 
radical cystectomy for bladder cancer--who is at risk? J Urol. 182: 2632-7, 2009.
 9. Tilki D, Reich O, Svatek RS, Karakiewicz PI, Kassouf W, Novara G, Ficarra V, Chade DC, Fritsche HM, Gerw-
ens N et al.: Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radi-
cal cystectomy: an international study of 243 patients. J Urol. 183: 1757-63, 2010.
 10. Shariat SF, Palapattu GS, Amiel GE, Karakiewicz PI, Rogers CG, Vazina A, Schoenberg MP, Lerner SP, 
Sagalowsky AI and Lotan Y: Characteristics and outcomes of patients with carcinoma in situ only at radical 
cystectomy. Urology. 68: 538-42, 2006.
 11. Schrier BP, Hollander MP, van Rhijn BW, Kiemeney LA and Witjes JA: Prognosis of muscle-invasive bladder 
cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol. 45: 
292-6, 2004.
 12. de Vries RR, Nieuwenhuijzen JA, Vincent A, van Tinteren H and Horenblas S: Survival after cystectomy for 
invasive bladder cancer. Eur J Surg Oncol. 36: 292-7, 2010.
 13. Burger M, Witjes JA, Babjuk M, Brausi M, Cheng C, Comperat E, Dinney C, Jager W, Otto W, Shah J et al.: 
Second international consultation on bladder cancer, in Soloway MS andKhoury S: Bladder Cancer, 2012, 
vol. Bladder Cancer, pp 249-268.
 14. Dhar NB, Klein EA, Reuther AM, Thalmann GN, Madersbacher S and Studer UE: Outcome after radical 
cystectomy with limited or extended pelvic lymph node dissection. J Urol. 179: 873-8; discussion 878, 2008.
 15. Herr HW and Donat SM: Outcome of patients with grossly node positive bladder cancer after pelvic lymph 
node dissection and radical cystectomy. J Urol. 165: 62-4; discussion 64, 2001.
 16. Leissner J, Ghoneim MA, Abol-Enein H, Thuroff JW, Franzaring L, Fisch M, Schulze H, Managadze G, Allhoff 
EP, el-Baz MA et al.: Extended radical lymphadenectomy in patients with urothelial bladder cancer: results 
of a prospective multicenter study. J Urol. 171: 139-44, 2004.
 17. Konety BR, Joslyn SA and O’Donnell MA: Extent of pelvic lymphadenectomy and its impact on outcome 
in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End 
Results Program data base. J Urol. 169: 946-50, 2003.
Summary and general discussion
131
chapter 9a
 18. Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE and Bajorin DF: Impact of the number of lymph 
nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol. 167: 1295-8, 2002.
 19. Herr HW: The concept of lymph node density--is it ready for clinical practice? J Urol. 177: 1273-5; discussion 
1275-6, 2007.
 20. Kassouf W, Agarwal PK, Herr HW, Munsell MF, Spiess PE, Brown GA, Pisters L, Grossman HB, Dinney CP 
and Kamat AM: Lymph node density is superior to TNM nodal status in predicting disease-specific survival 
after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol. 
26: 121-6, 2008.
 21. May M, Herrmann E, Bolenz C, Tiemann A, Brookman-May S, Fritsche HM, Burger M, Buchner A, Gratzke 
C, Wulfing C et al.: Lymph node density affects cancer-specific survival in patients with lymph node-positive 
urothelial bladder cancer following radical cystectomy. Eur Urol. 59: 712-8, 2011.
 22. Meijer RP, Nunnink CJ, Wassenaar AE, Bex A, van der Poel HG, van Rhijn BW, Meinhardt W and Horenblas 
S: Standard lymph node dissection for bladder cancer: significant variability in the number of reported 
lymph nodes. J Urol. 187: 446-50, 2012.
 23. Mertens LS, Meijer RP, van Werkhoven E, Bex A, van der Poel HG, van Rhijn BW, Meinhardt W and Horen-
blas S: Differences in histopathological evaluation of standard lymph node dissections result in differences 
in nodal count but not in survival. World J Urol, 2012.
 24. Splinter TA, Pavone-Macaluso M, Jacqmin D, Roberts JT, Carpentier P, de Pauw M and Sylvester R: A Euro-
pean Organization for Research and Treatment of Cancer--Genitourinary Group phase 2 study of chemo-
therapy in stage T3-4N0-XM0 transitional cell cancer of the bladder: evaluation of clinical response. J Urol. 
148: 1793-6, 1992.
 25. Meijer RP, Nieuwenhuijzen JA, Meinhardt W, Bex A, van der Poel HG, van Rhijn BW, Kerst JM, Bergman 
AM, van Werkhoven E and Horenblas S: Response to induction chemotherapy and surgery in non-organ 
confined bladder cancer: a single institution experience. Eur J Surg Oncol, 2013.
 26. Griffiths G, Hall R, Sylvester R, Raghavan D and Parmar MK: International phase III trial assessing neoadju-
vant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term 
results of the BA06 30894 trial. J Clin Oncol. 29: 2171-7, 2011.
 27. Meijer RP, Mertens LS, van Rhijn BW, Bex A, van der Poel HG, Meinhardt W, Kerst JM, Bergman AM, Fioole-
Bruining A, van Werkhoven E et al.: Induction chemotherapy followed by surgery in node positive bladder 
cancer. Urology. 2013, 2013.
 28. Kibel AS, Dehdashti F, Katz MD, Klim AP, Grubb RL, Humphrey PA, Siegel C, Cao D, Gao F and Siegel BA: 
Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for 
staging of muscle-invasive bladder carcinoma. J Clin Oncol. 27: 4314-20, 2009.
 29. Yoshida S, Koga F, Kawakami S, Ishii C, Tanaka H, Numao N, Sakai Y, Saito K, Masuda H, Fujii Y et al.: 
Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to 
induction chemoradiotherapy against muscle-invasive bladder cancer. Urology. 75: 387-91, 2010.
 30. Mertens LS, Fioole-Bruining A, van Rhijn BW, Kerst JM, Bergman AM, Vogel WV, Vegt E and Horenblas S: 
FDG-PET/CT in Monitoring Response of Pelvic Lymph Node Metastases to Neoadjuvant Chemotherapy in 
Bladder Cancer. J Urol, 2012.
 31. Ghoneim MA, Abdel-Latif M, el-Mekresh M, Abol-Enein H, Mosbah A, Ashamallah A and el-Baz MA: Radical 
cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol. 180: 121-7, 2008.
 32. Hautmann RE, Gschwend JE, de Petriconi RC, Kron M and Volkmer BG: Cystectomy for transitional cell 
carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol. 176: 486-92; discus-
sion 491-2, 2006.
 33. Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R and Studer UE: Radi-
cal cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy. J Clin Oncol. 
21: 690-6, 2003.
132
9 34. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail 
M et al.: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. 
J Clin Oncol. 19: 666-75, 2001.
 35. Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, 
Sagalowsky AI et al.: Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a 
contemporary series from the Bladder Cancer Research Consortium. J Urol. 176: 2414-22; discussion 2422, 
2006.
 36. Zehnder P, Studer UE, Skinner EC, Dorin RP, Cai J, Roth B, Miranda G, Birkhauser F, Stein J, Burkhard FC 
et al.: Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystec-
tomy for bladder cancer: a comparative study. J Urol. 186: 1261-8, 2011.
 37. Mertens LS, Meijer RP, Meinhardt W, van der Poel HG, Bex A, Kerst JM, van der Heijden MS, Bergman 
AM, Horenblas S and van Rhijn BW: occult lymph node metastases in patients with muscle invasive bladder 
cancer: incidence after neoadjuvant chemotherapy and cystectomy versus cystectomy alone. BJU Int, 2013.
 38. Blick C, Hall P, Pwint T, Al-Terkait F, Crew J, Powles T, Macaulay V, Munro N, Douglas D, Kilbey N et al.: 
Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy 
for patients with muscle-invasive transitional cell carcinoma of the bladder. Cancer. 118: 3920-7, 2012.
 39. Hall RR: Updated results of a randomised controlled trial of neoadjuvant cisplatin (C), methotrexate (M) and 
vinblastine (V) chemotherapy for muscle-invasive bladder cancer: Proc Am Soc Clin Oncol, 2002.
 40. Winquist E, Kirchner TS, Segal R, Chin J and Lukka H: Neoadjuvant chemotherapy for transitional cell carci-
noma of the bladder: a systematic review and meta-analysis. J Urol. 171: 561-9, 2004.
 41. Burger M, Mulders P and Witjes W: Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer 
is low among major European centres: results of a feasibility questionnaire. Eur Urol. 61: 1070-1, 2012.
 42. David KA, Milowsky MI, Ritchey J, Carroll PR and Nanus DM: Low incidence of perioperative chemotherapy 
for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol. 178: 451-4, 
2007.
 43. Cote RJ and Datar RH: Therapeutic approaches to bladder cancer: identifying targets and mechanisms. Crit 
Rev Oncol Hematol. 46 Suppl: S67-83, 2003.
 44. Shariat SF, Chade DC, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, 
Jeldres C et al.: Combination of multiple molecular markers can improve prognostication in patients with 
locally advanced and lymph node positive bladder cancer. J Urol. 183: 68-75, 2010.
 45. Stadler WM, Lerner SP, Groshen S, Stein JP, Shi SR, Raghavan D, Esrig D, Steinberg G, Wood D, Klotz L 
et al.: Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the 
bladder based on p53 status. J Clin Oncol. 29: 3443-9, 2011.
 46. Mertens LS, Meijer RP, Kerst JM, Bergman AM, van Tinteren H, van Rhijn BW and Horenblas S: Carboplatin 
based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin 
unfit patients? J Urol. 188: 1108-13, 2012.
 47. Meijer RP, Meinhardt W, van der Poel HG, van Rhijn BW, Kerst JM, Pos FJ, Horenblas S and Bex A: Local 
control rate and prognosis after sequential chemoradiation for small cell carcinoma of the bladder. Int J 
Urol, 2012.
 48. James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, Crundwell M, Sizer B, Sreenivasan T, 
Hendron C et al.: Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J 
Med. 366: 1477-88, 2012.
 49. Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C, Shen Y, Pisters LL, Grossman HB, Swanson DA 
and Millikan RE: Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a 
retrospective review of the M. D. Anderson cancer experience. J Urol. 172: 481-4, 2004.
Summary and general discussion
133

b
C
h
a
p
te
r
9
NEDERLANDSE SAMENVATTING
HOOG RISICO BLAASCARCINOOM: STADIËRING, RISICO EVALUATIE 
EN BEHANDELOPTIES
“Misschien is niets geheel waar, en zelfs dàt niet.”
-Multatuli-

9Inleiding
De Nederlandse Kankerregistratie vermeldt een incidentie van 6149 nieuwe 
patiënten met blaaskanker in 2011. Blaaskanker komt vaker bij mannen voor dan bij 
vrouwen (verhouding 3,4:1,0). Bij mannen betreft het 5,2% van alle voorkomende 
maligniteiten. Hierbij betreft het in ongeveer 70% van de gevallen een niet-spierinvasief 
blaascarcinoom, waarbij de blaastumor zich beperkt tot het urotheel (Ta, carcinoma 
in situ) of maximaal ingroeit tot in de lamina propria van de blaaswand (T1). Bij het 
spierinvasieve blaascarcinoom, groeit de tumor tot minimaal in de detrusor-spier (≥T2)1. 
Roken is de belangrijkste risico-factor voor het ontwikkelen van blaaskanker. Bij mannen 
speelt roken in 50-65% van de gevallen een rol en bij vrouwen in 20-30% van de 
gevallen. Na het stoppen met roken daalt het risico op blaaskanker met 40% in de 
eerste vier jaar tot een 60% afname na 25 jaar2. 
De behandeling van een niet-spierinvasief blaascarcinoom bestaat voornamelijk uit 
transurethrale resectie, eventueel gevolgd door chemotherapeutische blaas-spoelingen. 
Daarmee kan de blaas vaak behouden worden. In het geval van een spierinvasief 
blaascarcinoom is een meer agressieve behandeling noodzakelijk, bestaand uit een 
pelviene lymfeklierdissectie gecombineerd met een radicale cystectomie (RC) of een 
vorm van radiotherapie.  
Hoog-gradige niet-spierinvasieve blaastumoren
Hoog-gradig niet-spierinvasieve blaastumoren vormen een groep van urotheelcarcinomen 
met een hoog risico op recidieven en een significant risico op progressie naar een 
spierinvasief blaascarcinoom (MIBC). Carcinoma in situ (CIS) is een voorbeeld van een 
dergelijke hoog-gradige niet-spierinvasieve blaastumor. De studie die werd beschreven in 
hoofdstuk 2 toont aan dat CIS inderdaad een ziekte is met een hoog risico op recidieven 
(68.9%) en een hoog risico op progressie naar een spier-invasief blaascarcinoom (18.9%). 
In deze studie leek de concomitant CIS groep een slechtere prognose te hebben met 
een kortere blaas-sparende periode en een slechtere overleving (OS) vergeleken met 
primaire en secundaire CIS, echter deze verschillen waren niet statistisch significant3. 
Om een andere risico-profiel voor CIS van de blaas op te stellen werd door Hudson et 
al. een voorstel gedaan om CIS in subgroepen te verdelen, waarbij patiënten werden 
geïdentificeerd met hoog-risico CIS (diffuus CIS, betrokkenheid van urethra prostatica, 
over-expressie van p53) versus patiënten met laag-risico CIS (focaal CIS, afwezigheid 
van over-expressie p53). Wanneer sprake blijkt van BCG-falen zouden patiënten met 
hoog-risico CIS een radicale cystectomie moeten ondergaan, terwijl aan patiënten met 
laag-risico CIS een andere vorm van blaas-sparende therapie kan worden aangeboden4. 
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Lymfeklier stadiëring
In geval van progressie van een niet-spierinvasief blaascarcinoom na conservatieve 
behandeling, of in geval van een primair spierinvasief blaascarcinoom, is een pelviene 
lymfeklierdissectie beiderzijds (PLND) gecombineerd met een radicale cystectomie 
en urinedeviatie de gouden standaard. Daarbij is de kwaliteit van de PLND van groot 
belang5-7. De kwaliteit van de chirurgische resectie wordt vaak gemeten aan de hand 
van het aantal verwijderde lymfeklieren8,9. Verder worden lymfeklier parameters zoals 
de lymph node density gebruikt als voorspellende factoren voor de ziekte-specifieke 
overleving10-12. In hoofdstuk 3 worden twee studies beschreven met deze lymfeklier-
aantallen als onderwerp. De histopathologische uitkomsten van de PLNDs in twee 
verschillende ziekenhuizen werden vergeleken. Deze twee studies tonen statistisch 
significante verschillen tussen de twee pathologie afdelingen bij het beoordelen van de 
lymfeklier aantallen na PLND voor blaascarcinoom, ondanks vergelijkbare anatomische 
klierdissecties door dezelfde ervaren operateurs13,14. Desalniettemin werd geen statistisch 
significant verschil gevonden in het aantal tumor positieve lymfeklieren. Verder werden 
geen verschillen gevonden in de totale overleving en de recidief-vrije overleving tussen 
beide ziekenhuizen13,14. Blijkbaar is naast een nauwgezette anatomische chirurgische 
lymfeklierdissectie ook een gestandaardiseerde histopathologische evaluatie uiterst 
belangrijk. Totdat een gestandaardiseerde methode van histopathologische evaluatie 
is vastgesteld zou men dan ook terughoudend moeten zijn om de aantallen van 
gerapporteerde lymfeklieren te gebruiken als indicator voor kwaliteit van chirurgie en de 
lymph node density als prognostische factor. 
Multi-modulaire behandeling van blaaskanker
Bij de behandeling van het spierinvasieve blaascarcinoom bestaat multi-modulaire therapie 
voornamelijk uit neoadjuvante/inductie chemotherapie (NIC) gevolgd door chirurgie 
of radiotherapie. De studie die in hoofdstuk 4 wordt beschreven geeft een overzicht 
van het behandelresultaat van patiënten met een lokaal-gevorderd en/of klier-positief 
blaascarcinoom, die geschikt waren voor chirurgie en eerst werden behandeld met 
NIC in het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis. De 
respons op chemotherapie werd beoordeeld na twee kuren chemotherapie. Eerdere 
publicaties hebben aangetoond dat in afwezigheid van respons na twee kuren, 
verdere chemotherapie geen toegevoegde waarde heeft15. Deze studie bevestigd dat 
de prognose van patiënten met een lokaal-gevorderd en klier-positief blaascarcinoom 
over het algemeen zeer matig is: ondanks inductie chemotherapie en consoliderende 
lokale therapie was de mediane OS 18 maanden en de 5-jaars OS 27.2%. Patiënten met 
een complete pathologische respons op inductie chemotherapie na chirurgie hebben 
een significant betere prognose (mediane OS 74 maanden en 5-jaars OS 53.8%). 
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chemotherapie (ycN-status) waren predictieve factoren voor OS16.
Bij de meeste studies waarin het potentiële voordeel van NIC werd onderzocht, werden 
klier-positieve patiënten geëxcludeerd, terwijl deze patiënten met een zeer matige 
prognose hypothetisch de meeste winst zouden kunnen behalen17. In hoofdstuk 7 wordt 
een studie beschreven, waarin alleen klier-positieve patiënten zijn geïncludeerd. In deze 
studie blijkt dat een op de vier patiënten na NIC een complete pathologische respons 
bereikt met daarbij een significante verbetering van de ziekte-specifieke overleving (DSS) 
(mediane DSS 127 maanden en 5-jaars DSS 63.5%). In deze serie waren de klinische 
en pathologische respons op NIC voorspellende factoren voor de overleving. Verder 
is een klinisch geïsoleerde lymfeklier respons geassocieerd met een betere overleving 
vergeleken met een geïsoleerde lokale respons in de blaas 18. 
In hoofdstuk 4 wordt ingegaan op de beperkte nauwkeurigheid van de huidige 
beeldvormende technieken met betrekking tot de klinische stadiëring. De negatief 
voorspellende waarde van de klinische stadiëring met de huidige beeldvorming was 
62.5%. Dit betekent dat bij 37.5% van de patiënten met een complete klinische respons 
na chemotherapie, toch nog rest-tumor wordt gevonden bij chirurgie16. De introductie 
van nieuwe beeldvormende modaliteiten zoals de FDG-PET/CT-scan en bijvoorbeeld 
diffusion-weighted magnetic resonance imaging (MRI) voor en na de NIC zouden de 
klinische stadiëring en respons evaluatie kunnen verbeteren 19-21. 
De beperkingen van de huidige beeldvormende technieken wordt ook weerspiegeld 
door de occulte lymfeklier metastasen die worden gevonden na PLND en cystectomie 
bij patiënten met een MIBC. Dit percentage van occulte kliermetastasen is zeer 
afhankelijk van het primaire tumorstadium: 2-5% in ≤pT1, 8-18% in pT2 en  36-46% 
in ≥pT3 tumoren22-27. Hypothetisch zal het gebruik van NIC dit percentage occulte 
kliermetastasen bij patiënten met MIBC reduceren. Om deze hypothese te toetsen werd 
in een studie een serie van klinisch klier-negatieve MIBC patiënten (cN0), behandeld 
met of zonder NIC, met elkaar vergeleken (hoofdstuk 6). Deze patiënten ondergingen 
allen een RC, waarbij consequent een zelfde PLND template werd gebruikt. Bij patiënten 
met een lokaal-gevorderd blaascarcinoom (cT3-4), kwamen LN metastasen significant 
minder vaak voor in de NIC groep vergeleken met de groep zonder NIC (21.9% versus 
40.7%). Dit onderstreept de meerwaarde van NIC om occulte micrometastasen te 
behandelen28. 
Ondanks verschillende publicaties die deze multi-modulaire behandeling met 
pre-operatieve chemotherapie ondersteunen, is deze behandelstrategie nog niet 
geaccepteerd als de standaardbehandeling van het lokaal-gevorderde en klier-positieve 
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blaascarcinoom17,29-32. Volgens een rapport van de National Cancer Data Base in 2007, 
werd peri-operatieve chemotherapy toegepast bij 11.6% van de patiënten met lokaal-
gevorderd en/of klier-positief blaascarcinoom in de Verenigde Staten33. De meest 
voor de hand liggende verklaring voor deze terughoudendheid met betrekking tot de 
toepassing van neoadjuvante chemotherapie is de verwachte toxiciteit. Idealiter zou een 
dergelijke toxische behandeling alleen gestart worden bij patiënten die, op basis van 
tumor karakteristieken, voordeel zullen hebben bij deze multi-modulaire therapie. Er zijn 
verschillende publicaties over de toepassing van moleculaire markers om de prognose 
en chemosensitiveit van blaastumoren te voorspellen. De toepassing van een combinatie 
van verschillende moleculaire markers (bijv. p53, pRb, p21 en p27) kan de basis vormen 
voor individualisatie van de behandeling van patiënten met spierinvasief en lokaal-
gevorderd blaascarcinoom 34-36. 
Cisplatin-ongeschikte patiënten
Wanneer patiënten geen cisplatin-bevattende combinatie chemotherapie kunnen 
ontvangen, worden zij veelal primair chirurgisch behandeld, omdat men in het algemeen 
ervan uitgaat dat andere combinaties van NIC (bijvoorbeeld carboplatin-bevattende 
combinatie chemotherapie) inferieur zijn ten opzichte van cisplatin-bevattende therapie. 
Echter in hoofdstuk 5 is een studie beschreven, waarin carboplatin-bevattende 
combinatie chemotherapie een redelijk alternatief blijkt te zijn voor cisplatin-ongeschikte 
patiënten met een lokaal-gevorderd blaascarcinoom. De betreffende studie toont dat 
behandeling met gemcitabine en carboplatin voor lokaal-gevorderd en/of klierpositief 
blaascarcinoom tot vergelijkbare klinische en pathologische respons rates en vergelijkbare 
overlevings uitkomsten leidt als cisplatin-bevattende therapie37. 
Sequentiële chemoradiatie voor klein-cellig 
blaascarcinoom
Een andere multi-modulaire behandel-optie bij blaaskanker bestaat uit sequentiële 
chemoradiatie (NIC gevolgd door uitwendige radiotherapie), voor patiënten met een 
limited disease klein-cellig blaascarcinoom (LD-SCCB). Deze blaas-sparende behandeling 
bij LD-SCCB blijkt redelijke resultaten te hebben: in 85.2% van de patiënten kan de 
blaas behouden blijven (hoofdstuk 8). Echter de prognose van deze patiënten met 
LD-SCCB, behandeld met sequentiële chemoradiatie blijkt matig met een mediane DSS 
van 47 maanden en een 5-jaars DSS van 39.6% 38. Vanwege de ervaringen met een 
verhoogd risico op lokale toxiciteit in de blaas na concurrente chemoradiatie werd in 
ons instituut een aantal jaar geleden besloten om de radiotherapie na de NIC toe te 
dienen. Echter recentelijk werd gepubliceerd over de voordelige effecten die gerelateerd 
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bevattende chemotherapie) waarmee het cytotoxische effect van de radiotherapie werd 
versterkt 39. Aangezien de technieken van de uitwendige radiotherapie in de afgelopen 
jaren zijn verbeterd en het risico op lokale toxiciteit is gereduceerd, mag verwacht 
worden dat concurrente chemoradiatie aan terrein zal winnen. Ondanks de resultaten 
van sequentiële chemoradiatie bij LD-SCCB zoals beschreven in hoofdstuk 8, blijft de 
optimale behandelstrategie voor patiënten met LD-SCCB, door de lage incidentie van 
de ziekte, controversieel. Sommige experts propageren NIC gevolgd door radicale 
chirurgie, met veelbelovende resultaten 40. Om de optimale behandelstrategie voor 
deze zeldzame en aggressieve ziekte te bepalen, zou een multi-center case-matched 
vergelijking tussen de verschillende behandelmodaliteiten (NIC gevolgd door chirurgie 
of radiotherapie) zeer waardevol zijn. 
Conclusies
Concluderend kan gesteld worden dat voor een verbetering van de matige prognose 
van patiënten met een hoog risico blaascarcinoom: 
- Een multi-disciplinaire aanpak essentieel is
- De klinische stadiëring en respons evaluatie met nieuwe beeldvormende technieken 
moet worden verbeterd
- Een moleculair gerichte therapie zal leiden tot individuele kanker behandeling 
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FUTURE PERSPECTIVES
“Videmus nunc per speculum et in aenigmate…”
-I Corinthians 13:12-

10
Imaging 
Clinical staging should be improved by more accurate imaging techniques. In this 
respect nuclear medicine imaging (fluorodeoxyglucose positron emission tomography/
computed tomography; FDG-PET/CT-scan) has been introduced, to visualize occult 
nodal and/or distant metastases. The results of the FDG-PET/CT-scan are promising 
both for initial staging and for response evaluation following neoadjuvant/induction 
chemotherapy (NIC) 1,2. Apolo et al. reported a high sensitivity (87%) and specificity 
(88%) for the FDG-PET/CT-scan in detecting metastatic bladder cancer3. However 
the FDG-PET/CT-scan is less appropriate for local staging of the bladder tumour, due 
to the FDG-activity in urine2. Thus for improved local staging of the bladder tumour 
another modality is required. This may be achieved by including diffusion-weighted 
magnetic resonance imaging (MRI) in the standard workup before and after induction 
chemotherapy 1,4,5. Potentially these imaging modalities can  be combined as FDG-PET/
MRI-scan. However the additional value of the MRI-bladder over the conventional 
contrast-enhanced CT-scan still needs to be substantiated. With increased reliability of 
clinical response evaluation, chemotherapy induced downstaging of the primary tumour 
could be used as a surrogate marker for treatment efficacy 6. 
Histopathology 
To reduce the interobserver variability between the pathology departments of different 
hospitals, the development of a standardized histopathological evaluation for bladder 
cancer specimens is important. This will require a close collaboration between urologist 
and pathologist. After such a standardization, parameters such as the number of reported 
lymph nodes and the lymph node density may be re-evaluated for their prognostic value.
Chemotherapy
The fact that preoperative chemotherapy is applied so infrequently for locally advanced 
and node positive bladder cancer indicates that a paradigm-shift is required to improve 
the outcome of these patients7. More accurate clinical staging will lead to improved 
selection of high-risk bladder cancer patients (locally advanced and node positive 
disease) eligible for NIC followed by surgery or radiotherapy and thus reduce the risk 
of overtreatment. Furthermore the evaluation of tumour biology and assessment of 
chemosensitivity of the individual bladder tumour will lead to personalized bladder cancer 
treatment. Nevertheless, until these innovations are achieved, NIC should be considered 
for all patients with locally advanced and/or node positive bladder cancer8-10. 
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Consolidating treatment 
Considering that one out of three patients harbours occult residual disease after NIC, 
consolidating local treatment is rational8. In the absence of other reliable ways to assess 
presence or absence of residual tumour, we favour surgery. However, although surgery 
may be important for staging and prognostic purposes, its role is unclear in node positive 
disease after NIC. More research is needed to clarify the role of consolidating surgery 
in these patients. Potentially, consolidating treatment after NIC may also be achieved 
by external beam radiation therapy. A prospective randomised clinical trial comparing 
surgery and radiotherapy after NIC may further elucidate this issue.
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“Write on my tablets all that was permitted,
All that was for our human senses fitted.
Then the events of this wide world I’d seize
Like a strong giant, and my spirit teaze
Till at its shoulders it should proudly see
Wings to find out an immortality.”
-John Keats-
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“ik draai een kleine revolutie af
ik draai een kleine mooie revolutie af
ik ben niet langer van land
ik ben weer water
ik draag schuimende koppen op mijn hoofd
ik draag schietende schimmen in mijn hoofd
op mijn rug rust een zeemeermin
op mijn rug rust de wind
de wind en de zeemeermin zingen
de schuimende koppen ruisen
de schietende schimmen vallen
ik draai een kleine mooie ritselende revolutie af
en ik val en ik ruis en ik zing”
-Lucebert -
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